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Abstract 
Kaposi's sarcoma -associated herpesvirus (KSHV), the newest member of the 
human herpesviruses, was first identified in 1994, and has been shown to be the 
etiological agent of Kaposi's Sarcoma (KS); a tumour most commonly associated 
with the onset of AIDS. KSHV is also involved in the development of other 
malignancies, including Multicentric Castleman's disease (MCD) and primary 
effusion lymphoma (PEL), both of which are B -cell lymphoproliferative disorders. 
The study of KSHV, as is the case with other herpesviruses from the 
Gammaherpesvirinae subfamily, is severely limited due to their species specificity 
and restricted growth in vitro. This has led to the increasing use of closely related 
murine gammaherpesviruses as a model system to study gammaherpesvirus 
pathogenesis. 
A common feature of the gammaherpesviruses is their incorporation of 
cellular homologous genes during viral evolution, presumably aiding in viral 
replication and dissemination. One such gene found in KSHV is vOX2, which has 
homology with the human OX2 gene (hOX2, also recently termed CD200). There 
are also homologous genes found in mice (mCD200) and rats (rCD200). This 
membrane bound protein is expressed on a wide variety of cell types, excluding 
myeloid derived cells. Recent studies have indicated that CD200 plays an important 
regulatory role in macrophage and microglia activation, through its interaction with 
a receptor (CD200R) found to be expressed predominantly on macrophage and 
microglia. 
Studies on the viral gene, vOX2, have indicated that this glycoprotein has a 
similar structure to the human CD200, an immunoglobulin superfamily gene, 
containing two extracellular domains, a single transmembrane region and a short 
cytoplasmic tail. In order to investigate the potential role of vOX2 in an in vivo 
system, a novel murid herpesvirus, murine gammaherpesvirus -76 (MHV -76), was 
utilised. MHV -76 is a natural deletion mutant of murine gammaherpesvirus -68 
(MHV -68), lacking four unique genes and eight viral tRNA -like genes from the left 
end of the MHV -68 genome. This deletion has provided an opportunity to generate 
a recombinant MHV -76 virus expressing vOX2 (MHV76 -vOX2) and a selectable 
iv 
marker (EGFP -HygR), thus allowing a functional study of vOX2 through the 
infection of mice. A control recombinant virus (MHV76 -IRES) was also generated, 
which only expressed the selectable marker (EGFP -HygR). The genomic structures 
of all recombinant viruses were verified by Southern blot analysis and the expression 
of the inserted genes was confirmed by northern blot analysis. The growth kinetics 
of MHV76 -vOX2 and MHV76 -IRES were compared with wild type MHV -76 in 
both an in vitro single -step and multi -step growth assay. The growth kinetics of the 
recombinant viruses was not significantly different from that of MHV -76. 
In vivo studies have indicated that vOX2 has an effect on viral replication; a 
10 to 100 -fold increase in viral lung titres was observed in mice infected with 
MHV76 -vOX2 compared to the control recombinant virus. Examination of lung 
sections showed that mice infected with the vOX2 recombinant virus elicited a 
strong influx of inflammatory cells, particularly peripheral mononucleocytes (PMN) 
and macrophages, resulting in perivascular and peribronchiolar inflammation. 
Unlike MHV -76, none of the recombinant viruses were able to establish latency in 
the spleen. Findings from infection of CD200 knock -out mice (C57BL /6 CD2004") 
with MHV76 -vOX2 support the possibility that vOX2 is playing an important 
immuno -regulatory role. These studies provide a starting point for further 
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CHAPTER ONE 
1.1 Herpesviridae 
Herpesviruses are highly disseminated in a wide range of organisms, 
including both vertebrates and invertebrates. At present there have been 
approximately 130 herpesviruses identified, however this is thought to be only a 
proportion of the number in existence with new members being discovered every 
year (Minson et al., 2000). Herpesviruses are generally well adapted and ubiquitous 
within their host species, with over 90% of the human population infected with the 
Epstein Barr virus (EBV) and over 95% sero -positive for varicella -zoster virus 
(VZV). The ability of herpesviruses to establish latency and co -exist with the host 
organisms for life is the principal reason for its evolutionary success. In most 
circumstances, the virus remains dormant within the host, and in immunocompetent 
organisms rarely manifest into overt disease. However, a wide spectrum of diseases 
can result following infection of an alternative host species or due to a variety of 
external stimuli affecting the natural host, for example, immune suppression 
resulting from an organ transplant or infection with other viruses, exposure to UV or 
simply stress. This is illustrated when observing infection of an individual with 
varicella -zoster virus (VZV). Following primary infection which causes varicella, 
more commonly known as chicken pox, VZV establishes lifelong latency in the 
dorsal root ganglia. Reactivation of the virus, commonly in elderly or 
immunocompromised individuals, leads to shedding of the virus, which may be 
asymptomatic but more commonly produces herpes zoster; a vesicular rash restricted 
to a dermatomal distribution, referred to as shingles. Acute reactivation of VZV can 
result in more severe acute pain that may progress to a chronic syndrome called post - 
herpatic neuralgia (PHN) (Arvin, 2001). 
It is due to the ability of herpesviruses to maintain life long latency and the 
wide spectrum of diseases caused that has lead it to be the topic of much scientific 
research. 
IN RC)i)IJC;I. ION 
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1.1.1 Characteristics of Herpesviruses 
Traditionally, grouping of viruses in the family Herpesviridae was based on 
the architecture of the virion (Figure 1.1). The virion consists of a core containing a 
large linear double -stranded DNA enclosed within an icosadeltahedral capsid, 
approximately 100 to 110nm in diameter, comprised of 162 capsomeres. The 
nuclear capsid is surrounded by an amorphous tegument that is predominantly 
composed of viral proteins, and is enclosed by the viral envelope. The viral envelope 
is derived from the host cell membrane and incorporates numerous viral glycoprotein 
spikes that protrude from the surface where they play an important role in cell 
adhesion and virus entry. 
Herpesvirus DNA genomes are linear and double stranded, however viral 
DNA circularises upon release from the capsid into the nucleus of infected cells and 
when in a latent form. Herpesvirus genomes range from 120 - 250kb, however 
variation between virion genome sizes of the same virus strain does occur. These 
differences are primarily due to the variation in copy number of reiterated terminal 
and internal repeat sequences, which can result in up to a 10kbp difference in 
genome length. Genome length can also vary due to spontaneous deletions, which 
has been known to occur in herpesviral strains of high -passage number, as observed 
in a laboratory strain of human cytomegalovirus, HCMV (Cha et al., 1996). 
Herpesviruses can also be grouped on the basis of their arrangement of terminal and 
internal repeat sequences, illustrated in Figure 1.2. 
All known herpesviruses share four major biological properties (Roizman and 
Pellett, 2001). 
1. They possess several open reading frames (ORFs) that specify enzymes 
involved in nucleic acid metabolism (e.g. thymidine kinase), DNA synthesis 
(e.g. DNA polymerase), and protein processing (e.g. protein kinases). 
2. Viral DNA synthesis and capsid assembly occurs in the nucleus. 
3. Infected cells are destroyed following lytic replication (the production of 
infectious progeny). 
4. All herpesviruses are able to remain latent in their natural host. During this 
latent stage, the viral genome forms a closed circular molecule, and only 
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limited subsets of viral genes are expressed. However. upon reactivation, the 
latent genome retains the capability to replicate and cause disease. 
Although herpesviruses possesses several similarities in virion structure and 
some biological properties, such as the ability to establish latency, there are many 
differences in other aspects such as host range and disease pathogenesis. It is these 
differences that lead to dividing the herpesvirus family into subfamilies. 
Gp 
E T 
Figure 1.1 An electron micrograph image of a HSV -1 virion. The 
negatively stained virion shows the icosahedral capsid (C) surrounded by 
the tegument (T). The glycoprotein spikes (Gp) seen on the outer 
envelope (E) appears larger than normal due to being permeabilised 
during the staining process. Photograph taken by Linda Stannard and 
reproduced from the Big Picture Book of Viruses, available at 
http: / /www.virology.net/Big _Virology /BVDNAherpes.html 
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Figure 1.2 Schematic illustrations of herpesvirus family genomes 
sequence arrangements. There are six classes of genomes A, B, C, D, E 
and F and examples are given in blue on the right hand side. The horizontal 
black lines represent unique or quasi- unique regions. Viruses in group A 
contain a sequence which is directly repeated at both termini, where as in 
group B the terminal sequences are reiterated numerous times at both termini. 
The sequence arrangement of group C is similar to that of group B, in that it 
possess terminal repeat (TR) at each end but also unrelated internal repeats 
(IR1 to IR4). The internal repeats are greater than 100bp and divide the 
unique region of the genome into several well delineated sections. In group D 
viruses the repeat sequence at one terminus is repeated internally in an 
inverted orientation (IR). The genome in group E is comprised of one terminus 
containing N copies of sequence A that is next to sequence B. The other 
terminus has a single repeated sequence A next to sequence C. The AN B and 
CA sequences are inserted in an inverted form internally (B'AN'C'). The 
inverted internal sequences in groups D and E divide the genome into a long 
(UL) and short (Us) domain, which can invert relative to each other leading to 
the formation of two and four isomers of viral DNA, respectively. Group F 
viruses, such as tree shrew herpesvirus, TSHV, no repeat sequences have 
been identified. (Adapted from Roizman and Pellett, 2001). 
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1.1.2 Classification 
Based on their biological properties, viruses in the Herpesviridae family were 
initially classified into three subfamilies; Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae (see Table 1.1 for examples). Although, more recently, DNA 
sequence conservation is also taken into consideration with the identification of new 
viruses. A phylogenetic tree showing the relation of each herpesvirus sub -family is 
shown in Figure 1.3. 
Gammaherpesviruses 
Rhadinovirus 














Figure 1.3 Phylogentic tree showing herpesvirus sub- 
families: Alapha -, Beta -, Gamma -herpesvirus. 
(Image adapted from Talbot and Whitby, 1999) 
1.1.2.1 The Alphaherpesvirus 
Members of this subfamily characteristically have a variable host range, 
relatively short reproductive cycle, spread rapidly in culture, efficient destruction of 
infected cells, and capacity to establish latent infections, primarily in the sensory 
ganglia. There are several genera within this subfamily, including Simplexvirus (e.g. 
Herpes Simplex Virus -1, HSV -1), Varicellovirus (e.g.Varicella -zoster virus, VZV), 
Marek's disease -like virus and Infectious laryngotracheitis -like virus. 
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Table 1.1 Examples of herpesviruses and their associated diseases. 




"Marek's disease -like 
viruses" 
Herpes simplex virus -1 
Herpes simplex virus -2 
Bovine herpesvirus -1 
Varicella zoster virus 
Equine herpesvirus -1 
Porcine herpesvirus -1 








Cold Sores, Keratitis 
Genital lesions 
Infectious rhinotracheitis, 
genital disease, abortions 
















Murine Cytomegalovirus Mice 
Human herpesvirus -6 
Human herpesvirus -7 
Epstein Barr virus 
Human Mononucleosis, Congenital 






Human Fever, Rash in infants 
Human 
Human Infectious mono -nucleosis, 
Burkitt's lymphoma, 
Nasopharyngeal carcinoma, 




Squirrel Fatal lymphoproliferative 
monkey disease in cotton tail rabbit & 
new world monkeys e.g. 
marmosets 
Human Kaposi's sarcoma, Body 
cavity based lymphoma, 
Multicentric Castleman's 
disease 
? Respiratory illness 
? Conjunctivitis, mastitis 
Lymphomas 
Equine herpesvirus -2 Horse 
Bovine herpesvirus -4 Cattle 
Murine gamma- Wood 
herpesvirus -68 mouse 
Rhesus monkey Rhesus 
rhadinovirus monkey 
Herpesvirus aeteles Spider 
monkey 
Alcelaphine Wilde - 
herpesvirus-1 beest 
Ovine herpesvirus -2 Sheep 
Lymphoproliferative disease 
in immuno- suppressed host 
Lymphomas in new world 
primates 
Malignant catarrhal fever in 
cattle, deer and other 
ruminants 
Malignant catarrhal fever in 
cattle, deer and other 
ruminants 
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1.1.2.2 The Betaherpesviruses 
A large proportion of members in the Betaherpesvirus sub -family exhibit a 
restricted host range, long reproductive cycle and slow progression of infection in 
culture; infected cells often become enlarged (cytomegalia). Latency can be 
maintained in secretory glands, leukocytes, kidneys and other tissues. This sub- 
family contains the genera Cytomegalovirus (e.g. Human Cytomegalovirus, HCMV), 
Muromegalovirus (e.g. Murine Cytomegalovirus, MCMC) and Roseolovirus (e.g. 
Human Herpesvirus -6, HHV -6). 
1.1.2.3 The Gammaherpesviruses 
Unlike the other subfamilies, the members of the Gammaherpesvirinae are 
limited to the family or order to which the natural host belongs. Most members are 
able to replicate in vitro in lymphoblastoid cells, and some in epithelioid and 
fibroblastic cells. However viruses from this group are usually specific for either T 
or B- lymphocytes. Latent virus is commonly detectable in lymphoid tissue. There 
are two genera within this subfamily: Lymphocryptovirus (e.g. Epstein -Barr virus, 
EBV) and Rhadinovirus (e.g. Herpesvirus Saimiri, HVS, and Kaposi's Sarcoma - 
associated Herpesvirus, KSHV). 
1.1.3 Herpesvirus Genes 
The number of genes encoded by herpesviruses can vary from the smallest 
genome encoding 70, to the largest genome that encodes up to 200 genes. However, 
these numbers are likely to be underestimates due to alternative splicing, 
translational frameshifiting and the identification of new open reading frames 
(ORFs). Most herpesviruses transcripts are comprised of a single major ORF flanked 
by a 30 -300óp 5' and 10 -30bp 3' nontranslated sequence, a promoter /regulatory 
sequence upstream of a TATA box and a polyadenylation signal. The ORFs are 
typically located close to each other and often overlap, resulting in some regulatory 
sequences that are within the coding sequence of others. Transcription can occur in 
both directions with some ORFs being expressed that are situated entirely antisense 
to each other, such as HSV -1 7134.5 and ORFs P and O (Lagunoff and Roizman, 
1994). 
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The majority of herpesvirus genes are transcribed by RNA polymerase II and 
are not spliced. Nonetheless, every herpesvirus does have a small number of spliced 
genes, some of which are used to alter differential regulation of a gene during 
different stages of their life cycle. Some herpesviruses also encode noncoding 
RNAs, such as the EBERs of EBV and the tRNAs of the Murine Gammaherpesvirus - 
68 (MHV -68). 
There are approximately 26 core genes found to be conserved within all 
subgroups from the herpesvirus family (Chee and Barrell, 1990). The conserved 
genes typically encode proteins involved in structural roles, such as the tegument, 
capsid and envelope, however some are also involved in DNA replication and 
nucleotide metabolism. Each of these genes are located within one of seven core 
gene blocks, which are conserved at the subfamily level. Most herpesviruses also 
possesses at least one gene of host orgin, with gammaherpesviruses encoding more 
cellular homologues than the other subgroups (Davison, 2002). These genes and 
other conserved genes within a subfamily may all play important roles in the virus' 
ability to infect and establish latency at a variety of levels ranging from inhibiting 
apoptosis to inducing or inhibiting host cell DNA replication, or immortalizing the 
host cell. 
1.1.4 Herpesvirus Lifecycle 
Following infection of a cell, there are two distinct routes a herpesvirus can 
undertake: lytic or latent. The lytic phase involves productive replication of the virus 
and release of the progeny with the ultimate destruction of the host cell. Whereas, 
latent infection results in the maintenance of the viral genome in a circular episomal 
form within the nucleus with limited expression of viral genes. The virus can 
maintain the latent state for long periods with no generation of progeny; in dividing 
cells the circular episome is amplified to give multiple copies per cell that are 
partitioned into daughter cells during mitosis (Sugden et al., 1979). The viral 
genome retains the ability to undergo reactivation to a lytic form, usually triggered 
by a stimulus, however the precise mechanisms are not fully understood. 
The majority of research has been performed on the a- herpesvirus prototype, 
HSV -1, and since many replication genes are conserved between herpesviruses the 
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general mechanisms can be applied to other herpesviruses. Therefore the following 
descriptions of the lytic stages of herpesvirus lifecycle will be primarily based on 
HSV -1, as reviewed by Roizman and Knipe (2001) and Whitley (2001). A 
schematic diagram of the infectious lifecycle of HSV -1 is outlined in Figure 1.4. 
1.1.4.1 Lytic Replication 
Initiation of viral infection commences with the attachment of the virus via its 
glycoproteins and the cell surface receptor, which in turn triggers fusion of the viral 
envelope with the plasma membrane. In the case of HSV -1, there are multiple 
attachment pathways including the interaction of viral glycoproteins gC and gB with 
cell surface -associated heparan sulphates (Shieh et al., 1992). It is thought that the 
various pathways arose as a result of the different cell types that HSV -1 naturally 
infects (epithelial cells and neurons) and thus these receptors are partially responsible 
for determining tropism, pathogenicity and spread. Following the initial interaction, 
glycoprotein gD binds with one of several cellular co- receptors, including members 
of the tumour necrosis factor (TNF) receptor family and members of the 
immunoglobulin superfamily (IgSF) (Cocchi et al., 1998; Montgomery et al., 1996). 
The next stage is the fusion of the viral envelope with the host cell membrane, which 
is mediated by the viral glycoproteins gD, gB and gH /gL, a heterodimer. Most 
herpesviruses encode homologs to gB, gH and gL. 
In contrast, EBV infection of B lymphocytes is mediated by binding of the 
EBV glycoproteins gp350/220 with the cellular receptor CD21 (Fingeroth et al., 
1984). EBV encodes a homologue of HSV gB, termed gp110, however it is not 
thought to have a similar function, as it does not localise on the viral envelope or cell 
surface (Gong et al., 1987; Gong and Kieff, 1990). There are also homologues of 
gH (gp85) and gL (gp25) which form a complex; the gp85 /gp25 /gp42 complex is 
implicated in the penetration of EBV into the cell (Haddad and Hutt -Fletcher, 1989; 
Wang et al., 1988). 
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Figure 1.4 Lytic replication of HSV -1. 
(Full legend on following page) 
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Figure 1.4 Lytic replication of HSV -1. Infection of a cell is initiated by 
(1) the binding of the virion to the extracellular matrix via the interaction 
of gB and gC with heparin sulphate and then gD with a cellular co- 
receptor. This is followed by (2) fusion of the viral envelope with the 
host cell membrane and uncoating of the virus, releasing the 
nucleocapsid and tegument proteins such as; VP16 and virion shutoff 
factor (Vhs). (3) The viral nucleocapsid attaches to microtubules and is 
transported to the nucleus where it (4) docks to a nuclear pore and 
releases the viral DNA. (5) Once in the nucleus the viral DNA 
immediately circularises. (6) VP16 is also transported to the nucleus 
where it interacts with the host transcriptional components to stimulate 
transcription of the immediate -early or a genes. (7) The mRNA 
transcripts are spliced and transported to the cytoplasm where they are 
translated. (8) The immediate -early proteins (a proteins) are 
transported into the nucleus to activate transcription of the early genes 
((3 genes) and also regulate transcription of the immediate -early genes. 
(9) Early gene transcripts are also transported into the cytoplasm and 
translated. (10) The primary functions of the early proteins is DNA 
replication and production of substrates for DNA synthesis, and are 
present in both the cytoplasm and nucleus. (11) Viral DNA synthesis is 
initiated from viral origins of replication and produces long 
concatermeric DNA molecules. (12) Late or y gene transcripts are 
generated and translated in the cytoplasm. These proteins are 
primarily involved in structural roles and required for viral assembly and 
egress. (13) Some of the y proteins are involved in the formation of the 
virus envelope and are made on and inserted into the rough ER. These 
membrane proteins are modified by glycosylation and transported to 
the Golgi apparatus for further modification, and then to the plasma 
membrane of the infected cell. (14) The newly replicated viral DNA is 
packaged into the preformed capsids and (15) together with some 
tegument proteins, bud from the inner nuclear membrane into the ER, 
(16) acquiring an envelope containing precursors of viral envelope 
proteins. There are two schools of thought regarding the passage of the 
enveloped virus from the lumen of the ER to the cell surface; (17) 
luminal pathway, where enveloped viral particle is transported in a 
vesicle to the Golgi or (18) de- envelopment pathway, where the 
enveloped virus fuses with the ER from within, releasing the capsid that 
buds into the Golgi. (19) The enveloped virus is transported to the 
plasma membrane for release by exocytosis (20) into the extracellular 
space. 
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After fusion of HSV -1 to the cellular membrane, the virus is uncoated and the 
nucleocapsid is transported, by the microtubular network, to the nucleus where the 
viral DNA is released and immediately circularises (Mabit et al., 2002). Tegument 
proteins are also liberated at this stage and are involved in several functions. 
Tegument protein VP16 augments basal level expression of genes and trans -activates 
the transcription of the immediate -early (IE) or a- viral genes by host cell RNA 
polymerase II, this in turn causes a cascade of gene trancription. In addition, VP 16 is 
also an important structural protein of the virion (Whitley, 2001; Wysocka and Herr, 
2003) and is involved in viral egress (Mossman et al., 2000). The virion host shut- 
off (Vhs) protein causes non -specific degradation of mRNA and aids in determining 
levels and kinetics of viral and cellular gene expression. (Viral replication is 
relatively fast, approximately 8 hours, so is not as greatly affected by the destruction 
of mRNA compared to the host cell) (Everly et al., 2002; Feng et al., 2001). 
IE genes were originally described as genes whose expression occurs in the 
absence of de novo protein synthesis, and in HSV -1 there are five genes: encoding 
for ICPO, ICP4, ICP22, ICP27 and ICP47. These genes are transcribed in the 
nucleus, spliced and then translated in the cytoplasm. Early genes (ß genes) are 
differentiated from the IE genes by their requirement for protein synthesis for 
expression. ICP4 is involved in auto -regulation transcription of the early genes. The 
early genes are also translated in the cytoplasm and are involved in viral DNA 
replication, and include the major DNA binding protein (ICP8), thymidine kinase 
and DNA polymerase. The late genes, or y genes, are not expressed until after the 
early proteins are generated, and require DNA replication for their expression. Late 
proteins primarily comprise the majority of the viral structural proteins required for 
viral assembly and egress. In addition, the late proteins also act as a self -regulatory 
control by down regulating transcription of both the immediate -early and early viral 
genes. 
Replication of HSV -1 DNA requires seven gene products which include the 
viral DNA polymerase (UL30) and processivity factor (UL42), a single stranded DNA 
binding protein (UL29), an origin- binding protein (UL9), and a helicase -primase 
complex (UL5, UL8 and UL52). Homologues of all of these gene products, except the 
origin- binding protein, have been identified in all three herpesvirus subfamilies. 
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Viral DNA synthesis occurs by a rolling circle mechanism (Garber et al., 1993) that 
gives rise to head -to -tail concatamers of progeny viral DNA, which are cleaved into 
monomers. These monomers are then packaged into mature capsids within the 
nucleus (Deiss and Frenkel, 1986). Following encapsidation of viral DNA, the 
DNA -containing capsids transfer from the inner nuclear membrane into the lumen of 
the endoplasmic reticulum (ER) by budding. However, the subsequent route for viral 
envelopment and egress is not fully understood, with two proposed models. The 
luminal model, proposes that the enveloped virus in the ER is transported via 
exocytic vesicular transport to the Golgi where viral glycoproteins undergo final 
maturation, but the envelope has originated from the inner nuclear membrane. 
Vesicular movement to the cell surface then transports the mature virions to be 
released. The alternative theory is the de- envelopment model, in which the 
nucleocapsids lose their first envelope when fusing from the outer nuclear 
membrane -ER into the cytoplasm. The mature viral envelope is acquired when re- 
enveloped into the Golgi and then also trafficked by vesicular movement to the 
exterior of the cell. Several recent studies have found evidence to support the de- 
envelopment model. For example, the retention of the viral glycoproteins gH and gD 
in the ER prevents their incorporation into the viral envelope of the mature virions 
(Browne et al., 1996; Skepper et al., 2001; Whiteley et al., 1999). In addition, 
differential ultracentrifugation found enveloped virions within the Golgi but not 
within other cellular compartments (Harley et al., 2001). Ultrastructural studies have 
also suggested that this occurs with EBV as well as other alphaherpesviruses (Gong 
and Kieff, 1990; Granzow et al., 2001). 
1.2.1.2 Latency 
Latency can be described as a state when the viral genome is maintained 
intact and genetically identical to an infectious particle, but without the highly 
regulated gene- expression cycle cascade. The ability to establish latency is a 
characteristic of all herpesviruses studied to date and any transcription that does 
occur is usually drastically reduced. Latency can be described as having three 
phases: establishment, maintenance and reactivation. 
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Establishment entails the entry of the virus into the appropriate cell; while at 
the same time suppresses viral gene expression, so as not to arouse the normal 
cytopathic results generated during productive infection. Following this, viral 
genomes need to persist and provide a reservoir of potential infectious particles in the 
event of reactivation. This is not a big issue for viruses such as HSV -1, which 
establishes latency in sensory neurons, as they are non -replicating cells and the virus 
can remain entirely dormant; thus requiring minimal viral gene expression. On the 
other hand, EBV establishes latency in dividing lymphatic cells and most 
transcription activity that occurs is in relation to ensuring the maintenance of viral 
genomes in dividing cells, immune evasion and ensuring that the infected cells do 
not undergo apoptosis. 
Gene expression during latency is limited and not conserved across the 
subfamilies. As previously mentioned, HSV -1 latency could occur without gene 
expression, however there is production of a single transcript, termed the latency - 
associated transcript (LAT). The LAT mRNA is spliced and a number of small 
ORFs (O and P) have been detected (Lagunoff and Roizman, 1994). Studies on 
mutant viruses lacking LAT found increased levels of expression of the immediate - 
early, early and late genes when compared to the rescued or wild -type viruses 
(Garber et al., 1997), therefore suggesting that LAT may be down -regulating 
expression of the lytic gene expression cycle. This idea is still unclear as more 
recent findings by Burton et al. (2003) seem to suggest otherwise. It has been 
demonstrated that expression of just the first 1.5kb of the 8.3kb -LAT -gene is able to 
inhibit apoptosis and enhance spontaneous reactivation of the virus (Jin et al., 2003; 
Peng et al., 2003). Alternatively, VZV establishes latency in trigeminal and dorsal 
root ganglia, and at least five ORFs (4, 21, 29, 62, 63) are transcribed during latent 
infection (Cohrs et al., 1996; Kennedy et al., 1990). 
By comparison to the y- herpesviruses, the molecular basis of the a- and 13- 
herpesvirus latency is poorly understood. EBV latent gene expression involves the 
expression of several proteins and will be discussed further in the following section 
on EBV. 
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1.2 Gammaherpesviruses 
The Gammaherpesvirinae sub -family includes several important human and 
animal pathogens, many of which have been studied extensively due to their 
association with transformation and oncogenesis. There are two genera in this sub- 
family: the Lymphocrytovirus (LCV), also known as Gamma -1 -herpesvirus (y1), and 
the Rhadinovirus (RDV), also known as Gamma -2- herpesvirus (y2). EBV is the 
only human LCV, and KSHV is the only human RDV. Lymphocrytoviruses have 
only been identified in primate species, predominately in Old World primates, where 
many are endemic. More recently, new LCVs have been identified in New World 
primates, including the golden -handed tamarin, squirrel monkey and white -face saki 
(Cho et al., 2001; de Thoisy et al., 2003). The RDVs, on the other hand, are found in 
a range of species, including both primates and non -primates. 
In addition to being the etiological agent of human diseases, 
gammaherpesviruses are known to also cause fatal diseases in animals. Several 
animal viruses, such as Equine herpesvirus -2 (EHV -2), Bovine herpesvirus -4 
(BHV -4) and Alcelaphine herpesvirus -1 (AIHV -1) can cause a variety of diseases 
including, abortion, pneumonia, malignant catarrhal fever and even death. 
Understanding the pathogenesis of these viruses is not only beneficial to the farming 
of herd animals, zoos and game farms, but also human disease; primarily due to their 
use as animal models of human diseases. 
Gamma -1 -herpesvirus 
1.2.1 Epstein -Barr Virus 
The Epstein -Barr virus (EBV) is the prototypic Lymphocryptovirus, 
discovered in 1964 by Epstein, Achong and Barr from a lymphoblastoid cell line 
derived from an endemic Burkitt's lymphoma biopsy (Epstein et al., 1965). EBV is 
ubiquitous in the human population, with over 90% of adults sero -positive for the 
virus. Like other gammaherpesviruses, EBV, has a restricted host range; humans are 
the natural host. Primary infection usually occurs in early childhood, resulting in an 
asymptomatic infection. However, when primary infection does not occur until 
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nearing adulthood a self -limiting lymphoproliferative illness, infectious 
mononucleosis (IM), can be the outcome. EBV is also associated with several 
tumours including Burkitt's lymphoma, nasopharyngeal carcinoma, post transplant 
lymphoproliferative disease, Hodgkin's disease and oral hairy leukoplakia, some of 
which will be discussed later in this chapter. 
1.2.1.1 The EBV Genome 
The EBV genome is a linear, double- stranded, 184 kbp DNA molecule, with 
0.5kb reiterated repeats at both termini and several internal repeats. In 1984, the 
EBV genome was the first herpesvirus to be fully sequenced (Baer et al., 1984), 
however the strain initially used had a 12kb deletion, which was later determined 
from another strain (Parker et al., 1990). 
1.2.1.2 EBV Infection 
The most common route of transmission of EBV is from the intermittent 
shedding of virus in saliva from EBV positive adults. EBV can infect primary B 
lymphocytes in vitro, resulting in the conversion of cells into continuous 
proliferation long term lymphoblastoid cell lines (LCLs). Viral replication in LCLs 
is minimal, with only a small number of cells spontaneously undergoing lytic 
replication. There is no in vitro system available that is fully permissive for EBV 
replication. EBV replication can be induced in some semi -permissive LCLs or 
Burkitt's lymphoma (BL) cell lines, following treatment with a phorbol ester, TPA 
(12- Qtetradecanolyphorbol -13- acetate), to allow studies on lytic infection. EBV can 
also establish latent infection in other cell types, including T cell or natural killer 
(NK) cells, however the efficiency is low (Kanegane et al., 1998; Shapiro et al., 
1982). 
As briefly mentioned earlier, EBV initiates infection by the interaction of the 
most abundant viral surface protein, gp350/220, with CD21: the cell surface receptor 
for the C3d component of complement. Following this, the gp85 (gH)/ gp 25 (gL) 
and gp42 complex is involved in mediating the co- receptor interaction of gp42 with 
human leukocyte antigen (HLA) Class II molecules, expressed on the surface of B- 
lymphocytes. However, studies have indicated that gp42 is not utilised in this 
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manner for infection of epithelial cells, as these cells do not express HLA Class II, 
whereas, gp42 is essential for efficient B- lymphocyte infection (Molesworth et al., 
2000; Wang et al., 1998b). 
EBV infection in its natural host is most often found in its latent phase, 
however in order to spread and infect new hosts the virus must reactivate and 
produce infectious virions. This switch from latent to lytic replication is as yet 
uncharacterised; it is associated with the expression of two immediate -early viral 
genes, BZLF1 and BRLF1, producing ZEBRA and Rta, respectively. Production of 
ZEBRA and or Rta triggers expression of the other IE factors and can act 
individually or in synergy on downstream targets to activate a cascade of events in 
the lytic cycle (Ragoczy et al., 1998). 
1.2.1.3 Latent infection of EBV 
The majority of studies on herpesvirus latency have been focused on EBV 
and its ability to establish latent infection in B- lymphocytes in vitro. During latency, 
EBV can only express a limited number of genes that include; six EBV nuclear 
antigens (EBNA) 1 -6, two latent membrane proteins (LMP), two small non - 
polyadenylated RNAs (or EBERs) and highly spliced BamA rightward transcripts 
(BARTs). Due to the complexity of EBV latency, and based on differential latent 
gene expression in EBV positive tumours and immortalized B -cell lines in vitro, 
EBV latency has been grouped into three types; Latency I, II and III (see Figure 1.5). 
Latency I phenotype is displayed in Burkitt's lymphoma (BL) cells; these are 
characterised by the limited expression of EBNA -1, EBERs and BARTs. Hodgkin's 
lymphomas and NPC cells exhibit a transcription pattern described as Latency II, 
where EBNA1, EBERs and the latent membrane proteins, LMP1 and LMP2, are 
expressed. In contrast, Latency III, also described as the growth program, involves 
expression of all the major latent transcripts (EBNA 1 -6, LMP1, LMP2, EBERs and 
BARTs). Latent infection in immortalised LCLs in vitro, and immunoblastic 
lymphomas in transplant recipients displays this Latency III phenotype. The reasons 
for these different types of latency in EBV infection are still not fully understood, 
however, it is thought that EBV utilises these different latency programs in order to 
manipulate the normal biology of B- lymphocytes to gain access to and remain 
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quiescent within the long -lived memory B -cell compartment. It has been proposed 
that latency III is essential for the establishment of EBV, as it allows the latently 
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Figure 1.5 Patterns of disease association and EBV latent gene 
expression in normal EBV infection and during Latency I, Il and 
Ill. EBERs, EBV encoded small RNAs; EBNA, EBV nuclear antigens; 
LP, leader protein; LMP, latent membrane protein. *Denotes this is 
the postulated phenotype of latency infected B cells in a normal EBV 
seropositive individual. It is unclear whether EBNA1 is consistently 
expressed (Tierney et al., 1994). 
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1.2.1.3.1 EBV Latent Genes 
EBV Nuclear Antigens (EBNAs) 
The Wp promoter is utilised for transcription of the first EBV mRNAs, which 
are differentially spliced to encode EBNA -LP and EBNA -2. These two proteins up- 
regulate transcription from both viral and cellular promoters, including Wp and Cp, 
an activatible upstream surrogate promoter (Evans et al., 1996; Woisetschlaeger et 
al., 1991). For instance, EBNA -2 up- regulates the cellular encoded genes for CD23, 
CD21, c-fgr and c -myc, and viral genes for the other EBNAs, LMP1 and LMP2. 
EBNA -LP has been found to enhance EBNA -2 up- regulation of viral and cellular 
gene transcription (Harada and Kieff, 1997). EBNA -LP has also been demonstrated 
to be important for efficient growth of LCLs, as cells infected with EBNA -LP 
mutants display a reduced transformation phenotype (Mannick et al., 1991). 
The EBNA -1 protein is present in all EBV infected cells, regardless of the 
state of infection. EBNA -1 mediates binding of the EBV genome to the host 
chromosome via the oriP or latent origin of replication, and thus aids in replication 
and maintenance or the viral genome. Previous studies have found that the unique 
glycine -alanine repeat in EBNA -1, acts as a cis -inhibitory signal for proteasomal 
degradation, which in turn blocks endogenous presentation of CTL epitopes within 
these EBV infected cells (Levitskaya et al., 1997). EBNA -3A, 3B and 3C are 
successively placed in the genome and are transcriptional regulators. They all have 
the ability to bind and stably associate with RBP -Jk, and by competing for the site 
with EBNA -2, are able to limit the function of EBNA -2. EBNA -3A and EBNA -3C 
are essential for B -cell growth transformation; however, in vitro studies have found 
this not to be the case with EBNA -3B, which is dispensable (Thomkinson and Kieff, 
1992). 
Latent Membrane Proteins (LMP) 
The first ORF of EBV encodes an important transforming protein, LMP l . 
LMP 1 has been shown to have to ability to transform rodent fibroblasts and is 
essential for immortalisation of primary B- lymphocytes to a lymphoblastoid cell line 
(Wang et al., 1985, 1998a). LMP1 has been demonstrated to mimic the B- 
lymphocyte activation antigen CD40, a member of the TNF receptor family 
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(Hatzivassiliou et al., 1998; Kilger et al., 1998). The LMP1 protein has six 
transmembrane domains and a 199 amino acid carboxy terminal cytoplasmic tail, 
which causes multimerization, the property that mimics ligand- induced CD40 
receptor aggregation. This generates a constitutively active signal and a cascade of 
events including the activation of NF -KB and JNK, and induction of bcl -2, bclx, mcll 
and A20 gene expression (Damania et al., 2000). 
Two forms of LMP2 are expressed, LMP2A and LMP2B, which are both 
similar in structure; twelve transmembrane domains linked by loops and a short 
cytoplasmic C- terminus. LMP2A possesses an additional 119 amino acid 
cytoplasmic N- terminus, which when phosphorylated associates with the SH2 
domain of the Lyn, Fyn, Syk, and Csk kinases, aiding in intracellular calcium 
mobilisation and cytokine production (Burkhardt et al., 1992; Longnecker et al., 
1991; Scholle et al., 1999). Although LMP2A is not an essential protein, it is 
involved in preventing reactivation to a lytic state, and thus plays a critical role in 
establishment and maintenance of latent infection. It has been suggested that 
LMP2B may be involved in regulation of LMP2A (Longnecker, 2000). 
EBV- encoded RNAs (EBERs) 
There are two non -translated RNAs encoded by EBV during latency; these 
are also the most abundant RNAs present. EBER -1 is transcribed by RNA 
polymerase III and II, whereas, EBER -2 is only transcribed by RNA polymerase III. 
Recent studies have found that EBERs can induce the secretion of IL -10, which 
might stimulate growth of infected B cells and suppress cytotoxic T cells (Kitagawa 
et al., 2000). It also appears that the EBERs are able to mediate resistance to 
interferon -a- induced apoptosis in Burkitt's lymphoma cells (Nanbo et al., 2002). 
Other studies have also suggested that expression of the EBERs may increase the 
tumorigenicity of Burkitt's lymphoma (Komano et al., 1998, 1999). 
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1.2.1.4 EBV- associated Diseases 
EBV infection is associated with a variety of diseases in immunocompotent 
individuals, such as infectious mononucleosis (IM), Burkitt's lymphoma (BL), 
nasopharyngeal carcinoma and Hodgkin's disease. However, EBV infection in 
immunosupressed individuals can also result in severe illnesses, including post - 
transplant lymphoproliferative disease (PTLD). 
1.2.1.4.1 Infectious Mononucleosis 
In more affluent societies, primary infection of EBV is often delayed until 
adolescence or adulthood, and is commonly associated with IM, also know as the 
"kissing disease" due to its route of transmission. IM symptoms can range from mild 
transient fever to several weeks of pharyngitis, lymphadenopathy, splenomegaly, 
hepatocellular dysfunction and general malaise. However, these disease symptoms 
are unlikely to be the direct result of viral replication; IM is believed to be an 
immunopathologic disease in which the symptoms are the result of pro -inflammatory 
cytokines, such as IL -1, IFN -y and TNF -a. High levels of these pro -inflammatory 
cytokines are secreted by the large numbers of T- lymphocytes infiltrating various 
tissues throughout the body during IM (Niedobitek et al., 1997; Verbeke et al., 
2000). IM is self -limiting and in most cases does not develop complications 
although, prolonged fatigue, hypersomnia and short-lived depressive disorder may 
occur after IM (Macsween and Crawford, 2003). 
1.2.1.4.2 Burkitt's Lymphoma 
Burkitt's Lymphoma (BL) was first described in children in equatorial Africa 
and New Guinea (Burkitt, 1962). In this endemic form of BL over 97% of cases are 
EBV positive, while the more rare sporadic form has only a 20 -30% association with 
EBV. There is a third form, AIDS -associated BL, which has a higher incidence of 
BL than the endemic or sporadic BL of childhood; 30 -40% of tumours from this 
group are EBV positive. BL malignancies are commonly presented at extranodal 
sites, most frequently in the jaw, but have also been found in the CNS and the 
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abdomen. In the absence of treatment, BL tumours can grow quickly and can result 
in death within several months. 
All BL tumours display the same homogenous population of malignant cells 
that are morphologically similar to germinal centre B cells. Chromosomal 
translocations are present in BL cells where the c -myc oncogene on chromosome 8 is 
brought under the influence of the IgH enhancer on chromosome 14, or more rarely 
by the light -chain loci on chromosomes 2 or 22. This chromosomal translocation 
results in the constitutive expression of c -myc and uncontrolled cell proliferation. 
Mutations in the gene encoding the tumour suppressor p53 have also been detected in 
about a third of cases of BL (Gaidano et al., 1997). Viral gene expression in BL cells 
is restricted to the pattern seen in type I latency; in addition to the EBERs and 
BARTs, only EBNA -1 is expressed. As previously mentioned the EBERs may play 
an important role in this tumour and it has recently been reported that EBER 
expression may be positively regulated by c -myc (Niller et al., 2003). 
1.2.1.4.3 Nasopharyngeal Carcinoma 
Nasopharyngeal carcinoma (NPC) is a tumour derived from the epithelium of 
the nasopharyngeal surface and is seen throughout the world but varies in incidence 
and histological subtype. There are two classifications of NPC; those that are 
classified as keratinised have observable epithelial differentiation, whereas the non - 
keratinised NPC have undifferentiated epithelial cells. NPC has a high incidence 
among people from Southern China and Inuit races, where most tumours are of the 
non -keratinised type and preferentially affect middle aged men. Sporadic cases of 
both classes of NPC are seen in Europe and North America but these numbers are 
small in comparison to those seen in Southeast Asia. EBV has been identified in all 
cases of non -keratinised NPC and most cases of keratinised NPC in Southeast Asia, 
and approximately 30% of this class of tumours from Europe (Nicholls et al., 1997). 
NPC cells are believed to exhibit a latency II phenotype (see Figure 1.5), 
however LMP1 detection is variable and LMP2 protein expression has not been 
unequivocally demonstrated. Studies have also indicated that there are several co- 
factors that may have an impact on the pathogenesis of the disease and geographic 
distribution, such as genetic susceptibility (Lu et al., 1990). Environmental factors 
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such as diet have also been indicated; consumption of traditional salt fish dishes that 
contain carcinogenic nitrosamines and herbal remedies containing tumour -promoting 
phorbol esters have been implicated as risk factors (Armstrong et al., 1998; 
Hirayama and Ito, 1981; Zou et al., 1994). Thus a number of environmental factors, 
dictated by diet or lifestyle, and a genetic predisposition may all contribute to NPC. 
1.2.1.4.4 Post -transplant Lymphoproliferative Disease 
Post -transplant lymphoproliferative disease (PTLD) is a life -threatening 
complication associated with organ transplantation and the treatment with 
immunosuppressive drugs to prevent graft rejection. EBV has been etiologically 
associated with PTLD by virtue of its presence in the majority of PTLD lesions. 
PTLD often develops in sites considered unusual for other lymphomas, such as the 
G.I. tract, CNS or the transplant organ (Penn and Porat, 1995; Thomas et al., 1990). 
The incidence of PTLD is variable ranging from 1% to over 20 %, which is primarily 
due to EBV status prior to the transplant and the type of organ transplanted; levels of 
immunosuppressive drugs vary depending on the organ e.g. heart and lung 
transplants require a higher dose than renal or liver transplants (Rickinson and Kieff, 
2001). Over 50% of these cases are associated with primary EBV infection and the 
disease is understandably seen to be of higher risk to paediatric transplant recipients 
(Ho et al., 1985). 
PTLD arises as an opportunistic tumour in an environment where there is 
intense T -cell immune suppression, thus allowing the latently infected B -cells to 
survive and proliferate. Early lesions are often polyclonal, however later progress to 
a monoclonal lymphoma. EBV infected cells within the lymphomas exhibit a type 
III latency, as characterised by expression of all the latent proteins (Tanner and 
Alfieri, 2001). However, these EBV positive cells are only a small proportion of the 
cells within the tumour mass; CD4+ T cells make up the majority of cells and studies 
have found these cells necessary for the establishment of tumours (Veronese et al., 
1992). Tumour regression is often observed following the reduction of 
immunosuppressive therapy, which allows re- establishment of EBV -specific T -cell 
immunity, however this also risks rejection of the transplanted organ and PTLD often 
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recurs (Macsween and Crawford, 2003). More recently, adoptive immunotherapy 
has been utilised, whereby the use of cultured EBV specific CTLs has been used with 
some success, and in turn avoids the risk of graft rejection (Hague et al., 2002; 
Rooney et al., 1998). 
1.2.1.4.5 Hodgkin's Disease 
Hodgkin's lymphomas (HL) are characterised by Hodgkin and Reed - 
Sternberg (H -RS) cells and in most cases, derived from germinal -B cells. The 
precise mechanism of EBV involvement is unclear, but there are several factors that 
suggest that EBV has a causative role in the pathogenesis of this disease. It was first 
noticed that antibody titres against EBV were elevated for months or years before the 
onset of the disease, in addition the incidence of developing HL increases three -fold 
in individuals with a previous history of IM (Mueller et al., 1989). Furthermore, 
EBV DNA has been detected in over 50% of Hodgkin's disease tumours. 
In HL the expression pattern of EBV- encoded genes is limited to type II 
latency, and resembles that seen in endemic NPC. It is possible that the expression 
of the LMPs results in the activation of the NF -KB pathway and consecutive up- 
regulation of anti -apoptotic genes, thus allowing the pre -apoptotic H -RS cell - 
progenitors to survive negative selection in the germinal centre. However, as only 
50% of cases are EBV -positive, it is highly likely that there are other agents or 
events that aid in the malignant transformation seen in the EBV- negative cases 
(Thomas et al., 2004). As seen with current immunotherapy treatment for PTLD, 
several pilot studies are underway to assess the potential use of CTL therapy for 
Hodgkin's disease (Chapman et al., 2001; Roskrow et al., 1998; Su el al., 2001). 
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1.3 Animal Gammaherpesviruses 
There are several important reasons for studying animal gammaherpesviruses 
particularly due to the large degree of homology between the human and animal 
viruses from this subgroup. Understanding genome arrangement and disease 
pathogenesis due to animal herpesviruses infection may give an insight into 
mechanisms that are utilised by some of the human herpesviruses such as EBV and 
KSHV. As previously mentioned both EBV and KSHV have an extremely restricted 
host range in vivo which has hindered studies of pathogenesis and an even greater 
reason for the utilisation of animal models. 
1.3.1 Herpesvirus Saimiri 
Herpesvirus Saimiri (HVS) is the classical prototype of the Rhadinoviruses 
and is ubiquitous in its natural host, the squirrel monkey (Saimiri sciureus). HVS 
infection is asymptomatic and establishes lifelong persistence in this species, 
whereas experimental infection of other New World primates can result in acute 
peripheral T -cell lymphomas (Fickenscher and Fleckenstein, 2001). Lymphoblastoid 
cell lines have been established from tumours from New World primates such as the 
marmoset and owl monkey. In contrast to EBV and KSHV, HVS replicates 
productively in vitro and is able to immortalise both monkey and human T -cells 
(Biesinger et al., 1992). Transformed human T cells harbour HVS but do not release 
infectious virus, the viral genome remains exclusively in an episomal state that does 
not integrate into the cellular genome (Fickenscher et al., 1996). It is due to these 
features that HVS has been recently viewed as a potential gene therapy vector and 
studied by several groups (Smith et al., 2001; Stevenson et al., 2000). 
The HVS genome is comprised of a 112.9kb unique region flanked at either 
end with 1.4kb terminal repeat sequences (Figure 1.6). There are 76 major ORFs and 
a set of seven U -RNA genes (Albrecht et al., 1992). Like other viruses in the 
herpesvirus family, HVS contains gene blocks with highly conserved genes but also 
unique blocks possessing the transforming oncogenes and genes with cellular 
homology. Many of the cellular homologues are similar to those found in KSHV and 
































































































































































































































































































































































CHAPTER CANE IN ï ROOl_IC I ICON 
and vbcl -2. Studies have found that although the HVS ORF73 has only limited 
sequence homology with LANA of KSHV, it may function in a similar manner. It 
has recently been determined that HVS ORF73 is required for episomal maintenance 
and is able to regulate viral gene expression to suppress lytic replication in 
permissive cells (Calderwood et al., 2004; Schafer et al., 2003). Another similarity 
with KSHV may be the gene expression pattern during latency, as studies using a 
human lung carcinoma cell line containing episomal HVS DNA showed latent 
expression of ORFs 71, 72 and 73, which correspond to the v -FLIP, v -cyc and 
LANA homologues respectively (Hall et al., 2000). 
HVS isolates are divided into three subgroups A, B and C, based on sequence 
divergence at the left end of the unique region of the genome and pathogenic 
properties (Medveczky et al., 1989, 1984). Subgroups A and C are highly oncogenic 
and in vivo infection can result in the formation of lymphomas, however only 
subgroup C is able to transform human T cells in vitro (Biesinger et al., 1992). All 
three subgroups possess an ORF encoding a saimiri transformation -associated 
protein (STP), although only subgroup C also encodes Tip (tyrosine kinase 
interacting protein); STP and Tip are transcribed from a biscistronic mRNA 
(Fickenscher et al., 1996). Subgroup B contains a non -transforming STP gene, STP - 
B (Choi et al., 2000a). It has been reported that STP -C interacts with cellular ras, 
and that in the lesser pathogenic subgroup A, STP -A interacts with cellular src 
kinase (Jung et al., 1991; Jung and Desrosiers, 1995). All STPs and Tip are essential 
for transformation in cell culture and in vivo, however they are dispensable for both 
in vitro and in vivo replication (Duboise et al., 1998). 
The use of HVS as a model to study herpesvirus pathogenesis has several 
advantages given the amount of homology with other herpesviruses and that the virus 
is able to replicate and transform cells in vitro. However, studies in vivo do pose 
several limitations, primarily those of cost and the restrictions on primate research. 
Another animal model allows the utilisation of a natural gammaherpesvirus infection 
within laboratory mice; this model allows viral pathogenesis in vivo to be studied 
without many of the prohibitive aspects associated with primate research. 
Furthermore, with the ability to generate transgenic mice, the host immune system 
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can be manipulated in such a manner to allow studies to be performed that focus on 
the effects of individual viral genes on pathogenesis. 
1.3.2 Murine Gammaherpesviruses 
In 1980 during a field study in Slovakia five novel herpesviruses were 
isolated from murid hosts including MHV -60, -68 and -72 from the bank vole 
(Clethrionomys glareolus) and MHV -76 and -78 from the yellow- necked wood 
mouse (Apodemus flavicollis) (Blaskovic et al., 1980). 
1.3.2.1 MHV -68 and MHV -76 
In the past a large amount of research has focused on MI-IV-68 due to its use 
as a model for gammaherpesvirus infection in a natural host species. Following the 
isolation of MHV -68 it was shown to be genetically related to other viruses in the 
Rhadinovirus subgroup, such as EBV and HVS (Efstathiou et al., 1990a). The 
MHV -68 genome consists of 118kbp of unique DNA flanked at each end by variable 
numbers of 1.23kbp terminal repeat regions. Sequencing of the genome has 
identified 73 protein- coding ORFs and 8 tRNA -like molecules (Figure 1.6) 
(Efstathiou et al., 1990b; Virgin et al., 1997). A more recent study on MHV -76 has 
shown this virus to be a deletion mutant of MHV -68. The genome of MHV -76 is 
essentially identical to that of MHV -68, except for a 9,538óp deletion at the left -hand 
end of the genome resulting in the loss of four unique genes of MHV -68 (M1, M2, 
M3 and M4) and the eight viral tRNA -like genes (vtRNAs) (Macrae et al., 2001). 
The majority of ORFs in both viruses are co- linear and homologous to regions in 
other y- herpesviruses (Figure 1.6). It is therefore not surprising to find that MHV -68 
and MHV -76 possess several functional homologues of cellular genes including bcl- 
2 (M11), G- protein -coupled receptor (GPCR) (ORF 74), cyclin D (ORF 72) and a 
complement - regulatory protein (ORF 4). 
During lytic infection there is a conventional cascade of gene expression, 
immediate early genes such as ORF 50 (Rta) and ORF 73 (LANA homologue), early 
genes such as Thymidine kinase (ORF 21) and late genes such as gp150 have been 
identified (Ebrahimi et al., 2003). The glycoprotein gp150 may play an equivalent 
role to gp350/220 of EBV, as in addition to sequence homology, antibodies to this 
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protein neutralise virus infectivity in the absence of complement; thus suggesting a 
potential role in binding or penetration (Stewart et al., 1996). Gp150 is located on 
the surface of the virion and in infected cells localises to the nuclear margins, in the 
cytoplasm and on the cell surface. 
The pattern of viral gene expression during infection in the lung differs 
remarkably to that seen during infection of the spleen, i.e. lytic versus latent 
infection. As the virus enters the latent phase of infection, gene expression is 
progressively shut down, however, the expression pattern can vary depending on the 
cell type. For instance, M2 expression is only detected in B cells in the spleen and 
not in splenic macrophage or dendritic cells, which also harbour latent virus (Macrae 
et al., 2003). ORF 73 encodes a protein that shares homology with KSHV LANA 
and is found to be the most abundant expressed viral transcript in latently infected 
S1l cells (Martinez -Guzman et al., 2003). Studies have shown that ORF 73 is 
critical for the establishment of splenic latency (Moorman et al., 2003). Induced 
mutations in other latency- associated proteins encoded by ORF 74, a GPCR 
homologue, and M11, a viral bc1-2 homologue, have both displayed a decreased 
ability to reactivate from latency (Gangappa et al., 2002; Lee et al., 2003; Verzijl et 
al., 2004). Expression of some of these latent proteins, such as ORF73, ORF 74 and 
M 11 have been detected in the lung 100 days post -infection (Nash et al., 2001; Roy 
et al., 2000); thus also suggesting the respiratory tract as a site of persistent infection. 
1.3.2.2 Pathogenesis 
The natural route of infection is still unclear, however by analogy with other 
animal 7- herpesviruses it seems likely that the respiratory tract is the primary target. 
Studies have shown that following intranasal infection of four- to six- week old 
laboratory mice, MHV -68 results in productive infection in alveolar epithelial cells 
and is accompanied by bronchiolitis (Sunil- Chandra et al., 1992). An inflammatory 
response initially comprised of macrophage is seen to peak at approximately 3 days 
post- infection (p.i.), which is then followed by a CD8+ T cell response peaking at day 
7 and finally resolves by the second week. The virus is then transported via the 
mediastinal lymph node (MLN) where dendritic cells, macrophages and B cells 
become infected. It is believed that these infected dendritic cells are initially 
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responsible for transporting the virus to the draining lymph node where they seed B 
cells (Selvarajah, 2001). 
Following infection of the lymph node, B cells undergo a rapid expansion 
that is accompanied by an increase in the number of latently infected B cells, which 
traffic to the spleen and other lymphoid compartments. Due to the influx and rapid 
expansion of latently infected B cells in the spleen, splenomegaly (mononucleosis) is 
commonly observed. Latent viral levels peak at approximately two weeks post 
infection and then reduce to levels of about 1 infective centre per 5x105 splenocytes 
to 1 infective centre per 106 splenocytes after 3 to 4 weeks, and maintain this 
established level of latency for life (Usherwood et al., 1996). Studies have suggested 
that long term latency is preferentially established in CD40( +) memory B cells (Kim 
et al., 2003). However, in addition to splenic B cells, latent virus has also been 
found to persist in splenic macrophage and dendritic cells and in lung epithelial cells 
(Flano et al., 2003; Stewart et al., 1998). Long -term infection of BALB /c mice with 
MHV -68 can lead to the development of lymphoproliferative diseases (LPD), similar 
to that observed with EBV infection. Over a period of 3 years 9% of mice develop 
LPD, with over 50% of these being categorised as high grade; the frequency 
increases following treatment with immunosuppressive agents (Sunil- Chandra et al., 
1994). 
Like MHV -68, it is believed that MHV -76 also follows the same course of 
infection after the intranasal infection of inbred laboratory mice, as depicted in 
Figure 1.7. Studies by Macrae et al. (2001) have observed that MHV -76 has a more 
attenuated pathology than MHV -68. A more severe and rapid inflammatory 
response occurs following infection of the lung with MHV -76; viral levels peak at 
day 4 p.i. and are undetectable by day 10 p.i., whereas MHV -68 infection sees a peak 
at day 6 p.i. and clearance by day 12 p.i. MHV -76 also establishes latency in the 
spleen, although at a lower level than MHV -68, but MHV -76 does not induce 
splenomegaly. These in vivo differences observed between the two viruses imply 
that the absent genes (M1 -M4 and 8 vtRNAs) play a role in pathogenicity, but are 
not required for lytic replication or the establishment of latency. 
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Figure 1.7 Schematic representation of key events during MHV -76 
infection in vivo following intranasal infection. Image (A) depicts 
the predominant organs involved during infection and (B) outlines the 
viral load. Initial lytic replication occurs in the lung and peaks at about 
4 days post infection (p.i.)(red line shows viral titers in the lung (B)). 
Infectious virus is cleared to undetectable levels by 10 days p.i. This is 
followed by seeding to lymphoid tissue by macrophage (MO) and 
dendritic cells (DC), followed by amplification of latent virus and further 
dissemination, predominantly by latently infected memory B cells and 
possibly by MO. A peak of latent virus is observed at day 10 and is 
followed by a gradual decrease to a persistent low level of latent virus 
in the spleen (indicated by green line). 
32 
CHAPTER ONE INTRODUCTION 
Both MHV -68 and MHV -76 are able to infect fibroblast and epithelial cell 
lines from a number of species in vitro and establish lytic and latent infection in vivo 
making them an ideal system for the study of y- herpesvirus replication, pathogenesis 
and virus -host interaction (Simas and Efstathiou, 1998). The ability to study these 
viruses both in vitro and in vivo has many benefits that will ultimately lead to a better 
understanding of gammaherpesviruses. 
These viruses, like others, may be manipulated to allow an individual gene to 
be investigated by the creation of knock -out or knock -in viruses. Both MHV -68 and 
MHV -76 have recently been used in this manner, enabling the function of a gene to 
be studied in cell lines and also infection in mice (Clambey et al., 2000; Macrae et 
al., 2003; Townsley et al., 2004). 
1.4 Kaposi's Sarcoma -associated Herpesvirus 
KSHV, also known as Human Herpesvirus -8 (HHV -8), is the most recent 
human herpesvirus to be identified and is believed to be the etiological agent of 
Kaposi's Sarcoma (KS). However, KSHV is also closely associated with primary 
effusion lymphomas (PEL) and some forms of Multicentric Castleman's Disease 
(MCD). Unlike most herpesviruses, KSHV is not ubiquitous in the general 
population; only a small number of people are infected with KSHV in developed 
countries, whereas in some areas of Africa a large proportion of the population 
display serological evidence of exposure to the virus (Moore and Chang, 2001). 
Prior to the AIDS epidemic, cases of KS were rare and strictly associated to 
geographic clusters within the Mediterranean and Eastern Europe. However, the 
tumour's unusual epidemiological pattern (increased number and broader geographic 
spread) in the 1980's spurred researchers belief that an infectious agent was an 
etiological factor contributing to the onset of KS. This research lead to the 
identification of a new herpesvirus, KSHV. In 1994 Chang and Moore's group 
(1994) initially identified herpes -like sequence in an AIDS -associated KS lesion 
using representational difference analysis. 
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Although information on the epidemiological transmission of KSHV is 
limited, there is speculation that there are two main modes of viral transmission, 
sexual and non -sexual. In developed countries, sexual transmission is thought to be 
the most common route of infection as KSHV has been detected in semen 
(Blackbourn and Levy, 1997). Virion particles have also been detected in saliva; this 
may be a possible route of transmission in endemic African areas where infection can 
occur in childhood (Pauk et al., 2000; Vieira et al., 1997). Vertical transmission, 
from mother to child, of KSHV has also been observed in parts of Africa (Mayama et 
al., 1998; Sitas et al., 1999), however, these non -sexual routes of transmission in 
endemic areas are still not fully understood. Finally, KSHV can be transmitted 
iatrogenically via organ transplantation. Transmission from blood products is 
uncommon (Moore and Chang, 2001). 
1.4.1 Disease Associations 
1.4.1.1 Kaposi's Sarcoma 
Kaposi's Sarcoma (KS) is a mesenchymal tumour, involving blood and 
lymphatic vessels that often presents as purple- reddish -brown lesions and nodules on 
the lower extremities. KS was first described in the 1870's by an Austro- Hungarian 
dermatologist, Moritz Kaposi, where he described an "idiopathic multiple pigment 
skin sarcoma" seen on the lower extremities in elderly men (Kaposi, 1872). One 
patient described died of gastrointestinal (G.I.) bleeding 15 months after the initial 
appearance of the skin lesions and an autopsy showed visceral lesions in the lung and 
G.I. tract. This form of KS is now known as "classical" KS; since this first 
description there have been four clinical variants of KS that are histologically 
identical but are distinguished by epidemiology factors and disease severity (Hengge 
et al., 2002b). 
(i) Classical KS - This form of KS is characterised by benign, indolent 
tumours often limited to the extremities of elderly white males that are of 
Ashkenazi Jewish or Mediterranean descent. Classic KS rarely 
metastasises and is not considered to be fatal. 
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(ii) Endemic African KS - This form was first described in the 1960's when it 
was noted that an unusually high prevalence of KS was occurring in 
localised areas throughout sub -Saharan Africa. In this population, KS is 
not only seen in adult men and women, but also children; it is a more 
aggressive form of KS and can be fatal in children particularly when there 
is lymph node involvement. 
(iii) Iatrogenic KS - This form of KS is seen in iatrogenic immunosupressed 
organ transplant recipients and in patients that are on immunosuppressive 
drugs. The development of KS is due to either primary infection with 
KSHV or reactivation of latent virus. Disease onset is often chronic and 
rapidly progressive but withdrawal of the immunosuppressive drugs 
usually results in spontaneous remission. 
(iv) AIDS -associated KS - This is the best -known form of KS and is estimated 
to be 300 times more common in AIDS patients than other 
immunosupressed groups and 20,000 times more common than in the 
general population. AIDS -KS is an aggressive and quick onset form, and 
the transmission route of HIV seems to influence the risk of KS 
development; homosexual men are at much greater risk than men with 
haemophilia (21:1). KS lesions were the first clinical manifestation in 
about one quarter of AIDS patients prior to the introduction of HAART 
(highly active anti -retroviral therapy); since then the incidence of AIDS - 
KS in the western world has become uncommon. However, it is still a 
major opportunistic infection in AIDS patients from developing countries. 
KS growth is stimulated by various proinflammatory cytokines and growth 
factors such as tumour necrosis factor -a (TNF -a), interleukin -6 (IL -6), basic 
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), 
aiding in the formation of a hyperblastic polyclonal lesion. It has been demonstrated 
that several KS cells also express some of the corresponding receptors with high 
affinities for several of these cytokines; both the cytokines and their receptors 
enhance inflammation and angiogenesis in an autocrine manner (Arvanitakis et al., 
1997; Hengge et al., 2002a; Mesri, 1999; Nicholas et al., 1997). These lesions are 
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complex and comprised of a variety of cell types. Early lesions contain irregular 
endothelial lined spaces that surround normal dermal blood vessels, which are also 
accompanied by a variable inflammatory infiltrate. At the later nodular stage, the 
lesions are predominately made -up of spindle cells and slit -like vascular spaces 
containing erythrocytes. The spindle cells are believed to be the neoplastic 
component, however their origin is disputed. KS spindle cells have been found to 
express markers for smooth muscle cells, macrophages and dendritic cells (Nickoloff 
and Griffiths, 1989; Sturzl et al., 1992). It has been shown that the vascular 
endothelial growth factor receptor- 3 (VEGFR -3) is expressed on all KS spindle cells 
(Dupin et al., 1999; Jussila et al., 1998). As this marker is most commonly 
associated with expression on lymphatic endothelium and neoangiogenic vessels (but 
not by mature vascular endothelial cells), it is likely that the KS spindle cells are 
derived from an endothelial lineage, which can differentiate into lymphatic cells 
(Boshoff and Weiss, 2001). 
Boshoff and Weiss (2001) have outlined the four main observations that, 
when viewed together provide evidence that KSHV is the etiological agent of KS. 
These findings include; 
(i) KSHV DNA can be detected by PCR in all forms of KS and is rarely 
found in other mesenchymal tumours. 
(ii) Patients positive for HIV and carrying a higher load of KSHV are at 
greater risk for developing KS. 
(iii) Serological studies indicate that incidence of classic and AIDS -KS 
correlates broadly with the prevalence of virus infection within the 
population. 
(iv) In advanced KS lesions, latent KSHV transcripts can be detected in most 
spindle cells. 
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1.4.1.2 Primary Effusion Lymphomas 
Primary effusion lymphomas (PEL), or body cavity -based lymphomas, are a 
non -Hodgkin B -cell lymphoma and present as malignant effusions in the visceral 
cavities in the absence of a solid tumour mass. KSHV has been identified in PELs 
but not in other non -Hodgkin lymphomas. PELs are most commonly seen in HIV 
positive individuals in the advanced stages of AIDS, however are occasionally seen 
in HIV -sero- negative patients (Nador et al., 1996). As PEL cells seem to lack 
several adhesion molecules and `homing markers' that are associated with other 
diffuse lymphomas, it is thought that this may add to the unusual effusion phenotype 
of the lymphoma (Boshoff et al., 1998). As expression of B-cell markers seems 
limited to CD138, a molecule associated with late stage B -cell differentiation, and 
the frequent detection of a mutation in the 5' non -coding of BCL -6, it is thought that 
PEL cells are pre -terminally differentiated, post- germinal centre stage B cells 
(Gaidano et al., 1999). 
Compared with KS, PEL cells contain a very high copy number of KSHV 
(Boshoff and Chang, 2001). In addition to the establishment of cell lines direct from 
PEL, the BCP -1 cell line was established from peripheral blood taken from a patient 
with PEL; thus implying that malignant cells may be present and disseminated in the 
peripheral blood (Arvanitakis et al., 1996; Boshoff et al., 1998). Some of these cell 
lines are infected with both KSHV and EBV, while some are only positive for 
KSHV. KSHV is present in a latent state and lytic in vitro infection can be induced 
by phorbol esters or butyrate. It is therefore due to the ability to study both lytic and 
latent gene expression in vitro, that PEL cells are invaluable to the study of KSHV. 
1.4.1.3 Multicentric Castleman's Disease 
There are two forms of Castleman's disease; those being (ï) localised 
Castleman's disease, a single angiofollicular lymph -node hyperplasia and (ii) 
multicentric Castleman's disease (MCD), a multisystem involvement with 
generalised lymphadenopathy (Hengge et al., 2002a). It is highly likely that there is 
more than one cause of these diseases, as KSHV is not detected in all cases; KSHV 
has been detected in nearly all MCD cases when the individual is also HIV -positive 
and in 40 -50% of HIV- negative cases ( Chadburn et al., 1997: Corbellino el aL. 1996: 
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Soulier et al., 1995). A role for KSHV in MCD pathogenesis is implied as 
symptoms of the disease are exacerbated proportionally to the viral load of KSHV 
detected in peripheral blood mononuclear cells (Grandadam et al. , 1997). 
KSHV is present in plasmablasts of B -cell lineage within MCD; these cells 
are not present in cases of MCD that are KSHV- negative (Dupin et al., 2000). Viral 
IL -6 is highly expressed in these MCD plasmablasts, even higher than levels detected 
in PEL or KS, thus suggesting that over expression of this cytokine may play a role 
in MCD pathogenesis (Katano and Sata, 2000; Parravicini et al., 2000; Staskus et al., 
1999). KSHV predominately expresses lytic transcripts in MCD. Finally, MCD, in 
HIV -positive patients, does not commonly resolve through treatment with HAART 
(Dupin et al., 2000; Zietz et al., 1999). 
As a point of interest, there have been a few cases in which an individual has 
developed two or even three independent KSHV- associated tumours, i.e. KS, PEL 
and MCD, however this is uncommon (Jones et al., 1998). 
1.4.2 Genome 
KSHV, the only human Rhadinovirus, is closely related to HVS and is 
believed to have separated from the H.Saimiri lineage at about the same time as the 
host Old and New World Monkeys lineage separated, approximately 35 million years 
ago (McGeoch and Davison, 1999). 
The KSHV genome is approximately 165kb in length and contains a long 
unique region, LUR (145kb), flanked with variable numbers of terminal repeats 
(801 by each); the LUR encodes at least 87 genes. Due to the high degree of 
homology with HVS, most of the KSHV genes have been consecutively named after 
a HVS counterpart (Figure 1.6). However, KSHV also possesses several genes 
which are not homologous to any in HVS, these genes are given a K prefix e.g. ORF 
K1 to K15. Many of these are unique to KSHV and share homology with cellular 
genes (see Table 1.2), a characteristic of KSHV that will be discussed in more depth 
later in this chapter. 
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Table 1.2 KSHV- encoded proteins homologous with cellular proteins. 
Viral 
protein 
Viral Cellular Expressior Possible Function(s) Pattern ORF Homologue 
ORF 4 ORF4 Complement binding 
protein (CBP) 
Inhibits complement- mediated 
lysis 
Lytic 
Escape from host immune 
response 
vIL-6 K2 IL-6 Activated gp130 independently Lytic 
Autocrine and paracrine growth 
stimulation 
Angiogenesis 
VMIP-I K6 Macrophage Binds both CC and CX Lytic 
vMIP-II K4 inflammatory receptors -* Chemoattraction 
vMIP-III K4.1 proteins Angiogenesis 
VIRF K9 Interferon regulatory 
factor 
Blocks IFN- and IRF- mediated 
transcriptional activation. 
Lytic 
Inhibition of p300 and p53 
Oncogenic 
v-Bcl-2 ORF16 Bcl -2 family protein Inhibits apoptosis, Bcl -2 and Lytic 
Bax binding 
v-FLIP ORF71 FLICE inhibitory 
protein 




v-Cyclin ORF72 D-type cyclin Associates with CDK6 - Latent 
Inactivation of pRB 
Promotes G1 to S phase 
transition 
vOX2 K14 CD200 (or OX2) Regulatory/transportation 
control of macrophage 
Lytic 
? Adhesion 
vGPCR ORF74 IL-8 GPCR Constitutively active GPCR Lytic 
Binds IL -8 
Oncogenic and angiogenic 
Gene names are taken from the literature and function based on experimental 
evidence referred to in text, except for those in italics that are based only on 
homology to characterised genes. Gene expression patterns are taken from Jenner et 
al. (2001). 
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A high degree of conservation is maintained within KSHV with less than 
0.4% nucleotide variation between the central genomic region of KSHV isolated 
from a KS lesion and from a BC -1 PEL cell line (Neipel et al., 1998; Russo et al., 
1996). A higher degree of variation is seen within the internal direct repeat region 
and areas adjacent to the end terminal repeat sequences, particularly in ORF 75 and 
within the TRs; variants based on variation in these areas have been identified but do 
not follow phylogenetic clusters (Poole et al., 1999; Zong et al., 1999). However, 
the genetic variation in ORF K1 has lead to the division of KSHV into four strains, A 
to D. These strains can be associated with geographic location, as strain A is more 
often observed in classic Mediterranean KS, B and C in Africa and strain D is most 
common among Asian isolates (Hayward, 1999; Zong et al., 1999). 
1.4.3 Viral Life Cycle and Gene Expression 
As previously mentioned, viral transcripts have been identified in several cell 
types in vivo, including B- lymphocytes, macrophages, endothelial cells, and 
epithelial cells (Blasig et al., 1997; Boshoff et al., 1995; Diamond et al., 1998; 
Schulz, 1998). KSHV is able to infect several human cells in vitro, such as B cells, 
endothelial cells, epithelial cells and fibroblast cells. In addition, KSHV can infect a 
variety of animal cells, such as owl monkey kidney cells, baby hamster kidney 
(BHK) fibroblast cells, Chinese hamster ovary (CHO) cells, and primary embryonic 
mouse fibroblast cells (Blackbourn et al., 2000; Flore et al., 1998; Moses et al., 
1999; Renne et al., 1998). Unless chemically stimulated, only latent KSHV infection 
is observed during in vitro infection of these cells and as yet, there is no suitable cell 
culture system to support a natural ongoing lytic replication. 
This broad cellular host range for KSHV suggests that the virus may be 
interacting with one or more ubiquitous host cell surface molecules to gain access to 
the target cells. Research has demonstrated that the KSHV glycoproteins gB (ORF 
8) and K8.1A are able to bind with glycosaminoglycans, such as heparan sulfate, on 
the cell surface (Akula et al., 2001; Birkmann et al., 2001; Wang et al., 2001). K8.1 
is a unique gene to KSHV and encodes the spliced products K8.1A and K8.1 B. The 
K8.1 ORF is a positional homologue of EBV gp350/220, which mediates the initial 
attachment of EBV to B cells. Recent studies have shown that KSHV gB contains an 
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RGD motif that is able to bind specifically to integrin a3 ß 1 and thus is likely to be a 
cellular receptor for KSHV entry (Wang et al., 2003). The a3ß1 integrin is 
expressed on a broad range of cell types, including those cell types susceptible to 
KSHV infection (Wang et al., 2003). Although blocking this integrin binding site 
was shown to reduce infectivity in human foreskin fibroblast cells, studies using cells 
derived from human embryonic kidney cells (293T) did not observe any reduction in 
infectivity. This suggests that there may be other cellular receptors, which at present 
are still unknown (Akula et al., 2002; Inoue et al., 2003). 
In addition to gB, KSHV also encodes counterparts of gH (ORF22) and gL 
(ORF47), as possessed by other herpesviruses. Observations using a cell -based assay 
with susceptible cells as targets showed that only gB, gH and gL are required for 
virally- induced membrane fusion (Pertel, 2002). On the other hand a more recent 
paper has suggested that KSHV infection of human fibroblast cells occurs through 
endocytosis and not fusion to the cell membrane (Akula et al., 2003). As viral entry 
into a cell is a complex and often a multi -step process, cell attachment and 
internalisation can be distinct steps, which may both need to be focused on when 
studying viral entry. 
KSHV encodes two lytic transcriptional activators, K -bZIP (ORF K8) and 
RTA (replication and transcription activator) (ORF 50). These genes act as a master 
control switch that cause a cascade of lytic viral gene expression and are homologues 
of the EBV Zta and Rta. RTA is the major transactivator and induces expression of 
Kb -ZIP, an immediate -early gene product (Sun et al., 1999). RTA autostimulates its 
own expression and acts as a positive feedback mechanism and thus controls the lytic 
gene transcription cascade (Gradoville et al., 2000). KSHV contains many of the 
common genes required for replication and virion assembly as encoded by other 
herpesviruses, however, KSHV also possess several more homologues of cellular 
proteins. For instance, with particular reference to DNA synthesis enzymes, in 
addition to DNA pol (ORF 9), TK (ORF 21), and ribonucleotide reductase (ORF 60 
and 61) genes, KSHV also encodes genes encoding thymidylate synthase (ORF70), 
dihydrofolate reductase (ORF2) and FGART (N- formylglycinamide ribotide 
amidotransferase, ORF75). It is thought that these homologues may either be 
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supplementing the G1 and S phase regulated cellular genes or extend the S -phase of 
DNA synthesis during the cell cycle (Cinquina et al., 2000). 
In vitro lytic replication of KSHV can be triggered by chemical agents, 
including butyrate and the phorbol ester, TPA (12-O- tetradecanoylphorbol -13- 
acetate), as seen with EBV (Miller et al., 1997). The natural trigger for reactivating 
KSHV infection is still unknown, however simultaneous infection with other viruses, 
such as HIV, may play a role in this switch from latency. 
The precise pathway taken for viral assembly and egress is still unclear but it 
is thought that primary envelopment occurs in the nuclear membrane. This is 
followed by de- envelopment; the capsid then binds into the trans -golgi network 
(TGN) and is finally secreted out of the cell. On entry into a new host cell, the linear 
KSHV genome re- circularises at its terminal repeat region to form a circular 
episome, which is tethered to the cellular chromosome by the latency- associated 
nuclear antigen (LANA) encoded by ORF 73. This association allows the equal 
segregation of latent viral genomes to daughter cells during mitosis. The origin -of- 
plasmid replication (ori -P), the actual site where LANA binds the viral DNA has 
been identified to lie within the terminal repeat of KSHV; the C terminus of LANA 
binds to a 20 -bp imperfect palindrome within the terminal repeat (Garber et al., 
2001). Viral gene expression is minimal during latency, where the primary roles are 
involved with evading the host immune responses; the virus relies on cellular nucleic 
acid replication machinery for survival and the expression of its latent proteins. 
Two polycistronic transcripts located at the right end of the genome are 
constitutively expressed in PEL cells; their levels do not increase following 
induction. The first transcript (5.3 Kb) encodes LANA (ORF 73), v- cyclin (ORF 72) 
and v -FLIP (ORF 71), while the second smaller transcript (1.7kb) is a spliced variant 
of the first; it only encodes v- cyclin and v -FLIP (Sarid et al., 1999; Talbot et al., 
1999) (Figure 1.8). 
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Figure 1.8 Alignment of genes 
from the right end of the KSHV 
genome and mRNA transcripts 
from ORFs 71 to 74 encoding 
v -FLIP, v- cyclin, LANA, v -OX2 
and v -GPCR, respectively. 
Diagram adapted from Talbot 
et al., 1999. 
1.4.3.1 Latent nuclear antigen (LANA -1, LNA -1) 
LANA -1 (encoded by ORF 73) is a protein of approximately 200KDa in size. 
KSHV -infected PEL cells and KS- spindle cells can be verified for the presence of 
latent virus by staining for LANA -1 ( Ballestas et al., 1999); as LANA -1 is one of the 
few proteins expressed during latency, antibodies to LANA -1 are often used as 
serological evidence for infection (Dupin et al., 1999). 
LANA -1 is an important nuclear protein involved in a variety of roles 
essential for the establishment of latency. Firstly, LANA -1 is required for the long- 
term maintenance of viral episomal DNA. By acting as a "molecular bridge ", 
LANA -1 tethers the viral episome to the host chromosome and aids in efficient 
segregation of episomes to progeny nuclei. The C- terminus of LANA -1 binds 
preferentially and directly to the terminal repeats (TRs) of KSHV, whereas the N- 
terminus mediates attachment to nuclear chromatin during interphase and to mitotic 
chromosomes (Piolot et al., 2001; Viejo -Borbolla et al., 2003). Studies on LANA -1 
have demonstrated it is essential, and identified areas of importance within the 
protein required for DNA binding, replication and episome persistence ( Ballestas and 
Kaye, 2001; Komatsu et al., 2004). 
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Secondly, it has been demonstrated that LANA -1 has the ability to modulate 
the cellular transcription program in KSHV- infected cells, through the direct 
interaction with a variety of host cellular proteins including RING3, mSin3A, 
CREB -2 (Cyclic AMP response element binding protein), and CBP (Krithivas et al., 
2000; Lim et al., 2000; Platt et al., 1999; Radkov et al., 2000). More importantly 
LANA -1 has been reported to bind to p53 and repress the expression of p53- 
dependent promoters, thus downregulating their transcriptional activity and their 
ability to induce apoptosis (Friborg et al., 1999; Katano et aL, 2001). In addition, 
LANA -1 can mediate the expression of E2F- dependent transcription by interacting 
with the retinoblastoma protein (pRB). Therefore by competing with E2F for pRb, 
LANA -1 has released E2F to activate the transcription of genes involved in cell cycle 
progression and avoid cell cycle arrest. Although, under normal circumstances 
aberrant E2F activity would trigger apoptosis via the p53 pathway, this is also 
inhibited by LANA -1. Therefore LANA -1 allows KSHV infected cells to promote 
cell cycle progression whilst inhibiting apoptosis ( Radkov et al., 2000). These 
functions are similar to those seen in other oncogenic proteins such as the large T 
antigen of SV40 and the E6/E7 protein of HPV. 
Although no obvious sequence homology is shared between LANA and the 
EBV nuclear antigen -1 (EBNA -1), they are partially orthologous (functionally 
equivalent). EBNA -1 is responsible for episomal maintenance and transcriptional 
regulation. More recently, the ORF 73 from HVS has been shown to possess a cis - 
acting sequence that enables the efficient persistence of episomes in HVS infected 
cells (Calderwood el aL, 2004; Verma and Robertson, 2003). 
1.4.3.2 v- Cyclin (vCYC) 
ORF 72 encodes a protein, v- cyclin, that shares homology with human D- 
type cyclins and the v- cyclin of HVS; as KSHV -v- cyclin has only 32% amino acid 
identity with the HVS v- cyclin, it is surprising that they also share several 
biochemical features (Li et al., 1997). Cyclins are utilised during the progression 
through the cell cycle; human cyclin D is primarily generated during the GI and S 
phase, and activates the cyclin- dependent kinases (CDK4 and CDK6), which 
phosphorylate target proteins such as pRB. In vitro studies have shown that KSHV 
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v- cyclin is able to phosphorylate pRB following the formation of a complex with 
CDK6, in a similar manner to v- cyclin from HVS, and to a lesser extent forms a 
complex with CDK4 (Godden -Kent et al., 1997; Li et al., 1997). v- Cyclin also 
possesses another advantage in that unlike the cellular cyclins, it is resistant to the 
CDK inhibitors p16, p21 and p27 and thus avoids G1 arrest (Swanton et al., 1997). 
The evasion of p27 arrest is mediated by the direct phosphorylation of p27 by the v- 
cyclin/CDK6 complex resulting in the degradation of p27 (Ellis et al., 1999; Mann et 
al., 1999). The v- cyclin/CDK6 complex also has the ability to phosphorylate histone 
H1, Cdc25a, Id -2, E2F -4, orcl and cdc6 (Duro et al., 1999; Godden -Kent et al., 1997; 
Laman et al., 2001; Li et al., 1997; Mann et al., 1999). 
In cells with elevated levels of CDK6, v- cyclin not only accelerates entry into 
S phase, but also results in apoptosis independent of pRB and p53 (Ojala et al., 
1999). This is likely to be due to the phosphorylation of the cellular anti -apoptotic 
factor Bc1-2 by the v- cyclin/CDK6 complex that renders it inactive ( Ojala et al., 
2000). KSHV also encodes a viral homologue of the cellular Bc1 -2, v- Bc1-2, that can 
inhibit the v- cyclin/CDK6- induced apoptosis, however as v -Bc1-2 is only expressed 
during lytic infection it is not clear if it plays a relevant role during latency. v- Cyclin 
is expressed during both latency and lytic viral replication of KSHV (Dittmer et al., 
1998; Sarid et al., 1998). 
1.4.3.3 v -FLIP 
Normal cell death can be induced via the engagement of the death receptor 
e.g. Fas, resulting in the recruitment of intracellular adapter molecules such as the 
Fas- associated death domain (FADD). These molecules can in turn interact and 
activate the upstream capsases via the interaction with the death effector domain 
(DED) or caspase recruitment domain (CARD), thus resulting in the activation of 
downstream caspases and ultimately death of the cell (Ashkenazi and Dixit, 1998; 
Djerbi et al., 1999; Thornberry and Lazebnik, 1998). Several y- herpesviruses and the 
molluscipox virus encode a protein able to prevent cell death by this route, therefore 
allowing extended viral replication. Viral FLICE (FADD -like IL-lß-converting 
enzyme) -inhibitory proteins (vFLIPs) were first identified and knowing that many 
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viruses possesses cellular homologues, cellular FLIPs were later identified (Irmler et 
al., 1997). 
KSHV v -FLIP contains two DEDs and protects cells from Fas- mediated 
apoptosis by inhibiting caspase activation and thus permits clonal growth. Studies in 
which mice were injected with v- FLIP -expressing B cells developed aggressive 
tumours by preventing death receptor -induced apoptosis triggered by CTLs; thus 
displaying a role as a tumour progression factor (Djerbi et al., 1999). It is therefore 
feasible that one role for v -FLIP is to prevent apoptosis triggered by CTLs, which 
may also explain the close linked expression of its neighbouring ORF encoding v- 
cyclin. As v- cyclin possesses an IRES (internal ribosome entry site), it is likely that 
this allows the bi- cistronic transcript to be expressed as required throughout the cell 
cycle, thus protecting infected cells from CTL- mediated apoptosis; unlike cap 
dependent expression, an IRES is not susceptible to inhibition of translation in the 
G2 /M phase (Bieleski and Talbot, 2001; Grundhoff and Ganem, 2001). Furthermore, 
this protein is believed to be involved in the pathogenesis of KS, due to the detection 
of v -FLIP transcripts in late stage KS lesions and the reduced levels of apoptosis 
(Sturzl et al., 1999a). 
LANA -1, v- cyclin and v -FLIP are the predominant proteins detected during 
latency, although expressions of other viral transcripts such as K7, nut -1 (T1.1/PAN 
RNA) and vOX2 (K14) have been detected. It is believed that detection of these 
transcripts are due to the small minority (1 %) of spontaneously lytic cells, as over a 
100 -fold increase in expression is observed following lytic induction (Jenner et al., 
2001). It should be noted that this expression pattern is the norm in both KS lesions 
and PEL tumours; however, KSHV infected cells in MCD lymph nodes display a 
different pattern of gene expression. Only a small proportion of cells in MCD are 
KSHV positive, and in addition to expressing LANA, many also co- express several 
other proteins, including vIL -6, K8.1, K10 and K11. It is unknown if there are more 
cells present undergoing lytic replication or if in MCD there is a expanded pattern of 
latent KSHV gene expression (Moore and Chang, 2001). 
Another transcript detected in PEL cell lines is K15 (Paulose- Murphy et al., 
2001), although it is upregulated with TPA induction of the latent virus. ORF K15 
encodes a transmembrane protein that is not only located in a similar location to 
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EBV's LMP -2A, but K15 shares features with both LMP -1 and LMP -2A. In short, 
K15 has SH2, SH3 and TNFR- associated factor (TRAF) binding domains and is able 
to activate NK -KB pathways, but can also bind to the HS 1 associated protein X -1 
(HAX -1), a protein with anti -apoptotic function (Brinkmann et al., 2003; Choi et al., 
2000b; Sharp et al., 2002). Additionally, the T0.7 transcript, containing Kaposin 
(K12) is also present in many spindle cells of advanced tumours (Staskus et al., 
1997) and will be discussed further in the following section. 
1.4.4 Molecular Mimicry 
KSHV possesses numerous genes encoding proteins that share striking 
homology with cellular proteins (Table 1.4 and Figure 1.9). Several of these ORFs 
encode proteins that are involved with KSHV pathogenesis by a variety of means 
such as disrupting cellular signal transduction pathways, including interferon - 
mediated anti -viral responses, cytokine- regulated cell growth, apoptosis and cell 
cycle control (Figure 1.9). 
1.4.4.1 Anti -apoptotic viral genes 
Most DNA viruses contain genes that are able to inhibit apoptosis. As 
mentioned earlier, KSHV encodes two anti -apoptotic genes v -FLIP and v- Bc1 -2. v- 
FLIP has the ability to protect against Fas /APO1 mediated apoptosis by inactivating 
various caspases, whereas v- Bcl -2, can block both Bax- mediated and virally induced 
apoptosis (Cheng et al., 1997; Friborg et al., 1998; Sarid et al., 1997). 
1.4.4.2 Viral cytokine homologues 
1.4.4.2.1 Viral macrophage inflammatory proteins (vMIPs) 
The ability to control inflammatory responses is an advantage; several 
herpesviruses have captured and modified cellular chemokine and chemokine 
receptors, thus allowing them to modulate the host immune response (Choi et al., 
2001; Parry et al., 2000). KSHV encodes three multifunctional CC chemokines, 
vMIP -I, vMIP -II, and vMIP -III, which all share between 25 -40% homology at the 
amino acid level with the cellular macrophage inflammatory protein a (MIP -la) 
(Moore et al., 1996; Nicholas et al., 1997). vMIP -I and vMIP -III are chemokine 
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receptor agonists, whereas vMIP -II has a more unusual broad spectrum of receptor 
binding activities. vMIP -II can block the cheomoattractant signalling of CC 
chemokine receptor 1 (CCR1), CCR2, CCR3, CCR5 and CXCR4 by acting as a 
competitive antagonist (Kledal et al., 1997; Murphy, 2001). 
1.4.4.2.2 vIL -6 
A potential role of IL -6 in KS and MCD was suspected long before the 
discovery of the virus, let alone its viral homologue, vIL -6; proliferation of cultured 
KS cells was enhanced in the presence of IL -6 and a correlation between elevated IL- 
6 levels and disease development in MCD was observed (Ishiyama et al., 1996; 
Miles et al., 1990; Yoshizaki et al., 1989). Initial findings by Molden et al. (1997) 
showed that unlike cellular IL -6 (hIL -6), vIL -6 could activate specific JAK/STAT 
signalling via interactions with the gp130 signal transducing surface marker, 
independently of the IL -6Ra subunit (gp80). Although it has been disputed whether 
vIL -6 is able to associate with the IL -6Ra subunit (Aoki et al., 1999; Li et al., 2001), 
a recent study by Boulanger et al. (2004) supports and verifies that vIL -6 can also 
form a hexameric complex with gp130 and IL -6Ra, which has enhanced signalling 
potency. 
Additionally, like hIL -6, vIL -6 is able to induce VEGF expression that 
mediates angiogenicity; vIL -6 is able to affect both B -cell lineage haematopoiesis 
and angiogenesis (Mesri, 1999; Hoischen et al., 2000). Studies have shown that vIL - 
6 can stimulate all of the known hIL -6 induced signalling pathways, therefore 
potentially contributing towards disease progression through the activation of IL -6 
stimulated growth and anti -apoptotic pathways (Osborne et al., 1999). 
1.4.4.3 Genes associated with transformation 
1.4.4.3.1 Kl 
KSHV contains several ORFs that share similarities to other genes with 
transformation properties. K1 is located at a position equivalent to the oncogenes 
LMP1 of EBV and STP of HVS. The extracellular domain of the K1 protein has 
homology with the variable region of the lambda chain of the immunoglobulin (Ig) 
light chain, and is similar to Ig -a and Ig -ß. The cytoplasmic tail contains a 
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functional ITAM (immuno- receptor tyrosine -based activation motif) (Lee et al., 
1998a). The ITAM in Kl is able to elicit signals that in turn activate cellular 
transduction events (Lagunoff et al., 1999). In addition, Kl is also able to down - 
regulate B -cell receptor (BCR) surface expression, as the amino- terminal of the 
protein can specifically interact with the [1. chains of BCR complexes and inhibit its 
intracellular transport (Lee et al., 2000). Various studies support a potential 
pathogenic role for K1. A recombinant HVS, in which STP was replaced with 
KSHV K1, was able to transform T lymphocytes and induce lymphomas in common 
marmosets (Lee et al., 1998b). In addition, a recent study also found the 
development of a salivary gland tumour and increased inflammatory response in 
mice infected with a recombinant murine gammaherpesvirus (MHV -76) expressing 
the KSHV Kl gene (Douglas et al., 2004). 
1.4.4.3.2 vGCR/ vGPCR 
Another gene with a potential role in increasing the tumorigenicity of virally 
infected cells is vGCR, a homologue of the human receptor for the angiogenic 
chemokine IL -8 (IL -8R); vGCR is a constitutively active seven- transmembrane 
protein. This protein is expressed during the early phase of lytic infection and can 
bind to a broad spectrum of chemokines including IL -8, MGSA, NAP -2, and 
RANTES (Cesarman et al., 2000; Ho et al., 1999). Studies on vGCR have found 
that the N- terminal extracellular region is not necessary for constitutive signalling, 
whereas it plays a more crucial role in the binding of chemokine ligands (Ho et al., 
1999). It has been demonstrated that the angiogenic response by vGCR is mediated 
by the up- regulation of VEGF, which can activate the protein kinases JNK/SAPK 
and p38MAPK and trigger a cascade of signal transduction pathways similar to other 
inflammatory cytokines (Bais et al., 1998). More recently, Cannon et al., (2003) 
have shown that expression of vGCR during latency in PEL cells, increased the 
expression of vIL -6 and VEGF, two cytokines also involved in the pathogenesis of 
KSHV- associated diseases. 
1.4.4.3.3 vIRF 
Many viruses have evolved various means to overcome cellular IFN defence 
mechanisms, such as EBNA -2 of EBV which inhibits IFN signalling by interfering 
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with the induction of IFN- stimulated genes (Kanda et al., 1992). In KSHV the K9 
ORF encodes vIRF, a unique viral protein that shares 13% amino acid identity with 
several IFN regulatory factors (IRFs). vIRF expression reduces transcriptional 
activation induced by IFN - a/ß /y (Gao et al., 1997; Li et al., 1998), but does not 
compete with the cellular IRF -1 for DNA binding nor form a complex with IRF -1 
(Zimring et al., 1998). Additionally, vIRF displays oncogenic properties as in vitro 
expression induced transformation of rodent fibroblast cells and tumours in nude 
mice (Li et al., 1998). It is believed that these properties are in part due to the 
interaction of vIRF with p300 and CREB- binding protein (CBP) ( Burysek et al., 
1999; Li et al., 2000; Seo et al., 2000). This results in the displacement of PCAF 
from the p300 complex and in turn inhibits the histone acetyltransferase (HAT) 
activity of p300, thus leading to the downregulation of transcriptional activation of 
the early inflammatory gene promoter (Burysek et al., 1999). Jayachandra et al. 
(1999) also demonstrated that induction of the myc protooncogene is required for 
cell transformation by vIRF and that vIRF increases myc transcription. 
More recently studies have shown that vIRF can interact with p53 and inhibit 
p53- mediated transcriptional regulated apoptosis (Nakamura et al., 2001; Seo et al., 
2001). Finally, vIRF has the ability to auto -activate its own promoter, thus enabling 
the expression of this protein to be regulated to efficiently evade host tumour 
suppressor pathways (Wang and Gao, 2003). 
1.4.4.3.4 Kaposin 
T0.7 is an abundantly expressed latent transcript containing three small 
ORFs, derived from ORF K12 (Kaposin) and either of two reading frames within 
repetitive elements (DR1 and DR2) upstream of K12 (Sadler et al., 1999). This 
transcript has been detected by in situ hybridisation in all KS tumours throughout all 
stages, i.e. early to late, and in PEL and MCD (Sturzl et al., 1997, 1999b). 
Expression of these proteins are upregulated following induction of lytic viral 
replication in both KS and PEL cell lines (Sadler et al., 1999), and therefore may 
serve functions during both latency and lytic replication. Studies on K12 have 
shown that this protein has transforming properties (Kliche et al., 2001; Muralidhar 
et al., 1998, 2000). Muralidhar et al., (1998) observed the transformation of Rat -3 
cells due to the expression of K12, this led to the development of high grade, highly 
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vascular, undifferentiated sarcomas following injection of athymic mice. However, 
research on K12 is limited and complex; the potential multiple biological functions 
that this protein may possess are still not fully known. 
1.4.4.4 Modulators of Immune responses 
1.4.4.4.1 K3 and K5 
The ability to outwit and evade the hosts defence system is a high priority 
during viral infection. There are two major branches of the immune system: (i) the 
early non -specific or innate response includes the use of interferons, NK cells and 
macrophage, whereas (ii) the specific or adaptive response is lead by CTLs, helper -T 
cells and anti -viral antibodies (Ploegh and Watts, 1998). As CTLs recognise viral 
antigens presented as peptides bound to class I MHC (MHC I) expressed on the 
surface of infected cells, it is to no great surprise that many viruses have evolved 
mechanisms to evade CTL recognition. For example, HSV -1 encodes a protein, 
ICP47, that binds to TAP and prevents assembly of MHC I in the ER, whereas 
EBNA -1 of EBV is not efficiently processed and not presented by MHC I (Fruh et 
al., 1995; Hill et al., 1995; Levitskaya et al., 1995). KSHV encodes two proteins, K3 
and K5, which are able to drastically down- regulate surface expression of MHC I. 
Unlike other viral evasion methods, K3 and K5 do not influence the expression or 
intracellular transport of MHC I, but employ a unique mechanism whereby they 
induce rapid endocytosis of MHC I (Coscoy and Ganem, 2000; Ishido et al., 2000). 
K3 and K5 exhibit 40% amino acid identity with each other and are expressed 
during the early lytic cycle of viral replication. Although K3 and K5 share similar 
sequence and function, they differ in specificity; K3 down -regulates all four HLA 
allotypes (A -D), whereas K5 only down -regulates HLA -A and -B (Ishido et al., 
2000). Even though some protection is given against CTLs, these cells are now more 
susceptible to NK cell clearance. However, K5 is also able to repress ICAM -1 and 
B7 -2, both of which are ligands for NK- cells; thus K5 expression can also reduce 
NK -cell mediated cytotoxicity (Ishido et al., 2000). Interestingly, it has recently 
been suggested that K3 and K5 may aid in evading host immune responses during 
latent infection, as expression of MHC I is also reduced on cells harbouring latent 
virus (Tomescu et al., 2003). 
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1.4.4.4.2 vOX2 
Another transmembrane protein that may be involved in immune regulation is 
vOX2, encoded by ORF K14. This protein shares remarkable homology with the 













Figure 1.9 KSHV proteins influence on cellular transduction 
pathways. Proteins expressed by KSHV are indicated in red 
and more detailed descriptions are given in the text of section 
1.4.4. 'Activated' pathways are indicated by 4 and `blocked' 
pathways are indicated by - ii (Image adapted and modified 





Many cells express a vast number of surface molecules that are involved in a 
variety of roles. The immunoglobulin superfamily (IgSF) domains are the most 
predominant on the surface of leukocytes and approximately a third of all surface 
proteins fall into this group (Preston et al., 1997). The OX2 protein, recently 
assigned CD200, is a leukocyte IgSF glycoprotein similar to other glycoproteins such 
as N -CAM, Thy -1 and L1. These proteins are involved in mediating interactions 
between cells of the nervous system. 
CD200 was initially identified by mAb's raised against glycoproteins 
prepared from rat thymocytes; first termed OX2 due to the screening being 
performed at Oxford University and all antibodies generated were termed OX 1, 
OX2, OX3 etc. (McMaster and Williams, 1979). Since its identification, 
homologues of the protein have been found in both humans (hCD200) and mice 
(mCD200) (McCaughan et al., 1987a), which also share a similar broad expression 
pattern. The CD200 cell- surface glycoprotein is expressed on a wide range of cell 
types (Table 1.3), including thymocytes, activated T cells, B cells, follicular dendritic 
cells, neurons, vascular endothelium, kidney glomeruli, the granulosa of 
degenerating copora lutea, trophoblasts and some smooth muscle (Barclay, 1981; 
Barclay and Ward, 1982; Bukovsky et al., 1983, 1984; Webb and Barclay, 1984). 
1.5.1 CD200 and its interaction with the CD200 receptor 
Like many other members from this group of surface proteins, the 
extracellular portion of CD200 is comprised of two IgSF domains, which are 
organised in a similar manner to the costimulatory molecules B7 -1 and B7 -2; these 
genes are genetically linked to each other and CD200 (Borriello et al., 1997). Many 
IgSF proteins are involved in the control of the immune system. However, due to a 
short cytoplasmic region with no known signalling motifs, CD200 is not thought to 
be directly involved in signalling. CD200 has recently been shown to interact with 
another surface glycoprotein termed CD200- receptor (CD200R or OX2R) (Figure 
1.10). Like CD200, the receptor consists of two IgSF domains also in the common 
V /C2 set arrangement, but in contrast CD200R also possesses a longer cytoplasmic 
region (67 a.a compared with 19 a.a in CD200). The cytoplasmic tail contains three 
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tyrosine residues that can be phosphorylated, one of which is contained within an 
NPXY PTB- binding motif, thus suggesting that it can signal (Wright et al., 2000, 
2003). Genes sharing homology to the receptor have also been found in both mice 
and rats, termed mCD200R and rCD200R respectively. 
CD200R was initially found to be expressed only on cells of myeloid lineage 
and a small subset of T cells as detailed on Table 1.3 (Borriello et al., 1997; Preston 
et al., 1997). More recently, a group from the University of Oxford, have detected 
CD200R expression in humans and mice to be strongest on macrophage and 
neutrophils but also on other leukocytes including monocytes, mast cells and some 
subsets of T lymphocytes (Wright et al., 2003). 
Table 1.3 Summary of tissue distribution of human and mouse 
CD200 and CD200R 
CD200i 
Activated T Cells 
B Cells 






Some smooth muscle 














Mast Cells Dendritic Cells 
fData summarised from mouse, rat and human due to the similar expression 
pattern, references from (Barclay, 1981; Barclay and Ward, 1982; Bukovsky et 
al., 1984; Webb and Barclay, 1984; Wright et al., 2001). Human and mouse 
CD200R expression graded with cells expressing larger amounts at the top 
and smaller amounts towards the bottom of the column, results summarised 
from (Wright et al., 2003). 
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Figure 1.10 Schematic representation of CD200:CD200R 
Iigand:Iigand- receptor interaction. Both CD200 and CD200R 
are IgSF glycoproteins comprised of two extracellular domains 
(V /C2 arrangement), a single transmembrane region and a 
cytoplasmic region; CD200 only posses a short sequence with no 
known signaling motifs, while on the other hand CD200R 
encodes a longer cytoplasmic region with three tyrosine residues 
(o ) that can be potentially phosphorylated and involved in signal 
transduction. CD200 is expressed on a wide range of cells, 
whereas CD200R is restricted to cells of myeloid -lineage and 
some subset of T cells. The interaction interface involves the N- 
terminal domain, resulting in a cell -cell interaction spanning four 
IgSF domains, similar to many interactions found between T cells 
and antigen presenting cells. 
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In humans, both the CD200 and CD200R gene are located near to each other 
on chromosome 3 and are transcribed in the same direction, unlike mCD200 and 
mCD200R, which are both found on mouse chromosome 16 but transcribed in 
different directions (McCaughan el al.. 1987b; Wright et al., 2003). Further 
phylogenetic analysis of CD200R and other IgSF proteins indicates that CD200 and 
its receptor are closely related to each other and likely to have evolved from a 
common ancestral protein (Figure 1.11) (Wright el al., 2000). 
._._ I ;. 1 ',I 1 
Figure 1.11 Phylogenetic analysis of 
human CD200, CD200R and some 
human herpesvirus entry proteins. 
The N- terminal Ig domains of hCD200; 
hCD200R; human herpesvirus entry 
proteins HveB, C and D; and other 
human Ig -like proteins (CD56, CD80, 
and CD86) were aligned using 
ClustalW, manually refined and then 
construction of a Neighbour -joining tree 
with 1000 bootstrap trials (In Hve 
proteins and CD56, only the membrane 
distal two domains were compared). 
Redrawn with permission from Wright 
et al., 2003. 
Using soluble fusion proteins and recombinant proteins, Wright el al. (2003) 
were able to confirm that both the mouse and human CD200 bound to their 
respective receptors and that hCD200:hCD200R interact with an equilibrium - 
binding affinity (KD) of 0.5µM at 37 °C and a kinetic off rate (K01) of -0.15 s-1, 
similar to those seen in equivalent interactions in mice and rats (Wright et al., 2000, 
2003); these values are typical of many leukocyte protein membrane interactions. 
Cross species binding was also tested, revealing that hCD200 was able to interact 
with both mouse and rat CD200R, although binding to mCD200R was weaker 
(Wright et al., 2003). 
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Another unusual feature possessed by both CD200 and CD200R when 
compared with other IgSF proteins, is the high amount of potential N- linked 
glycosylation sites; CD200R has eight sites in the human and rat and ten in mouse 
sequences (Wright et al., 2000, 2003), whereas the six predicted sites in CD200 are 
conserved in all three species (Borriello et al., 1997; Clark et al., 1985; McCaughan 
et al., 1987a). Following analysis of mutagenesis studies (Preston et al., 1997) and 
comparison with other IgSF interactions (van der Merwe et al., 1993), it has been 
suggested that the CD200:CD200R immunoglobulin binding is not mediated by 
carbohydrate but by protein (Wright et al., 2000). The high carbohydrate content is 
likely to be involved in directing orientation of the protein in relation to the 
membrane and preventing unwanted cis -interactions (Wright et al., 2000). 
An additional commonality shared between the CD200Rs is three tyrosine 
residues detected within the cytoplasmic region that is conserved between species. 
Furthermore, rCD200R has been shown to be phosphorylated following treatment 
with pervanadate (Wright et al., 2000). At present the mechanism and pathway for 
signal transduction via the CD200R cytoplasmic receptor is still unknown. 
Finally, a recent paper has commented on the findings that the human 
CD200R gene can generate different protein isoforms through alternative splicing, 
resulting in the formation of a truncated soluble protein containing only the V 1g 
domain (Vieites et al., 2003). Functional studies have not been performed on the 
different isoforms, however both membrane -bound and soluble versions have been 
detected in the thymus, liver, spleen and placenta by Northern -blot analysis (Vieites 
et al., 2003). On a similar note, a gene related to the human receptor, termed CD200 
receptor -like (hCD200RLa), and an additional four genes in mice have been detected 
(mCD200RLa_d), which have all presumably evolved from recent gene duplications 
(Wright et al., 2003). Analysis suggests that the hCD200RLa is non -functional, 
whereas mCD200RLa and mCD200RLb are able to pair with the activatory adaptor 
protein, DAP12 (possibly transmitting activating signals), but not with the mCD200 
ligand (Wright et al., 2003). 
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1.5.2 CD200: CD200R Function Studies 
A variety of roles for CD200 in antigen presentation have been proposed 
including both stimulatory (Borriello et al., 1997) and tolerogenic (Gorczynski et al., 
1999a, 1998, 2000d). In addition, CD200 has also been suggested to generate a 
down -regulatory signal on myeloid -lineage cell populations (Barclay et al., 2002; 
Hoek et al., 2000). Although CD200 was identified over 20 years ago, insights into 
its importance and function are only just coming to realisation, and a full 
understanding of its role within the immune system is still not clear. Early studies by 
Borriello et al. (1997) indicated that mCD200 has the ability to mediate a 
costimulatory signal to murine CD4+ T cells leading to proliferation. The expansion 
of T cells was seen to neither be independent of the B7 /CD28 pathway nor result in 
detectable levels of IL -2, IL -4 or IFN -y; however, T cell proliferation was inhibited 
by approximately 80% by anti- mCD200 mAb ( Borriello et al., 1997). Additionally, 
several studies by Gorczynski's group (Clark et al., 2001a, 2001b; Gorczynski et al., 
1999a, 1999b, 1999e, 2000a, 2000b, 2000e, 2002a, 2002b, 2002c) have shown that 
CD200 expression contributes toward not only the survival of allografts and 
xenografts but also successful pregnancies. Observations by this group have found 
that mCD200 expression increased following the treatment of mice with portal vein 
(pv) donor -specific immunisation, which promotes renal allograft survival 
(Gorczynski et al., 1998). Furthermore, antibodies to CD200 abolished graft 
prolongation in both the mouse renal allograft and rat small intestinal allograft model 
(Gorczynski et al., 1998, 1999c), and additionally blocked the polarization of T cells 
to produce type 2 cytokines (IL -4, IL -10, IL -13) that are normally induced by pv 
immunisation. Further investigations using a soluble immunoadhesion, CD200:Fc 
(extracellular domain of CD200 linked to a mutated murine IgG2aFc region) 
exemplified previous findings, as T cell allostimulation and type I cytokine 
production (IL -2 and IFN -y) were blocked by CD200:Fc and both allograft and 
xenograft survival was prolonged (Gorczynski et al., 1999b, 2002c). 
These studies and several others by Gorczynski's group (Gorczynski el al., 
1999b, 2000d, 200la, 2004) present evidence supporting their hypothesis that CD200 
is involved in the delivery of a "coregulatory" signal that is able to modify the 
functional outcome of the TCR:Ag encounter. More specifically, a negative 
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"tolerizing" signal to the T cells involved in the graft survival experiments. When it 
later became apparent that CD200 interacts with its receptor, CD200R (expressed on 
a sub -population of activated T cells, predominately ySTCR+ T cells, and 
macrophages), the CD200:CD200R engagement was consistent with their hypothesis 
that these proteins were indeed involved in an immunoregulatory role. 
With respect to CD200's involvement as an immunoregulatory protein 
involved in pregnancy, Th1 cytokine- dependent abortions in CBA /JxDBA /2 mouse 
models have been linked with the down -regulation of CD200 on trophoblast and in 
decidua preceding the abortion process. This was evident as the addition of soluble 
CD200:Fc results in a marked decrease in abortion. Whereas in an opposing system, 
the administration of CD200 mAb was found to boost abortion rates (Clark et al., 
2001a, 2001b). Furthermore, it has been demonstrated that CD200 is able to activate 
production of indole amine 2,3- dioxygenase (IDO) by antigen- presenting 
macrophage that can in turn suppress antigen -specific T cell responses (Gorczynski 
et al., 2002b). In a recent study by Clark et al. (2003), data supports the findings that 
CD200 expression on placental trophoblasts from successful human pregnancies 
displayed the Thl -*Th2 shift previously observed in mouse models (Clark et al., 
2001a). Thus down -regulation of CD200 may also be a reason for foetus rejection in 
humans. Further studies on first trimester termination and spontaneous miscarriage 
tissue samples need to be investigated to verify CD200 expression patterns and the 
mechanism of suppression. It is still not clear if suppression was due to: co- 
stimulation of antigen- activated yST cells releasing cytokines IL -10 and TGF -ß that 
inhibit Thl -type response; activation of IDO; or by some alternative mechanism. 
Strong evidence supporting the CD200:CD200R interaction playing a 
regulatory role is seen in data from Barclay's group at Oxford University. The most 
striking observations were made using C57BL /6 CD200 knockout (KO) mice. The 
phenotypic changes of these CD2004" mice elucidated the importance of CD200 on 
the regulation of myeloid- lineage cells; these mice were normal in all aspects of 
appearance, life -span and behavioural patterns, but did possess an increase in the 
number of macrophage and granulocytes within the spleen, and enlarged mesenteric 
lymph nodes, also due to an increase population size of macrophages (Hoek el al., 
2000). Additionally, the resident CNS macrophage, microglia (MG), also displayed 
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features of activation, including increased CD 11 b and CD45 expression, less 
ramified, shorter glial processes and a disordered arrangement, in contrast to the 
ordered and ramified appearance seen in wild -type mice (Hoek et al., 2000). The 
MG in the spinal cord also formed clustered groups, a phenotype normally associated 
with neurodegeneration. Using the facial transection model allowed localised MG 
activation to be studied; in CD200 "/- mice a fast MG response was detected just 2 
days after surgery with a peak at day 4, compared with days 4 and 7, respectively, in 
wild -type mice (Hoek et al., 2000). 
Other experiments were performed on these KO mice to investigate disease 
progression using two autoimmune models involving myeloid lineage cells. 
Experimental autoimmune encephalomyelitis (EAE), a model whereby the migration 
of activated T lymphocytes, macrophage and granulocytes to the CNS results in the 
activation of MG, tissue damage and neurological deficits including paralysis. These 
manifestations are induced in wild -type mice after injection with MOG (myelin 
oligodendrocyte glycoprotein) peptide and the development of the resultant 
pathogenesis occurs significantly earlier in CD2004- mice, along with a greater 
number of activated macrophage and MG (Hoek et al., 2000). EAE was also shown 
to be exacerbated in rats when MDG peptide was administered with an anti -CD200 
mAb (Wright et al., 2000). 
The second model, collagen -induced arthritis (CIA), mimics rheumatoid 
arthritis and also involves an autoimmune response due to the same cell types as seen 
in EAE. Following an injection of collagen, the incidence of disease in wild -type 
mice is reasonably low ( <10 %), due to their relative resistant to CIA, whereas an 
incidence of over 50% and early onset of disease was observed in the CD200 "'" mice. 
These results were further corroborated by data showing that wild -type mice became 
more susceptible to CIA when infected with an adenovirus encoding a soluble Ig- 
fused CD200R (Hoek et al., 2000). Furthermore, administration of CD200:Fc or 
anti- CD200R to DBA/1 mice, which are susceptible ( >50 %) to CIA, resulted in the 
suppression of disease development (Gorczynski et al., 2001b, 2002a). A passing 
comment should be made at this point with regards to the more recent finding that 
some mast cells have been shown to express the CD200 receptor (Wright et al., 
2003) and that both the EAE and CIA models are dependent on functional mast cells 
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(Lee et al., 2002; Secor et al., 2000). Therefore, it is possible that some of the results 
observed may also be due to a contribution from the mast cell population. 
Other studies on myeloid activity within the retina of CD200 KO mice found 
that not only were there greater numbers of activated MG but that MG migration 
may also be mediated via the ligation of CD200R (Broderick et al., 2002; Dick et al., 
2001, 2003). 
In summary many of these studies have provided data to support the theory 
that CD200 interaction with the CD200R results in the down -regulation of myeloid - 
derived cells. Further evidence elucidating this proposed role is the finding that 
CD200R associated with SH2- containing inositol phosphatase (SHIP), which is 
consistent with a role in down -regulation of phagocytic activities (Barclay et al., 
2002). However, this does pose several questions (reviewed by Nathan and Muller, 
2001); if the CD200:CD200R combination results in the down- regulation of myeloid 
cells, does this imply that these cells would normally be active all the time and if so, 
what overrides the CD200 signal, and then finally how is homeostasis restored after 
an inflammatory response is no longer required? It is more likely that the 
CD200:CD200R interaction is involved in modulating myeloid cell functions such as 
proliferation, survival, trafficking and migration. 
More recently it has been proposed that CD200 may be a "don't eat me 
signal" or as coined in a review by Elward and Gasque (2003), a self associated 
molecular pattern (SAMP). Their hypothesis states that SAMPs are utilised as a 
mechanism to control the human and cellular innate immune response, in a manner 
similar to MHC Class I expression by host cells evading killing by natural killer 
(NK) cells. Therefore it is possible that CD200 and other SAMPs are signals 
assisting with the control of phagocytosis and associated inflammatory responses. 
Indeed, if CD200 is truly involved in distinguishing between "eat me" and 
"don't eat me" signals or alternative control mechanisms of myeloid- derived cell 
populations or T cells, it is highly likely that this would be an advantageous target for 
pathogens. Therefore it is not so surprising to find that several viruses have acquired 
a viral homologue of CD200. 
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1.5.3 Viral Homologues of CD200 
Although it is not unusual to observe molecular piracy occurring during viral 
evolution, it is uncommon for viruses to encode proteins with IgSF domains 
compared to vertebrates where they are extremely common. CD200 homologues 
have been found in both the Betaherpesviridae (HHV -6 and HHV7) and the 
Gammaherpesviridae (KSHV and Rhesus Rhadinovirus [RRV]), but also more 
recently in viruses from the Poxviridae (Myxomavirus [MYX], Yaba -like disease 
virus [YLDV], Yaba monkey tumour virus, shope fibroma virus, and lumpy skin 
disease virus) (Table 1.4). Information regarding characterization studies on most of 
the viral homologues has yet to be reported. Illustrated in Figure 1.12 are schematic 
representations of the CD200- homologues for KSHV, RRV, MYX and YLDV. Like 
their cellular counterpart, many viral CD200s are also highly glycosylated and share 
some conserved sites. However, in contrast to the membrane -bound cellular CD200, 
the viral CD200s encoded by the Poxviridae are truncated, only encoding the V -like 
Ig domain, several of which are not membrane bound (i.e. produce a soluble protein) 
(Figure 1.12). 
As viral homologues of CD200 are present in a range of evolutionary 
disparate viruses, it suggests that the gene was captured independently several times 
during viral evolution. This is further supported by the fact that many closely related 
viruses (to those encoding a viral CD200 homologue), such as HVS or the swinepox 
virus do not possess a CD200 homologue. Therefore it can be assumed that 
acquiring host CD200 has its advantages in viral evolution and thus may play an 
important role in the lifecycle of many viruses. 
1.5.4 KSHV K14 
KSHV encodes a unique ORF known as K14 or vOX2 (Accession number 
U75698) that generates a membrane bound protein that shares remarkable homology 
with the human CD200 IgSF protein (Figure 1.12). vOX2 is expressed as a 
bicistronic message along with vGPCR (Figure 1.8) as an early product during lytic 
replication (Jenner et al., 2001; Paulose -Murphy et al., 2001; Talbot et al., 1999). 
Limited information is available on KSHV vOX2 and its role in viral 
pathogenesis. Importantly, vOX2 has been reported to bind with the human CD200R 
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and intriguingly, with near identical kinetics to the hCD200:hCD200R interaction 
(Barclay et al., 2002; Foster -Cuevas et al., 2004). One intriguing feature additionally 
possessed by vOX2, but not its cellular counterpart, CD200, is the encoding of a 
tripeptide sequence Arg -Gly -Asp (RGD) (Figure 1.12). Although it is not known if 
this motif is functional; the RGD sequence is commonly associated with binding to 
integrins, which are involved in cell adhesion, cell migration, thrombosis and 
lymphocyte interactions (Hynes, 1987, 1992, 1999). An RGD motif found in the 
foot and mouth disease virus (FMDV) P1 protein is believed to be involved in the 
virus -receptor interaction (Baxt and Becker, 1990; Fox et al., 1989; Grubman and 
Baxt, 2004). 
In 2002, Chung et al., reported data suggesting that vOX2 may act in an 
opposite manner to cellular CD200; instead of delivering a restrictive signal, their 
results implied that vOX2 may deliver an activating signal to myeloid -lineage cells. 
Therefore by promoting the production of inflammatory cytokines, vOX2 may be 
assisting angiogenic proliferation of KSHV- infected cells. In contrast to this paper, a 
more recent study by Foster -Cuevas et al. (2004) describe findings that not only 
describe the direct engagement of vOX2 with the host CD200R, but also the ability 
of this interaction to restrict TNF -a production by activated macrophages. Therefore 
via the direct cell surface engagement with CD200R, vOX2 may be able to regulate 
locally activated macrophage and subvert the host immune system, thus allowing 
increased viral replication. However, all of these findings have only been derived 
from in vitro studies using recombinant proteins; the role of vOX2 in vivo is still not 
know and may reveal a different role. 
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Table 1.4 Viruses possessing homologous genes to the cellular CD200 
Fruni . irus ORF Reference 











Capripox Lumpy skin 
disease virus 
U85 (Gompels and Kasolo, 
1996) 
U85 (Nicholas, 1996) 
K14 (Russo et al., 1996) 
R14 (Desrosiers et al., 1997) 
(Searles et al., 1999) 
M141 R (Cameron et al., 1999) 
S141 R (Willer et al., 1999) 
141R (Lee et al., 2001) 
Yb-C2R (Kilpatrick and 
Rouhandeh, 1985) 
LD138 (Tulman et al., 2001) 
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Figure 1.12 Schematic representation of the human CD200 protein and viral 
homologues from KSHV, RRV, MYX and YLDV. Ig domains of the variable (V) 
or constant 2 (C2) type are represented by circles. Positions of cysteines (S), 
forming the intramolecular disulfide bonds, and predicted sites for attachment of 
N- glycans (e) are indicated. NH2, amino terminus; COOH, carboxyl terminus; 
RGD, Arg -Gly -Asp. 
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1.6 Project Aims 
The potentially important role of CD200 within the complexity of the 
immune system in humans, mice and rats is only just becoming apparent. Recent 
findings of viral CD200- homologues is intriguing and suggests that this protein may 
play an important role in viral survival. The investigation of the role of KSHV's 
CD200- homologue, vOX2, will be important in getting closer to understanding 
KSHV pathogenesis. 
The core objective of this project was to characterise the vOX2 protein and 
gather a better understanding of the potential contribution of vOX2 to viral 
pathogenesis in vivo. This was achieved by: 
Protein expression studies 
Generation of MHV -76 recombinant viruses with the incorporation of 
vOX2 and selection markers (GFP- hygromycin resistance) 
Generation of appropriate control recombinant viruses 
In vitro and in vivo studies using recombinant viruses 
Thus allowing the role of vOX2 in viral pathogenesis to be investigated. 
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2.1 Tissue Culture 
2.1.1 Cell Lines 
All cells were obtained from in -house stocks (Table 2.1) and were cultured in 
sterile plasticware (Nunc) and incubated at 37 °C in a humidified atmosphere 
containing 5% CO2. Growth medium for all adherent and suspension cell lines is 
indicated in Table 2.1. 
2.1.2 Harvesting Adherent Cell Lines 
All adherent cell lines (Table 2.1) were harvested by trypsinisation, unless 
otherwise stated. Following decantation of medium from the flask, cells were briefly 
rinsed with 0.02% w/v versene, then incubated with 0.05% w/v trypsin for 3 -5 
minutes until the cells detached from the flask. Fresh medium was added to the cells, 
and then transferred to a sterile Falcon tube and the cells were pelleted by 
centrifugation at 500xg for 7 minutes. Cell pellets were resuspended in 10m1 fresh 
medium and counted. A new T175cm2 tissue culture flask with fresh medium would 
be reseeded with between 0.5 -5 x106 cells, depending on the next requirement of 
cells. 
2.1.3 Harvesting Suspended Cell Lines 
Viable cells were separated from dead cells by a ficoll gradient in all 
suspended cell lines. An equal volume of suspended cells were over -laid onto Ficoll- 
Hypaque (Pharmacia) and separated by centrifugal force (500xg for 20 minutes at 
4 °C), forming a buffy coat (interface between the medium and ficoll) of live cells 
and a pellet of dead cells. The buffy coat was collected and transferred to a new 
sterile universal and pelleted by centrifugation at 500xg for 7 minutes. The pellet 
was resuspended in 10m1 of fresh medium and counted. A gradient separation of live 
and dead cells was only performed approximately once every four weeks, fresh 
medium was added to the flask twice a week. If cells were required at times other 
than at the time of a gradient separation, an aliquot of suspended cells were taken and 













































































































































































































































































































































































































































































































2.1.4 Counting Cells 
Cells were counted by mixing a 1:1 mix of cell suspension with 0.4% Trypan 
Blue (Sigma), then loaded on to a haemocytometer. The unstained viable cells were 
counted per 1 mm square. 
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2.1.5 Transfection of Adherent Mammalian Cells 
2.1.5.1 Electroporation 
BHK -21 were harvested, counted and resuspended to 2.5 x 106 cells /ml. An 
8001A1 aliquot of the cell suspension (2x106 cells) was loaded into a chilled 4mm 
electroporation cuvette (EquiBio) followed by 5 -20µg of DNA. The mixture was 
thoroughly mixed and then electroporated using an Easyject electroporator (EquiBio) 
using the double pulse program (pulse 1:600V, 25µF, 99mQ, then following a 0.1s 
delay pulse 2: 250V, 1050µF, 99mS2). Immediately after electroporation, the mixture 
was transferred to 10m1 of fresh medium, and then sub -cultured into 2 wells of a 6 
well plate and incubated at 37 °C. 
2.1.5.2 Lipid -based using Effectene® Transfection Reagent (QIAGEN) 
Adherent cells were seeded in a 6 well plate 24 hours prior transfection, so 
that the cells were between 40 -80% confluent on the day of the transfection. A 
mixture containing 0.4µg DNA and DNA -condensation buffer (Buffer EC) to a total 
volume of 100111 was added to 3.2111 Enhancer and incubated at RT for 2 -5 minutes. 
After the addition of 101.xl Effectene Transfection Reagent to the DNA /Enhancer 
mixture, the sample was incubated for 5 -10 minutes at RT. The adherent cells were 
rinsed with PBS and then replaced with 1.6ml fresh medium. Fresh medium (6001.11) 
was added to the DNA mixture, mixed and immediately added drop -wise to the 
adherent cells, then incubated at 37 °C. Transiently transfected cells were harvested 
24 to 48 hours post -transfection. For the generation of secreted protein, growth 
medium was removed 24 hours post -transfection and replaced with the same amount 




2.1.6 Lytic Induction of KSHV Infected Cell Lines 
KSHV infected cell lines contain the virus in a state of latency. Lytic 
infection was induced following an overnight incubation with 3mM Butyrate 
(SIGMA). 
2.1.7 Inhibition of Glycosylation 
Glycosylation of proteins was inhibited by an overnight incubation of cells 
with 0.1 µg/ml Tunicamycin (SIGMA) 
2.1.8 Cell Lysis 
Cells were pelleted by centrifugation (500xg for 5 minutes), medium 
removed and then resuspended in an appropriate amount of cell lysis buffer (1 xPBS, 
1 %NaPO4, 2mM EDTA). Samples were mixed vigorously for 15 minutes. Cellular 
debris was pelleted by centrifugation (500xg for 1 minute). 
2.2 Molecular and Cloning Techniques 
2.2.1 Polymerase Chain Reaction (PCR) 
Most polymerase chain reactions (PCR) contained a reaction mixture 
comprised of 20mM Tris[pH8.4], 1.5mM MgC12, 0.25mM each of dATP, dGTP, 
dCTP and dTTP (Promega), lOpmol of each primer, 100 -500ng DNA template and 
1U Taq DNA polymerase (Promega) in a final volume of 504 All sets of reactions 
included a negative control, where template DNA was substituted with nuclease free 
H20. PCR primers were obtained from Sigma -Genosys or Invitrogen Life 
Technologies unless otherwise stated. A detailed list of sequence and cycling 
settings are described in Appendix 2. 
All reactions were set up in a contamination -free environment using barrier 
tips to minimize the risk of false positive reactions. PCR was performed in either 
thin -walled 0.5ml tubes or 0.2ml tubes on either a Biometra T3 Thermalcycler or 
Techne - Progene thermal cycler (both with heated lids). 30-40 cycles of PCR 
amplification was performed, consisting of an annealing (at primer specific 
temperatures), extension at 72 °C and denaturing stage at 95 °C, each stage was held 
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for 45 seconds unless otherwise stated (see Appendix 2 for primer specific annealing 
length and temperature). 
2.2.2 Purification of PCR Products 
Amplified DNA was purified using the QIAGEN PCR Purification System. 
Samples were mixed with a 5x volume of PB Buffer and then loaded into the spin 
cartridge. DNA bound to the membrane when the columns were centrifuged at 
12,000xg for 1 minute, the column was then washed with 700121 Wash Buffer (PE) 
and the membrane dried by centrifugation twice at I2,000xg for 1 minute. The DNA 
was recovered by the addition of 30 - 50111 Elution Buffer, incubated for 1 minute 
and then centrifuged for 2 minutes at I2,000xg. This same method was also used to 
`clean -up' a restriction digest reaction. 
2.2.3 Agarose Gel Electrophoresis 
DNA was analysed by electrophoresis on an agarose gel containing 0.5 -2% 
(w /v) agarose (Sigma) and 0.5µg /m1 ethidium bromide (Sigma) in TBE buffer. DNA 
samples were mixed 10:1 with gel loading buffer (15% w/v Ficoll type 400, 0.25% 
w/v bromophenol blue and 0.25% w/v xylene cyanol) and loaded into the gel. In 
conjunction with the samples, a DNA molecular weight marker (1µg of 1Kb DNA 
ladder or 1Kb Plus DNA ladder, Invitrogen) was also run. Electrophoresis was 
performed at 70 -130V in a horizontal tank (BIO -RAD) filled with 0.5x TBE buffer. 
DNA bands were visualized under ultraviolet light using an ultraviolet 
transilluminator (UVP). 
2.2.4 Gel Extraction of DNA 
DNA was extracted from an agarose gel using the Qiaquick Gel Extraction 
system (QIAGEN). The desired band of DNA (viewed by UVP) was cut out and 
transferred to a sterile 0.5ml eppendorf and weighed. Three times the volume buffer 
QG was added to one volume of gel (100mv100111) and heated at 50 °C until 
completely dissolved. One gel volume of isopropanol was added to the dissolved 
DNA mixture and samples were loaded into the spin cartridge. DNA was bound to 
the membrane by centrifugation of the cartridge at 10,000xg for 1 minute. The 
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cartridge was then washed with 750µ1 buffer PE and the membrane dried by 
centrifugation twice at 10,000xg for lminute. The DNA was eluted in 30 -5O111 of 
Elution Buffer, which was incubated for 1 minute and then centrifuged for 2 minutes 
at maximum speed. 
2.2.5 Ethanol Precipitation 
DNA was precipitated by the addition of 0.3 volume 7.5M ammonium acetate 
or 0.1 volume 3M sodium acetate [pH5.2], and then 3 volumes of 96% (v /v) ethanol 
(- 20 °C). The mixture was mixed thoroughly and incubated at -20 °C for 10 - 30 
minutes. The precipitated DNA was pelleted by centrifugation at 12,000xg for 5 
minutes, washed with 70% (v /v) ethanol, air -dried for 5 minutes and then 
resuspended in an appropriate volume of TE buffer. 
2.2.6 Quantification of DNA and RNA 
DNA and RNA samples were quantified using a Gene Quant II from 
Pharmacia Biotech. A 411l aliquot of the sample was loaded into a fine glass 
capillary and measured with a pathlength of 0.5mm at a 260nm absorbance. The 
Gene Quant II automatically calculated the concentration of DNA and RNA. 
Alternatively, approximate concentrations of DNA were made by visually comparing 
the intensity of DNA electrophoresed on an agarose gel with a known DNA 
concentration (1Kb DNA ladder, Invitrogen Life Technologies). 
2.2.7 Restriction Enzyme Digestion 
DNA restriction enzymes were obtained from either New England Biolabs or 
Roche and used according to the manufacturer's instructions. Buffers (x10) and 
BSA (x100) were supplied with the enzymes. Digest reactions were typically 
performed for 2 hours at 37 °C in a suitable volume containing 5 -10 units of enzyme 
per 1 -101.1g DNA. 
2.2.8 Blunt- ending DNA 
To blunt -end DNA following restriction enzyme digestion or PCR, 1U of T4 
DNA polymerase (Roche) and dNTP's (0.25mM of each dATP, dGTP, dCTP, dTTP) 
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was added and incubated at 12 °C for 15 minutes, then inactivated by incubation at 
75 °C for 10 minutes. 
2.2.9 De- phosphorylation of Linearised Plasmid DNA 
To inhibit self re- ligation of plasmid vectors, particularly a blunt -end ligation, 
the 5'- phosphate group on each end of the linear plasmid DNA was removed using 
shrimp alkaline phosphatase [SAP] (Roche). In a 10111 reaction, 1 U of SAP was 
added to up to 1pmol of DNA and 1111 10x buffer (0.5M Tris -HC1, 50mM MgC12 
[pH8.5]), then incubated at 37 °C for 1 hour and inactivated by heating to 65 °C for 15 
minutes. 
2.2.10 Ligation of DNA Fragments 
Ligation of DNA fragments were set up using a 1:1 -5 ratio of plasmid:insert 
fragment. Reaction mixture included lU T4 DNA ligase (Roche) and lx T4 DNA 
ligase buffer (30mM Tris- HC1[pH 7.8], 10mM DTT and 1mM ATP) (Roche) in a 
final volume of 10µ1, followed by overnight incubation at 4 °C for "sticky- ended" 
ligations and at room temperature for "blunt- ended" ligations. For rapid -ligation 
reactions, the mixture included lU T4DNA ligase (Roche) and 2x rapid -ligation 
buffer (60mM Tris -HC1 [pH7.8], 20mM MgC12, 20mM DTT, 2mM ATP and 10% 
(w /v) PEG) (Promega) in a final volume of 10111 and was incubated at room 
temperature for 5 -10 minutes. All ligation reactions included a negative control, in 
which dH2O replaced the DNA insert fragment, allowing the detection of self -ligation 
of the plasmid. 
2.2.11 Addition of BglII Linker 
Following linerisation of the plasmid at the desired site, the DNA fragment 
was ethanol precipitated (see 2.2.5) and resuspended in 101.1.l TE. A 50 -100 -fold 
molar excess of linker (3111) to DNA was added with 2111 IOx ligase buffer (500mM 
Tris -HC1 [pH7.5], 100mM MgC12, 100mM DTT, 10mM ATP), 1U T4 DNA ligase 
and made up to a final volume of 20111 with dH2O. The reaction was incubated over 
night at RT and then digested with BglII to digest excess linkers. 
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2.2.12 Site -Directed Mutagenesis 
Site -directed mutagenesis was performed on a fragment of KSHV DNA using 
the QuickChange® XL Site -Directed Mutagenesis Kit (Stratagene). HPLC -purified 
mutagenic primers were designed that possessed the required mutagenic site with 
approximately 10 -15 bases of correct sequence at either side. Reactions were set up 
as stated in the manufacturers protocol using; 1Ong of dsDNA template, 125ng of 
each primer, lx reaction buffer (100mM KC1, 100mM (NH4)25O4, 200mM Tris -HC1 
[pH 8.8], 20mM Mg504, 1% (v /v) Triton X -100, 1mg /m1 nuclease -free BSA, 
Stratagene), 1111 of dNTP -XL mix, 3µl QuickSolution and 2.5U Pfu Turbo DNA 
polymerase, in a total volume of 51111. Reactions were heated to 95 °C for 1 minute, 
then 18 cycles of 50 seconds denaturing at 95 °C, 50 seconds annealing at 60 °C, and 
extension at 68 °C for 2 minutes /kb of plasmid length (10 minutes for vOX2 -TOPO 
and 12 minutes for pSecTag2 -A). Following thermal cycling, 10U Dpnl restriction 
enzyme was added to the reaction and incubated at 37 °C for 1 hour to digest the 
parental (non- mutated) supercoiled dsDNA. A 2111 aliquot of the mutated dsDNA 
mixture was then transformed into XL 10 -Gold Ultracompetent cells (Stratagene). 
Once the competent cells (45111) had thawed gently on ice, 2111 0-ME mix was added 
and incubated on ice for a further 10 minutes, gently swirled every 2 minutes. Then 
2µ1 of the DpnI- treated DNA was added to the ultracompetent cells and incubated on 
ice for 30 minutes. Reactions were heat -pulsed at 42 °C for 30 seconds and then 
incubated on ice for 2 minutes. Following the addition of 0.5ml of SOC medium, the 
transformation reactions were incubated at 37 °C for 1 hour with shaking 225 -250 
rpm. An appropriate volume of each transformation reaction was plated on LB- 
ampicillin agar plates and incubated overnight at 37 °C. 
2.2.13 Transformation of Competent Bacteria by Heat Pulse 
Escherichia coli bacteria were either One Shot® TOP10 Competent Cells 
(Invitrogen Life Technologies) or Select96TM Competent Cells (Promega), unless 
otherwise stated, and were transformed according to the manufacturer's protocol. In 
brief, competent cells were thawed on ice and a 25111 aliquot transferred to a pre - 
chilled eppendorf. A 1 - 5111 aliquot of the ligation reaction was added to the 
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competent cells and incubated on ice for 30 minutes. Reactions were heat -shocked 
for 30 seconds at 42 °C, and then incubated on ice for 2 minutes and 250111 of pre - 
warmed SOC medium was added to each reaction. Following a 1 hour incubation at 
37 °C with shaking (225- 250rpm), 1001x1 -200µ1 of each transformation reaction was 
plated onto LB agar plates containing the appropriate selection antibiotic (10011g/m1 
ampicillin or 501.1g/m1 kanamycin, Sigma), and incubated at 37 °C overnight. For 
blue /white selection of positive colonies in TOPO TA cloning and pGEM -T Easy 
cloning, additional aliquots of 20µ1 200mM isopropyl ß -D thioglalactoside (IPTG) 
and 40111 2% (w/v) 5- bromo- 4chloro- 3- indoy°l- 13- D- galactoside (X -Gal) were added 
to the LB -Amp plate before the addition of the transformation reaction. 
2.2.14 Cloning PCR Products using TOPO TA Cloning Kit 
PCR products were directly cloned into pCR2.1 -TOPO (lnvitrogen) 
(Appendix 3), as described in the manufacturer's protocol. The kit provided a 
linearised plasmid with single 3'- thymidine (T) overhangs and Topoisomerase I 
covalently bound to the vector. The TOPO cloning reaction contained a final 
concentration of 200mM NaCl, IOmM MgC12, 1 -4111 fresh PCR product and l Ong of 
plasmid. The reaction was mixed gently and incubated for 5 minutes at room 
temperature, before transformation into One Shot Top 10 chemically competent cells 
(see 2.2.12). 
2.2.15 Cloning PCR Products using pGEM -T Easy Vector 
PCR products were cloned using pGEM -T Easy vector (Promega) (Appendix 
3) according to the manufacturer's instructions. A 10111 ligation reaction was 
prepared which included 2 x Rapid Ligation Buffer, SOng pGEM -T Easy Vector, 1- 
3111 PCR product and 3 Units T4 DNA ligase. The ligation reaction was incubated 
for 1 hour at room temperature and a 2111 aliquot used to transform One Shot Top 10 
chemically competent cells (see 2.2.12). 
2.2.16 Small Scale Preparation of Plasmid DNA (Mini- Preps) 
Mini -preps were usually performed using the alkaline lysis method via the 





manufactures protocol. An isolated bacterial colony was picked from an agar plate 
and grown up in 3 - 6 ml LB medium, with the appropriate antibiotic, overnight at 
37 °C on an orbital shaker. The bacterial solution was pelleted by centrifugation at 
10,000xg for 5 minutes in an eppendorf, and the bacterial pellet resuspended in 
250p1 lysis buffer, Buffer G1. A neutralisation buffer, Buffer G2 (25Oµ1), was then 
added gently mixed by inverting the tube six times and incubated for 5 minutes at 
RT. Buffer M3 (3501.1.1) was added and the solutions were mixed gently by inversion 
of the tube and the insoluble fraction was pelleted by centrifugation for 10 minutes at 
12,000xg. The supernatant was removed and loaded on to a spin column and the 
DNA bound to the membrane by centrifugation at 12,000xg for 1 minute. The spin 
column was then washed once with Buffer PE (750µ1) and dried by two 
centrifugation steps (12,000xg, 1 minute). DNA was eluted from the column by the 
addition of 50 - 75111 TE [pH 8.0], preheated to 70 °C, incubated for 1 minute before 
centrifuged for 2 minutes at 12,000xg. Samples were stored at 4 °C or -20 °C for 
long -term storage. 
2.2.17 Large Scale Preparations of DNA (Maxi -prep) 
Large Scale preparations of plasmid DNA were performed using anion 
exchange columns in the Endofree Plasmid Maxi Kit (QIAGEN) according to the 
manufacturer's instructions. Overnight bacterial cultures (250m1 for high yielding 
and 500m1 for low yielding) were centrifuged at 6,000xg for 15 minutes at 4 °C. The 
pellet was resuspended in 10m1 of Buffer P1 (50mM Tris [pH8.0], 10mM EDTA, 
10014ml RNase A), and then 10m1 of Buffer P2 (200mM NaOH, 1% (w /v) SDS) 
was added and gently mixed by inversion, followed by 5 minutes incubation at RT. 
A 10m1 volume of ice -cold Buffer P3 (3M potassium acetate [pH8.5]) was then 
added, mixed by gentle inversion and after 10 minutes incubation on ice, the mixture 
was filtered using a QIAfilter cartridge. Endotoxins were removed by the addition of 
2.5ml of Buffer ER and 30 minutes incubation on ice. A QIAGEN -tip 500 anion 
exchange column was equilibrated using 10m1 Buffer QBT (750mM NaCl, 50mM 
MOPS [pH7.0], 15% (v /v) isopropanol, 0.15% (v /v) Triton X -100), and the filtered 
lysate added to the equilibrated column and pulled through by gravitational force. 
The column was washed twice by the same method using 30m1 Buffer QC (1M 
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NaC1, 50mM MOPS [pH 7.0], 15% (v /v) isopropanol) and DNA eluted in 15ml 
Buffer QN (1.6M NaC1, 50mM MOPS [pH7.0], 15% (v /v) isopropanol). The DNA 
was precipitated by the addition of 0.7 volumes isopropanol and pelleted by 
centrifugation at 15,000xg for 30 minutes at 4 °C. The DNA pellet was washed with 
70% (v /v) ethanol before it was air -dried and resuspended in 200111 TE. 
2.2.18 DNA Sequencing 
DNA sequencing was performed in one of two ways. The first method was 
performed using the di -deoxy chain termination sequencing method by Mr Ian 
Bennet (Department of Veterinary Pathology, University of Edinburgh). Reactions 
were performed using a SequiTherm EXCEL II DNA Sequencing kit (cycle 
sequencing protocol) on a 4000L automated sequencing machine (MWG- Biotech). 
Alternatively, DNA sequencing was performed using the BigDye Terminator Cycle 
Sequencing reaction kit by Ms Jill Lovell (ICAPB ABI Sequencer, University of 
Edinburgh). BigDye reactions were prepared in 10µl volumes containing 4µì 
BigDye, 1.6 pmole primer, 2 -4µ1 DNA (200- 500ng). Reactions were placed in a 
thermal cycler for 25 cycles of 95 °C for 30 seconds, 50 °C for 20 seconds, and 60 °C 
for 4 minutes. The DNA product was then ethanol precipitated (see 2.2.5), and the 
pellet sent to ICAPB for sequencing. 
2.2.19 Sequence Analysis 
Sequenced DNA was compared with database sequenced using the basic 
alignment search tool (BLAST) programs on the NCBI web site 
http: / /www.ncbi.nlm.nih.gov /BLAST/ (Altschul et al., 1990). 
2.3 Virological Methods 
2.3.1 Generation of Recombinant Viruses 
Recombinant viruses were generated by co- transfection (electroporation) of 
BHK -21 cells with purified viral DNA (see 2.1.5.1) and an insert cassette fused to a 
portion of the viral genome, thus allowing homologous recombination to occur. 
In order to do this an extensive cloning procedure was undertaken to generate 
the insert cassette and it's fusion to a fragment of the viral genome. A schematic 
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diagram of the cloning strategy used to generate the plasmids used for the 
construction of the recombinant viruses is outlined in Figure 4.1. Using primers 
vOX -1 and vOX -2 the vOX2 ORF (128113- 128930 from KSHV) was amplified from 
BCP -1 DNA and cloned into the plasmid pCR2.1 -TOPO. The vOX2 ORF was then 
digested out using BspHI and NcoI, and inserted into pBVIRES.GFP, which was 
linearised with NcoI and then dephosphorylated. The IRES -vOX2 fragment 
(- 1.4Kbp) was cut from the plasmid first with NcoI and then XhoI, and cloned into 
the SmaI /Sall site in pHygEGFP1 to incorporate the CMV promoter and hygromycin 
resistant -EGFP (HygR -EGFP) fusion protein. The CMV 4 vOX2 fragment 
(-P5.4Kbp) was then cut out at the BsaBI site, however as this site was inhibited due 
to being blocked by dam methylation the plasmid was first transformed into dam 
negative competent cells, Epicurian Coli® SCSIIO Competent cells (Stratagene). 
The CMV - vOX2 fragment was digested with BsaBI, then a Bg11I site was added 
using a BgIII linker (see 2.2.11). Excess BglII sites were cut off following digestion 
with BglII. 
Due to difficulties separating the large CMV -3 vOX2 from the small 
backbone (-2.7Kbp), the insert was cloned into the BgIII site in pEGFP -N1, a 
kanamycin resistant vector (Appendix 3). The CMV -3 vOX2 insert was then cut 
out using the same BglII sites and ligated into the BamHI site of pBSIIKS -76LHE 
(plasmid generated by Macrae, 2002 ), which incorporates homologous DNA from 
the left hand end of the genome corresponding to 9539 -12569 of MHV -68. Two 
plasmids were generated: pBSIIKS -76LHE -vOX2F and pBSIIKS -76LHE- vOX2R. 
The plasmids were digested with PvuII and EcoRV to isolate the fused CMV-) 
vOX2 and 3Kb MHV -76 insert cassette and used in homologous recombination 
reactions to generate the recombinant viruses. 
BHK -21 cells were transfected by electroporation (see 2.1.5.1) with 5µg viral 
DNA (MHV -76) and 10µg of the linear homologous plasmid. Following 
transfection, the cells were placed into 6 -well plates and incubated at 37 °C overnight. 
The following day fresh medium containing 100pg/ml hygromycin was added to the 
wells, incubated at 37 °C and examined daily for the presence of viral plaques and 





2.3.2 Purification of Recombinant Viruses 
Following the generation of the recombinant viruses in 6 -well plates (see 
2.3.1), 4 -6 days later the infected cell monolayer was harvested in 1 ml of medium 
and viral particles released from the cells by freeze -thawing at -70 °C three times. 
Cellular debris was pelleted by centrifugation at 2,000xg for 5 minutes and the 
supernatant containing the virus, used in subsequent purification steps. 
All recombinant viruses were purified using a limiting dilution assay. BHK- 
21 cells were seeded and grown until approximately 60% confluent in a 96 well 
plate. These cells were then infected with serial dilutions (10 -1 to 104) of virus, with 
the aim of infecting cells at a concentration of 0.4 PFU /well, therefore a single 
plaque in 40% of the wells. The assay was incubated at 37 °C for 6 days and the 
lowest dilution well containing gfP expression was harvested by scraping the cells 
into the 2O0111 of medium. A 100µ1 aliquot of the sample was freeze -thawed at 
-70 °C three times to release virus particles and kept for further rounds of 
purifications. 
The remaining 1001Al sample was pelleted by centrifugation at 500xg for 5 
minutes, resuspended in 5011l TE buffer and freeze -thawed once. PCR grade 
Proteinase K (Roche) was added to a final concentration of 4001.tg/ml to each sample 
and incubated overnight at 55 °C. The Proteinase K was heat inactivated by a 10- 
minute incubation at 95 °C and then 101.1l of each sample was used as a template for 
PCR analysis (see 2.2.1). Plaques positive by PCR for the desired insert (vOX2 or 
IRES only) and correct orientation were subsequently used to infect the next round of 
limiting dilution assays. PCR for MHV -68 ORF 74 (vGCR) was used as a control to 
check for the presence of viral DNA. 
Viruses were purified until homogenous by PCR screening and after at least 3 
rounds of limiting dilution checked for the presence of wild -type virus (MHV -76) by 
PCR (primers Trepeat and M4 -B, see Appendix 2). If wild -type virus was still 
present at this stage a 6 well plate was infected with virus at a 10-3 dilution from a 96 
well plate. After 24 hours incubation at 37 °C, the cells were washed with medium 
and overlaid with medium containing 1% (w /v) LGT agar (Seaplaque® Agarose, 
Flowgen) and incubated at 37 °C for 5 days. The position of viral plaques expressing 
gfp were marked on the underside of the plate, and a Pasteur pipette was used to 
II Ilk )I ) 
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remove an agarose plug containing virus -infected cells. The agarose plug was 
transferred to a sterile tube containing 200µ1 of medium and freeze -thawed three 
times. The cellular debris was pelleted by centrifugation at 500xg for 5 minutes and 
the supernatant used in subsequent rounds of purification. Once PCR screening of 
plaques were positive for the desired insert and negative for wild -type virus, MHV- 
76, master stocks were made. 
Master stocks were made by infecting BHK -21 cells (3x10) with an MOI of 
approximately 0.01 and incubating on a shaker at 37 °C for one hour, then seeded in a 
T175cm2 tissue culture flask and incubated for 4 -6 days until 100% cytopathic effect 
(CPE) was observed. Cells that were still adherent were scraped into the medium 
and pelleted by centrifugation at 2,000xg for 20 minutes. The pellet was 
resuspended in 1ml of medium and freeze -thawed at -70 °C three times to release 
virus particles. Samples were then clarified by centrifugation at 2,000xg for 7 
minutes and the supernatant split into five CryoTubeTM vials and stored at -70 °C. 
2.3.3 Preparation of Viral Stocks 
(see 2.3.2 for generation of master stock) 
MHV -76 and the other recombinant viruses' working stocks were produced 
from sub -master stocks. Viral stocks were generated by infection of BHK -21 cells. 
Ten T175cm2 tissue culture flasks were seeded with a BHK -21 suspension (3x106 
cells per flask) of virally infected cells. Cells were infected with a MOI of 0.01 for 1 
hour at 37 °C on a shaker, and then incubated in flasks for 5 -7 days until 100% CPE 
was observed. 
All cells were scraped off into the medium and pelleted by centrifugation at 
2,000xg for 20 minutes at 4 °C. The cell pellet was resuspended in 3 -5 ml sterile PBS 
and disrupted by dounce homogenization for 30 strokes in a chilled tight -fitting 
Wheaton -Dounce homogeniser. The cell suspension was transferred to a glass 
universal and sonicated for 15 minutes, using a sonicating ice bath. After sonication, 
the suspension was clarified by centrifugation at 2,000xg for 20 minutes at 4 °C after 
which the supernatant was carefully removed and kept at 4 °C. The cell pellet was 
again resuspended in sterile PBS (1ml), dounce homogenized 30 times and clarified 
by centrifugation (2,000xg, 20 minutes, 4 °C), and the supernatant was removed and 
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added to the previous aliquot. Aliquots (50µl, 100111 and 200µ1) of the supernatant 
were stored in sterile CryoTubeTM vials at -80 °C. 
2.3.4 Titration of Infectious Virus 
Titration of infectious virus was performed by plaque assay on BHK -21 cells 
as previously described by Sunil- Chandra et al. (1992). Samples were thawed at 
37 °C and serially diluted 10 -fold in Glasgow's medium (4m1) in sterile plastic 
bijoux. A cell suspension of BHK -21 cells (2x106 cells per bijoux) was added to 
each dilution, incubated on a shaker for 1 hour at 37 °C, and plated into two 60mm 
Petri dishes to give duplicates. Growth medium was added to the petri dishes to give 
a final volume of 5m1. Negative controls containing uninfected BHK -21 cells were 
also included. All plates were incubated for 4 days in a humidified environment with 
5% CO2 and at 37 °C. Cells were fixed with 4% (v /v) neutral -buffered formaldehyde 
(Surgipath) for at least 30 minutes and then stained with 0.1% (w /v) toluidine blue 
for 15 -45 minutes. The number of plaques per dilution was counted using an 
inverted light microscope, and the number of plaque -forming units (PFU) was 
calculated per ml or per organ. 
2.3.5 Preparation of Purified Viral DNA 
Ten T175cm2 tissue culture flasks of BHK -21 cells were infected with virus 
in suspension at a MOI of 0.1. When 100% CPE was observed 4 -6 days later, the 
cells were scraped off into the medium and pelleted by centrifugation at 500xg for 20 
minutes at 4 °C. The cell pellet was resuspended in 3ml sterile PBS, and cells 
disrupted by dounce homogenisation (30 times) in a chilled Wheaton -Dounce 
homogeniser. The suspension was clarified by centrifugation at 2000xg for 20 
minutes at 4 °C and the supernatant was removed and stored at 4 °C. The remaining 
cell pellet was resuspended in 1m1 sterile PBS, dounce homogenised again for 30 
strokes and clarified by centrifugation at 2000xg for 20 minutes at 4 °C. The 
supernatant was removed and pooled with the previous aliquot of supernatant. 
Viral DNA was separated from the supernatant by ultra -centrifugation. The 
supernatant was overlaid on a sorbitol gradient (20% (w /v) D- sorbitol in PBS, 
Sigma), and pelleted by centrifugation at 22,100xg for 80 minutes at 4 °C. The viral 
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pellet was resuspended in 500111 of 50mM Tris [pH8.0], and 5m1 High Molecular 
Weight Extraction Buffer (02M Tris [pH8.0], 0.1M EDTA, 0.5% SDS (w /v)) was 
added. Proteinase K (Roche) was added to a final concentration of 1001.tg /m1 and the 
mixture was incubated overnight at 56 °C. Viral DNA was then gently extracted four 
times with phenol chloroform iso -amyl alcohol. The extraction was performed on a 
rotating tilting platform for 30 minutes each time, followed by a phase separation by 
centrifugation at 500xg for 5 minutes. The DNA solution was then extracted twice 
with chloroform iso -amyl alcohol. The DNA was precipitated with 0.3 volumes 
7.5M ammonium acetate and 3 volumes of cold 96% (v /v) ethanol, and then pelleted 
by centrifugation at 8,000xg for 30 minutes at 4 °C. The pellet was washed twice 
with 70% (v /v) ethanol, air -dried and resuspended in an appropriate amount of TE. 
2.3.6 In vitro Growth Curves 
A single -step growth curve and multi -step growth curve were performed on 
MHV -76 and the recombinant viruses in BHK -21 cells. A suspension of 4.8x106 
BHK -21 cells were infected with an MOI of 5 for the single -step growth curve and 
2.4x106 BHK -21 cells were infected with an MOI of 0.05 for the multi -step growth 
curve. Infection was performed in a sterile plastic universal and incubated for 1 hour 
at 37 °C while shaking. Cells were then pelleted by centrifugation at 12,000xg for 7 
minutes at 4 °C, washed twice with 10m1 of fresh medium, and then resuspended in 
24ml of fresh medium. A 1 ml aliquot was added to each well in a 24 well plate and 
incubated at 37 °C. Samples were taken in duplicate at appropriate time -points by 
scraping all the cells into the medium and stored in CryoTubeTM vials at -80 °C. 
Time -points for the single -step growth curve included: 0, 6, 12, 18, 24, 30, 36, 48, 60 
and 72 hours post infection, and for the multi -step growth curve included: 0, 12, 24, 
36, 48, 60, 72, 96, 120, and 144 hours post infection. All samples were freeze - 
thawed three times to release virus and infectious virus was measured by plaque 
assay (see 2.3.4). All titration reactions were performed in duplicate and on the same 
day using the same BHK -21 cells to ensure accurate comparison between values. 
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2.4 Southern Analysis of DNA (Southern Blotting) 
The DIG Luminescent Detection Kit (Roche) was used for Southern analysis 
of DNA. 
2.4.1 Digoxigenin (DIG) labelling DNA probes 
DNA fragments, between 400óp and 5Kbp, were isolated by agarose gel 
electrophoresis and quantified. An aliquot of 1 - 3µg of template DNA was added to 
ddH2O to a final volume of 16µ1, denatured by a 10- minute incubation in a boiling 
bath, and then quickly chilled in an ice /water bath. A 4µl aliquot of DIG -High Prime 
(Roche) was added to the denatured DNA, mixed and incubated at 37 °C overnight. 
The reaction was stopped by the addition of 21.11 0.2M EDTA [pH8.0] and heated to 
65 °C for 10 minutes. Probes were stored at -20 °C until used. Prior to immediate use 
for hybridisation, probes were denatured by heating to 100 °C for 5 minutes. 
2.4.2 Electrophoresis and Southern Transfer of DNA 
Viral DNA samples (21.tg per agarose gel lane) were digested with 10 - 20 
units of restriction digest enzyme overnight (see 2.2.7), and then loaded onto a 1% 
(w /v) agarose gel. Whereas, DNA samples extracted from tissue samples (see 2.8.6) 
were serially diluted and amplified by PCR (see 2.2.1), and then a 10 - 20111 aliquot 
loaded onto a 1% (w /v) agarose gel. A 51.11 aliquot of DNA Molecular Weight 
Marker III - digoxigenin-labeled (Boehringer Mannheim) was also loaded in one 
lane of the agarose gel. Once the gel was loaded, DNA samples were 
electrophoresed at 50 -80 volts for 4 -7 hours, visualized under ultraviolet light and 
photographed. The gel was rinsed in distilled water, then denatured by soaking in 
denaturing buffer (1.5M NaCl, 0.5M NaOH) for 20 -30 minutes with gentle agitation, 
and then rinsed again in distilled water. Neutralising of gel entailed soaking the gel 
in neutralising buffer (1.5M NaC1, 0.5M Tris -HCI [pH7.2], 0.001M EDTA) for 30 
minutes with gentle agitation. 
The DNA was then transferred overnight to a nylon membrane (Roche) by 
capillary transfer using 10x SSC. The blotting rig was assembled by covering a 
platform (above a tray of 10x SSC) with a 3MM filter paper (Whatman) wick, both 
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ends soaking in the 10x SSC. The gel was placed on top of the paper wick and the 
nylon membrane on top of the gel and flattened to ensure no air bubbles were 
present. The remaining exposed paper wick was covered with saran wrap. Three 
pieces (one pre- wetted) of 3MM filter paper were stacked on top of the membrane, 
followed by a stack of dry paper towels and a 500g weight to ensure capillary 
transfer during the night. 
The following morning the blotting apparatus was disassembled, membrane 
removed and rinsed briefly in 2x SSC. The DNA was UV cross -linked to the 
membrane using the "auto crosslink" setting on the Stratalinker 2400 (Stratagene) 
and either stored at 4 °C or pre- hybridised (see 2.4.3). 
2.4.3 Southern Blot Hybridisation using Digoxigenin -11 -dUTP 
The membrane was pre- hybridised by incubation in DIG Easy Hyb (Roche) 
at 50 °C for a minimum of 30 minutes in a rotating hybridisation oven (Techne 
Hybridiser HB -1). The pre- hybridisation buffer was discarded and replaced with the 
pre -warmed hybridisation solution (2111 DIG -labelled probe in 3.5ml DIG Easy Hyb) 
and incubated overnight at 50 °C in the hybridisation oven. The membrane was 
washed twice with 2x SSC, 0.1% (w /v) SDS for 5 minutes at RT, then washed twice 
with O.lx SSC, 0.1% (w /v) SDS for 15 minutes at 65 °C, rinsed briefly in washing 
buffer (0.1M Maleic acid, 0.15M NaCI; [pH7.5]; 0.3% (v /v) Tween 20), and then 
incubated for 30 minutes in lx blocking solution (blocking reagent dissolved in O.1M 
Maleic acid, 0.15M NaC1), at RT. Incubation for 30 minutes with the anti - 
digoxigenin- alkaline phosphatase (Roche), diluted 1:104 with 1 x blocking solution, 
was performed in a 20m1 volume at RT. Following this, the membrane was washed 
for two 15 minute incubations with washing buffer, transferred to a tray and soaked 
for 2 -5 minutes in detection buffer (0.1 M Tris -HC1, 0.1M NaC1 [pH9.5]), before a 
5 minute incubation with the chemiluminescent substrate CSPD (Roche) (diluted 
1:100 in detection buffer). The membrane was then briefly rinsed in detection 
buffer, placed on a piece of 3MM filter paper (DNA side up), sealed into a 
hybridisation bag and incubated for 10 minutes at 37 °C to enhance the luminescent 
reaction. The membrane was then exposed to autoradiographic hyper ECL film 
(Lumi -film chemiluminescent detection film, Roche) for 3 minutes to 3 hours at RT. 
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2.4.4 Stripping and Reprobing DNA Blots 
The alkali -labile form of DIG -11 dUTP enables an easy and efficient means of 
stripping the membrane. The membrane was rinsed thoroughly with ddH2O, 
followed by two 15 minute incubations in 0.2M NaOH, 0.1% SDS (w /v), at 37 °C, 
and then a 5 minute incubation in 2x SSC. The membrane was then prehybridised 
and hybridised with a second probe (see 2.4.3). 
2.5 RNA Analysis 
2.5.1 Direct Isolation of RNA from tissue or cells 
2.5.1.1 Isolation of total RNA using QIAGEN Rneasy Mini Kit 
Extraction of tRNA was performed using the QIAGEN RNeasy Kit, which 
required the disruption of up to 40mg tissue (amounts varied depending on tissue 
type) or up to 1x107 cells in Buffer RTL and then homogenisation by means of a 
QlAshredder. Following this, a one volume aliquot of 70% (v /v) ethanol was added 
and all samples passed through a RNeasy mini column by centrifugation at 8,000xg 
for 15 seconds. The columns were washed twice with 500111 Buffer RPE (8,000xg 
for 15 seconds) and tRNA eluted in two aliquots of 5O111 RNase -free water (8,000xg 
for 1 minute). 
2.5.1.2 Isolation of mRNA using SIGMA -Messenger RNA Micro Isolation Kit 
Messenger RNA was isolated directly from 102 to 106 cultured cells (or 10 - 
250mg tissue) using the Messenger RNA Micro Isolation Kit from Sigma. Cells 
were rinsed in sterile PBS and then incubated for 15 - 20 minutes in lml of pre- 
heated (45 °C) lysis buffer (Stock Buffer with RNase /Protein Degrader). The NaCl 
concentration was adjusted by the addition of 631.1l of sodium chloride (5M solution) 
to the 1 ml lysate solution, and then mixed and passed through a 21 gauge syringe 
four times to shear the DNA. A vial of oligo (dT) was then added to the lysate, 
gently rotated for 15 -20 minutes at room temperature, and followed by centrifugation 
of the suspension at 4,000xg for 8 minutes. The supernatant was discarded and 
oligo(dT) cellulose resuspended in 1.3ml binding buffer, mixed and supernatant 
discarded following centrifugation at 4,000xg for 4 minutes. This washing step with 
binding buffer was repeated another 3 times until the buffer was no longer cloudy. 
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After the final wash, the oligo(dT) cellulose was resuspended in 0.3ml of binding 
buffer and transferred to a spin column and centrifuged at 5,000xg for 10 seconds. 
The eluate was discarded and the spin column filled with binding buffer that was 
used to resuspend the oligo(dT) cellulose followed by centrifugation (5,000xg, 10 
seconds), and repeated 3 times. The addition of 200111 of low salt wash buffer was 
added, mixed and centrifuged (5,000xg, 10 seconds) to wash the rRNA from the 
cellulose. This was repeated a second time prior to the elution of the mRNA by the 
addition of 100p,1 of elution buffer, mixing, and centrifugation (5,000xg, 10 seconds), 
in a fresh RNase -free tube. This was also repeated, giving a final volume of 200µ1. 
The 200111 eluate was then mixed with 1Oµ1 glycogen carrier, 30111 sodium 
acetate (2M solution) and 600µ1 ice -cold absolute ethanol, and frozen on dry ice. The 
mRNA was recovered by centrifugation of the sample at 4 °C for 15 minutes at 
16,000xg, removal of the supernatant and resuspension of the mRNA pellet in 1 - 
1O111 of elution buffer and stored at -70 °C. 
2.5.2 Removal of DNA from RNA Preparations 
The RQ1 RNase -Free DNase system from Promega was used to remove 
DNA from RNA samples prior to RT -PCR. DNase digestion involved the use of 
1 unit of RQ1 RNase -Free DNase to a maximum of 1 11g of RNA. A 1 -81.11 aliquot of 
RNA, was mixed with 11.11 of 10x reaction buffer (400mM Tris -HC1 [pH8.0], 100mM 
MgSO4, 10mM CaCl2), the appropriate amount of RQ1 RNase -Free DNase (1U /111), 
and nuclease -free H2O to a final volume of IOµ1. The mixture was incubated for 30 
minutes at 37 °C and then stopped with the addition of 1111 RQ1 DNase Stop Solution 
(20mM EDTA [pH8.0]), and incubated at 65 °C for 10 minutes. The DNA free RNA 
was stored at -20 °C or immediately used in a RT -PCR reaction. 
2.5.3 Reverse -Transcription Polymerase Chain Reaction (RT -PCR) 
The ThermoScriptTM RT -PCR System (Invitrogen Life Technologies) was 
used for the generation of cDNA. In a 0.2ml tube 10pg - 5µg RNA was mixed with 
10µM gene -specific primer or 50µM Oligo(dT)20 primer, and up to a final volume of 
10µl with DEPC- treated water. The RNA and primers were denatured by an 
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incubation of 5 minutes at 65 °C and then placed on ice. A master reaction mix was 
made up of 4µ1 5x cDNA Synthesis Buffer (250mM Tris acetate [pH 8.4], 375mM 
potassium acetate, 40mM magnesium acetate), 1µl 0.1M DTT, 40U RNaseOUT, I µl 
DEPC- treated H20, 2µl 10mM dNTP Mix and 15U ThermoScript RT. A l01.t1 
aliquot of master reaction mix was added to each reaction tube on ice and transferred 
to a thermal cycler, incubated at 50 °C for 1 hour, followed by 5 minutes at 85 °C to 
terminate the reaction. Removal of the RNA template was carried out by the 
addition of 2 units of E.coli RNase H (2U /µl) to each reaction and incubated at 37 °C 
for 20 minutes. Samples of cDNA were stored at -20 °C or used immediately in a 
PCR (see 2.2.1). 
2.5.4 Labelling Northern Probes 
For the creation of dsDNA probes, DNA was radiolabelled using the 
Multiprime DNA labelling system kit (Amersham Biosciences). In brief, 
approximately 25ng of purified denatured DNA (100 °C for 2 minutes) and 501..tCi of 
32P -dCTP were mixed with buffer (solution 1; dATP, dGTP, and dTTP in Tris -HC1, 
MgC12, 2- mercaptoethanol), a primer solution (solution 2; Random hexanucleotides) 
and enzyme solution (solution 3; Klenow). The labelling reaction was mixed and 
then allowed to proceed for 1 hour at 37 °C. Unincorporated radionucleotides were 
separated from the labelled probe with a Sephadex G50 Nick Column (Amersham 
Biosciences). The column was rinsed with 2m1 of TE buffer [pH8.0], before the 
addition of 3ml of TE buffer to equilibrate the column. Subsequently, the labelled 
probe was added to the column, immediately followed by 400µ1 of TE buffer. The 
flow -through was discarded and a further 400µ1 of TE buffer added. The flow - 
through from this elution contained the radiolabelled DNA probe and was retained. 
Prior to use for hybridisation, radiolabelled probes were denatured by incubation at 
100 °C for 5 minutes and then chilled on ice. 
2.5.5 Northern Blotting 
Ten micrograms of total RNA was used per lane, and was initially diluted to a 
final volume of 61.11 with RNAse -free dH2O, and then mixed with l2111 of RNA 
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sample loading buffer (62.5% (v /v) deionized formamide, 1.14M formaldehyde, 
200µg /ml bromophenolblue, 2001.1g /ml xylene cyanole, 1.25x MOPS -EDTA- sodium 
acetate, 501.1g /ml ethidium bromide, SIGMA). Samples were incubated at 65 °C for 
15 minutes and then immediately chilled on ice. Molten agarose (144m1, 1.4 %) was 
cooled to 65 °C before the addition of 20m1 MOPS (0.2M) and 36m1 of formaldehyde 
(36 -38 %). The gel was subsequently set, loaded with RNA samples and 21..tg 
Transcript RNA marker (0.2 -10kb, SIGMA), and electrophoresed at 85V for 5 hours 
in running buffer (lx MOPS buffer). Following electrophoresis, the gel was rinsed 
four times in RNAse -free dH2O for a period of 10 minutes and then soaked in 10x 
SSC for a period of 15 minutes with gentle agitation. The membrane (Gene Screen 
Plus, NEN Lifescience Products) was also soaked for 15 minutes in 10 x SSC. The 
blot was assembled in the same manner as described for Southern blotting and left 
overnight (see 2.4.3). The following morning, the membrane was soaked in 2x SSC 
for 5 minutes with gentle agitation. The RNA was cross -linked to the membrane 
with a Stratalinker 2400 (Stratagene) and stored at 4 °C until hybridisation. The 
section of the membrane containing the ladder was cut off and soaked for 10 minutes 
in 1M acetic acid and then stained (0.2% (w /v) methylene blue, 0.4M acetic acid, 
0.4M sodium acetate) for approximately 10 minutes. Excess dye was gently rinsed 
off the ladder with dH2O and the membrane was allowed to air -dry. 
Northern blots were hybridised with dsDNA probes, generated as described 
in section 2.5.4. Pre -hybridisation (1 -2 hours) and hybridisation (4 -12 hours using 'A 
of the radiolabelled probe) were performed at 42 °C with Ultrahyb (Ambion). 
Membranes were washed in 2x SSC, 0.1% (w /v) SDS for 10 minutes at room 
temperature and then again in pre -warmed 2x SSC, 0.1% (w /v) SDS for 40 minutes 
at 65 °C with gentle agitation. The membrane was then dried on blotting paper and 
exposed to X -ray film (Kodak Biomax MS film, Amersham Life Sciences) either at 
RT or at -70 °C for 1 -20 hours. 
2.5.6 Stripping Northern Blots 
Double -stranded DNA probes were removed from northern blots by 
incubation of the nylon membrane with boiling dH2O containing 0.1% (w /v) SDS for 
15 minutes with gentle agitation. The process was repeated before incubation of the 
89 
l) 11). 1\:\ 
membrane in 2x SSC for 15 minutes with agitation. The membrane was then 
exposed to autoradiographic film to verify complete removal of the labelled probe. 
2.6 Protein Studies 
2.6.1 Production of secreted protein 
The extracellular portion of the vOX2 protein (nt 128113 -128927) was 
amplified by PCR (see 2.2.1) using primers Sec 1 and Sec2 (Appendix 2), and then 
excised at the restriction enzyme sites Xhol and HindIII (incorporated with the 
primers). This fragment of vOX2 was cloned into the Xholl HindIIl site of 
pCDNA3.1 /myc- His( -)A. Following verification of the correct clones by restriction 
enzyme digestion patterns, samples were transfected using the Effectene transfection 
reagent (QIAGEN) (see 2.1.5.2) into HEK293 cells and incubated for 24hours at 
37 °C. Transfection reactions were scaled up to use T175cm2 flasks. 
After the initial 24hour incubation, growth medium was removed and 
replaced with 10m1 Optimem (Gibco) and incubated for a further 24 -36 hours at 
37 °C. All the Optimem (containing secreted protein) was removed and purified for 
the myc -His6 tagged proteins using the SIGMA His -SelectTM HC nickel affinity gel. 
A 1ml aliquot of the His -SelectTM HC nickel affinity gel was pelleted by 
centrifugation at 5,000xg for 30 seconds, then rinsed twice with dH2O and twice with 
equilibrium buffer (50mM sodium phosphate [pH 8.0], 0.3M sodium chloride). The 
affinity gel was pelleted between each washing stage. The Optimem solution was 
then added to the affinity gel and gently mixed for 30 minutes at RT. The sample 
was pelleted again and remaining Optimem solution removed. The affinity gel was 
washed two times with 10 gel volumes of wash buffer (same as equilibrium buffer) 
for 4 minutes and then pelleted between washes. The pelleted affinity gel was mixed 
with 2 gel volumes of elution buffer (50mM sodium phosphate [pH8.0], 0.3M 
sodium chloride, 250mM imidazole) for 10 minutes, then pelleted by centrigfugation 
at 5,000xg for 5 minutes. The supernatant was removed and saved. Another 2 gel 
volumes of elution buffer was added and elution of the histidine proteins repeated. 
Aliquots of eluted protein were then concentrated using Viaspin4 columns 
from Vivascience. A 4m1 volume of protein was loaded into a Vivaspin4 column 
and concentrated to a 100 -3001.1l volume by centrifugation of the column at 5000xg 
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for 5 -7 minutes. Concentrated proteins were analysed by SDS -PAGE and Western 
blotting (see 2.6.2 and 2.6.3). In addition, approximately 1x106 transfected cells 
were pelleted and lysed in -100111 lysis buffer (see 2.1.8). An aliquot of the lysed 
cells was also analysed by SDS -PAGE and Western blotting. 
2.6.2 Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis 
(SDS -PAGE) 
SDS -PAGE analysis of proteins was performed using a BIO -RAD 
electrophoration and blotting system (by the method of Laemmli, 1970). The 
apparatus was assembled as stated in the manufacturer's instructions, ensuring the 
glass plates were clean and dry before use. Depending on the resolution required, 
resolving gels contained 10 %, 12% or 15% (w /v) acrylamide (BIO -RAD [40% (w /v) 
acrylamide: 2% (w /v) bis- acrylamide]), 375mM Tris [pH8.8], 0.1% (w /v) SDS, 
0.06% (w /v) ammonium persulphate and 0.08% (v /v) TEMED (Sigma). The 
resolving gel was poured and allowed to set before the stacking gel (5% (w /v) 
acrylamide, 125mM Tris [p1-16.8], 0.1% (w /v) SDS, 0.08% (w /v) ammonium 
persulphate and 0.2% (v /v) TEMED) was poured on top and a plastic comb inserted 
to form the sample wells. Once set, the gels were assembled in the tank and 500m1 
SDS -PAGE running buffer (25mM Tris, 250mM glycine, 0.1% (w /v) SDS) was 
added to the reservoirs. Samples for analysis were all diluted 1:2 with 2xLaemmli 
Loading Buffer (BIO -RAD) (50µl of ß- mercaptoethanol was added to every 950111 of 
buffer) and heated for 10 minutes at 95 °C. Samples were pelleted by centrifugation 
at 8,000xg for 2 minutes and then loaded onto the gel. In addition to the samples, a 
101.11 aliquot of Rainbow ladder (Amersham Bioscience) was loaded and run on the 
gel. Electrophoresis was performed at 30mA per gel, until the dye front had reached 
the bottom of the gel. 
2.6.3 Western blotting 
After analysis of protein samples by SDS -PAGE gel as previously described, 
the proteins were transferred to a nitrocellulose membrane hybond -ECL ( Amersham 
Biosciences) by the tank transfer system using a Mini -Trans Blot Cell (BIO -RAD). 
The transfer apparatus was assembled according to the manufacturer's instructions, 
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the tank filled with transfer buffer (25mM Tris, 250mM glycine, 20% (v /v) 
methanol) and the transfer was performed at 400mA for 1 hour. 
2.6.4 Immunoblotting 
Membranes were incubated in western blocking buffer (1% (w /v) BSA, 
0.05% (v /v) Tween -20 and 0.05% (w /v) Sodium Azide in PBS) containing 2% (v /v) 
normal rabbit or goat serum (depending on which species the secondary antibody 
was raised in), for approximately 1 hour at RT on a rotation bed. The membrane was 
then washed three times with PBS and then incubated with the primary antibody for 
1 hour to overnight. Antibodies, working dilutions and their source are outlined in 
Table 2.2. All antibodies were diluted in the western blocking buffer. After 
incubation with the primary antibody, the membrane was washed three times with 
PBS and then incubated with the secondary antibody for 1 hour to overnight. If 
required, the membrane was then incubated with a tertiary streptavidin conjugate for 
1 -3 hours. The membrane was then washed another three times and alkaline 
phosphatase (AP) activity detected. A BCIP/NBT tablet (Roche) was dissolved in 
IOml of dH2O and the membrane immersed in the solution for 5 - 45 minutes, then 
thoroughly rinsed in water and air -dried. 














Goat anti -rabbit Ig 









Mouse anti -myc 
1:2500 
(SIGMA) 
Goat anti -mouse 
linked to biotin 
1:500 
(SIGMA) 
Streptavidin - AP 
1:500 
(SIGMA) 
Suppliers are indicated in green, and working dilutions in blue. 
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2.7 Antibody Production 
2.7.1 Production of a GST Fusion Protein 
The vOX2 ORF was amplified by PCR using primers GEX1 and GEX2 (see 
Appendix 2 and 3) from DNA extracted from a BCP -1 cell line. The PCR product 
was then cloned into the pGEMT -Easy Vector (Progema), excised using Apal and 
SacII and purified. The vOX2 insert was then ligated into the bacterial expression 
vector pGEX -4T -1 (Amersham Pharmacia) in frame with the Schistosoma japonicum 
glutathione -S- transferase gene (GST), using the Smal site. Ligation and 
transformation of bacteria by heat pulse were performed (see 2.2.10 and 2.2.13). 
Clones positive after mini -prep and restriction enzyme digestion for the inserted 
DNA with Ndel and Xhol, were tested for expression of the fusion protein by loading 
a sample of an overnight culture on a SDS -PAGE gel for Western analysis (see 2.6.2 
and 2.6.3). 
2.7.2 Preparation of Glutathione Sepharose 4B 
The Glutathione Sepharose 4B (Amersham Pharmacia) matrix mixture was 
thoroughly mixed before a 1.33m1 aliquot is removed. The matrix was sedimented 
by centrifugation at 500xg for 5 minutes before removal of the supernatant. The 
matrix was then washed in 10m1 of cold PBS, to remove the ethanol storage solution, 
and then pelleted as before. After the supernatant was decanted, the matrix was 
resuspended in 1 ml PBS, resulting in a 50% slurry mix that was kept at 4 °C for up to 
1 month. 
2.7.3 Purification of GST -vOX2 Fusion Protein 
For the preparation of large -scale bacterial sonicates, overnight cultures were 
grown in LB containing 1001.1g /m1 ampicillin, of the clone of interest. The following 
day, cultures were diluted 1:10 fold into 200m1 fresh LB and ampicillin. Cultures 
were incubated at 37 °C in an orbital shaker and grown to log phase (2 -4 hours). 
Protein expression was then induced by the addition of IPTG (Invitrogen Life 
Technologies) to a final concentration of 0.1mM, and incubated for a further 3 hours. 
The bacterial culture was pelleted by centrifugation at 7,700xg for 10 minutes at 4 °C, 
and supernatant discarded (the pellet can be kept at -20 °C until used). The pellet was 
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resuspended in 10m1 ice -cold PBS with 100111 Proteinase Inhibitor (100x) (SIGMA), 
and cells disrupted by probe sonication for 30 -45 seconds. An aliquot of 20% (v /v) 
Triton X -100 was added to a final concentration of 1% (v /v) and mixed gently for 30 
minutes at RT. Cellular debris was pelleted out of the mixture by centrifugation at 
12,000xg (4 °C) for 10 minutes and set aside. To the supernatant, a 20011l aliquot of 
the 50% Glutathione Sepharose 4B slurry mix was added and mixed gently for 30 
minutes at RT. The absorbed fusion protein was concentrated by centrifugation of 
the suspension at 500xg for 5 minutes. The supernatant was discarded, the 
Glutathione Sepharose 4B pellet washed with 1001,tI of PBS and then pelleted by 
centrifugation at 500xg for 5 minutes. This was repeated twice more for a total of 
three washes. 
To elute the vOX2 -GST fusion protein, 10011l of glutathione elution buffer 
(10mM reduced glutathione in 50mM Tris -HC1 [pH 8.0]) was added to the pellet and 
incubated at RT for 10 minutes with gentle rotation. After centrifugation at 500xg 
for 5 minutes the supernatant containing the eluted protein was removed, and an 
additional l00111 elution buffer added to the pellet. This procedure was repeated 
twice to give three aliquots of eluted protein that were pooled and stored at -20 °C. 
To cleave the vOX2 protein from the GST the Glutathione Sepharose 4B 
pellet (with the fused protein) was resuspended in l00111 thrombin solution (500 
cleavage units in 0.5ml pre- chilled PBS, stored in aliquots at -80 °C), and mixed 
gently at room temperature for 4 -16 hours. The GST bound to the matrix is pellet by 
centrifugation at 500xg for 5 minutes and the supernatant containing the vOX2 
protein stored at -20 °C. 
The desired eluted protein and various samples along the procedure were 
analysed by Western Blot (see 2.6.4) for the presence of the vOX2 protein. 
2.7.4 Immunisation of a Rabbit for Antibody Production 
A 400µg sample of vOX2 -GST fusion protein was sent to Diagnostic 
Scotland for the immunisation of a rabbit. The rabbit was immunized and boosted 
three times over a three -month period. Blood samples were taken periodically after 
and before the immunisation process and the serum sample returned for analysis. 
94 
(II. A }'11R ' \\1)\11 111 )1)' 
2.7.5 Purification of Antibody from Rabbit Serum 
(using MAb Trap and HiTrap Desalting Kit) 
MAbTrapTM Kit (Amersham Pharmacia), an affinity chromatography kit, was 
used for the purification of the vOX2 -GST antibody, followed by the removal of low 
molecular weight contaminants using the HiTrap Desalting Kit (Amersham 
Pharmacia). The pre -packed column is filled with 1 ml Protein G Sepharose High 
Performance and was initially prepared by passing through 5ml of distilled H2O at a 
rate of 1 drop per second. The column was then equilibrated with 3m1 of lx binding 
buffer. The serum sample was prepared by extracting any particles that may be 
present by filtering the sample through a 0.45µm filter and then diluting 1:1 with l x 
binding buffer. The prepared serum sample (5m1) was then applied to the column 
and washed with 5 -10m1 of binding buffer until no material appears in the effluent. 
The antibody was eluted with 3 -5m1 1 x elution buffer and collected in 1 ml aliquots. 
The absorbance (A280) was measured and the first two 1 ml aliquots were pooled 
together. The purified IgG fractions were then desalted using the HiTrap Desalting 
column, packed with a size exclusion matrix Sephadex G -25 Superfine. The column 
was first equilibrated with 25m1 of sterile PBS and then loaded with 1.5ml of the 
purified IgG fraction. The high molecular weight components were eluted with the 
addition of 1.5ml of sterile PBS and collected in a tube and stored at -20 °C. Both 
columns were equilibrated with 1- 25ml 20% (v /v) ethanol for storage and future use. 
The antibody was tested by Western Blot analysis (see 2.6.4) 
2.8 Animal Experiments 
2.8.1 Infection of Mice 
All animal experiments were performed under a Home Office Personal and 
Project License issued under the Animal (Scientific Procedures) Act 1986. BALB /c 
and C57 /Blacks mice (3 -4 weeks old) were supplied from Harlan and kept in -house 
for one -week prior to use. Mice were anaesthetised with halothane (Menial) in an 
anaesthetic chamber and inoculated intranasally with 2x105 PFU virus, in 4Oµ1 sterile 
PBS. At various time points post- infection, mice were euthanased by CO2 
asphyxiation and tissues harvested for analysis. Spleen and MLN samples were 
either kept in complete RPMI medium on ice, snap frozen at -80 °C or in 10% (v /v) 
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neutral buffered formaldehyde (Surgipath). Lung samples were either snap frozen at 
-80 °C, inflated and stored in 10% (v /v) neutral buffered saline, or inflated with 50% 
OCT (in sterile PBS) (Surgipath) then frozen on dry ice and isopentane (methyl -2- 
butane) and stored at -80 °C. 
2.8.2 Determination of Spleen Weight 
Spleen weights were determined using a Mettler AE 163 balance (to the 
nearest mg). 
2.8.3 Infective Centre Assay for the Detection of Latent Virus 
Freshly harvested spleen samples (kept in complete RPMI medium) were 
teased to a single cell suspension using a scalpel blade in a 60mm Petri dish 
containing 3ml of complete RPMI medium (RPMI 1640 supplemented with 10% 
(v /v) FCS, 701Ag/ml penicillin, 1011g /ml streptomycin, 501AM ß- mercaptoethanol, 
2mM L- glutamine and 25mM HEPES) (Invitrogen Life Technologies). The cell 
suspension was then transferred to a sterile universal and pelleted by centrifugation 
at 600xg for 5 minutes at 4 °C. The supernatant was discarded and remaining red 
blood cells lysed by osmosis due to the addition of 1 ml of sterile dH2O and mixed, 
followed by the immediate addition of 9m1 of sterile PBS to establish equilibrium. 
The cellular debris was allowed to settle to the bottom of the universal and the top 
8m1, containing the cell suspension was carefully removed and pelleted in a fresh 
universal by centrifugation at 600xg for 5 minutes at 4 °C. The pellet was 
resuspended in 5ml complete RPMI medium and counted. 
Petri dishes were filled with 5m1 complete RPMI medium, 2x106 BHK -21 
cells and a 10 "1, 10 -2 or 10 
"3 
dilution of splenocytes. The mixture was gently agitated 
and incubation at 37 °C for 5 days. Monolayers were fixed with 4% (v /v) neutral 
buffered formaldehyde (Surgipath) for at least 30 minutes and then fixed with 0.1 % 
(w /v) toluidine blue for 15- 45 minutes. All assays were performed in duplicate. The 
number of plaques per spleen were counted using a light microscope. A 1.8ml 
aliquot of the excess splenocytes was kept in a CryoTubeTM and stored at -80 °C for 
other DNA analysis. 
This method was also used for the detection of latent virus in MLNs. 
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2.8.4 Titration of Infectious Virus in Lung Samples 
Lung samples stored at -80 °C were thawed and homogenized twice in a glass 
tissue homogeniser, in a total volume of 1.8ml Glasgow's complete medium. 
Samples were freeze -thawed to disrupt cell membranes and clarified by 
centrifugation at 2,000xg for 5 minutes at 4 °C. Titration of infectious virus was 
performed by plaque assay on BHK -21 cells (see 2.3.4). 
2.8.5 Analysis of Data 
Data was analysed using GraphPad Prism software (San Diego, California), 
version 3.0 for Windows. In all cases, a two -way analysis of variance with 
Bobferroni's post -test was used and p values are indicated in the text. 
2.8.6 Isolation of DNA from Mouse Tissue 
A QIAamp® DNA Mini Kit was used for the isolation and purification of 
DNA from mouse tissue samples. Approximately 25mg of lung tissue or 10mg of 
spleen tissue or 106 -107 splenocytes were resuspended in 180µ1 Buffer ATL. After 
the addition of 20µl of 19mg /m1 Proteinase K (Qiagen), samples were vortexed and 
incubated for 4 -16 hours at 56 °C with gently agitation. A 200111 aliquot of Buffer 
AL was added to all samples, mixed and incubated at 70 °C for 10 minutes before the 
addition of 200111 of ethanol (96 %) and final mix. The samples were then transferred 
to a QIAamp Spin column and passed through the column by centrifugation at 
6,000xg for 1 minute. The filtrate was discarded and column first washed with 
Buffer AW 1 (500µ1) and then Buffer AW2 (500µ1), with centrifugation at 6,000xg 
for 1 minute after each wash, and twice after the last wash to ensure all residual 
buffer was discarded. The QIAamp Spin Column was then transferred to a sterile 
collection tube to elute the DNA. Between 30111 to 40µ1 of Buffer AE was added to 
the column, incubated at room temperature for 5 minutes and then the DNA was 
eluted by centrifugation of the column at 6,000xg for 1 minute. This step was 
repeated to give a final volume of 60µ1 -80µ1 of DNA, samples were stored at -20 °C. 
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2.8.7 Simultaneous Isolation of RNA and DNA from Animal Tissue 
For the simultaneous isolation of RNA and DNA from animal tissue a 
QIAGEN RNA/DNA kit was used. This initially involved the homogenisation of the 
tissue samples with a mortar and pestle set in a liquid nitrogen bath, in order to keep 
the samples frozen. Once ground to a powder, with most of the liquid nitrogen 
evaporated off, the frozen samples were added to a cooled tube of lysis buffer 
(1.5m1) and then mixed. The homogenised samples were then passed through a 
QlAshredder column (Qiagen) by centrifugation at 10,000xg for 2 minutes. The 
elute was collected and 500111 of Buffer QRV1 was added, mixed and centrifuged at 
15,000xg (4 °C) for 20 minutes. The supernatant was transferred to a RNase -free 
collection tube and 0.8 volumes of ice -cold isopropanol added, mixed and incubated 
on ice for 5 minutes. Samples were then centrifuged at 15,000xg for 30 minutes at 
4 °C, supernatant discarded and 1501.il Buffer QRL1 added to the nucleic -acid pellet. 
The tubes were heated at 60 °C for 3 minutes and mixed to dissolve the pellet. 
An 1.35m1 aliquot of Buffer QRV2 was added, mixed and centrifuged at 5,000xg 
(4 °C) for 5 minutes, during which the QIAGEN -tips were equilibrated by the 
addition of lml of Buffer QRE. The supernatant was then applied to the QIAGEN- 
tip and allowed to enter the resin by gravity flow. The flow -through was set aside 
and kept at room temperature, for isolation of the DNA later. 
The QIAGEN -tips were then washed by the addition of 2m1 (2x 1m1) of 
Buffer QRW, and the RNA eluted by the addition of lml of pre- heated (45 °C) Buffer 
QRU. A 1 volume of ice -cold isopropanol was added to the RNA elute and kept on 
ice while the final extraction of DNA was made. 
The DNA elute from earlier was placed into the same QIAGEN -tip and 
allowed to enter the resin by gravity flow, this was then repeated with the eluted 
flow -through and finally the QIAGEN -tip was washed with 3ml (3x 1m1) of Buffer 
QC. The genomic DNA was eluted into 1ml of pre- heated (45 °C) Buffer QF. 
Room -temperature isopropanol (0.7 volumes) was added to the eluted DNA solution, 
mixed thoroughly, and incubated at room temperature for 10 minutes. The RNA (on 
ice) and the DNA were then centrifuged at 15,000xg for 30 minutes at 4 °C. The 
supernatant was carefully removed and the pellet was washed with ice -cold 70% 
(v /v) ethanol and then again pelleted by centrifugation at 15,000xg (4 °) for 20 
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minutes. The pellets were air dried for approximately- 10 minutes and the DNA 
dissolved in TE and RNA dissolved in RNase-free water. DNA 
were stored at -20°C. 
RNA samples 
2.8.8 Histopathology 
Lung, spleen and MLN samples taken from animal experiments were 
stored in various methods. Mice were euthanased by CO, asphyxiation i,,id the 
lungs were inflated via the trachea. Samples fixed in 10% (v % ) neutral buffered 
formaldehyde were processed routinely into paraffin wax-en-obeddedi sections at the 
Pathology Department. Easter Bush. Lung. spleen and MLN swindles were snap 
frozen in liquid nitrogen and sectioned at Easter Bush_ In .iution, some lames% 
samples were inflated with 50% (v/v) OCT en slowly frozen on mix of 
isopentane and dry-ice, and then also sent tO Easter Bush to be sectioned. One 
section from all samples was stained with haematoxylin and eosin_ and examined by 
light microscopy. 
2.9 Microscopy 
2.9.1 Fixation of Cells to Slides 
Cells were resuspended to 0.5 - 1x106 cells/ml int sPBS and either air-dried or 
attached by centrifugation using a Cytospin 2 (ThelintoShandon) onto a glass slide 
(BDH). Most cells were fixed by immersio f 'e slides into ice-cold 
methanol/acetone (1:1) for 2 minutes and then air-dried. Other cells and tissue 
samples (frozen) were fixed by incubating the slide in 4% tw/v) t Hbrmaldehyde in 
PBS for 10 minutes to 2 hours at RT. The slides were 
immediately, or air-dried and stored at -20cC. 
en washed in PBS and used 
2.9.2 Immunostaining 
Slides were incubated for a minimum of 30 minutes at RT in iIIMIDIUZIO-- 
blocking solution (1% (w/v) BSA, 1% tv/v) Triton-X-100 0,, hd 01% viilv)t Sodium 
azide. in PBS) with 2% (v/v) normal goat or rabbit serum (dependirrtz on which 
species the secondary antibody was raised in), to prevent non-specific antibody-- 
binding. The slides were then washed three times for three minutes with gentle 
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agitation) in PBS and incubated with an appropriate amount of diluted primary 
antibody for 1 hour at RT. After three washes with PBS, the slides were incubated 
for 1 hour at RT with the diluted secondary antibody. After the final three washes, 
with PBS, slides were allowed to dry and were mounted in fluorescent mounting 
medium (DAKO). Fluorescence was examined using a Nikon Diaphot 200 
Ultraviolet Microscope. 
Antibodies, working dilutions and their source are outlined in Table 2.3. All 
antibodies were diluted in the immuno -blocking buffer. 








Rabbit anti -MHV -68 
polyclonal 
1:250 
Goat anti -rabbit alexa 








vOX2 -GST polyclonal 
1:50 
4% PFA 





Mouse anti -FLAG 
1:200 
SIGMA 
Rabbit anti -mouse 







Rat anti- mCD200 
1:200 -2000 
Serotec 
Goat anti -rat alexa 









Working dilutions are indicated in blue and commercial suppliers in green. Abbreviations: 
PFA; paraformaldehyde. 
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Appendix 1: General Solutions 
Unless otherwise stated, all chemicals were obtained from Sigma or Merck BDH 
Hank's buffered salt solution 
(HBSS) 
150mM NaC1, 25mM HEPES, 5mM KC1, 
5mM glucose, 1mM CaC12, 1mM KH2PO4, 
1mM MgC12, 1mM Na2HPO4, 1mM MgSO4, 
0.001% (w /v) phenol red [pH 7.0] 
Luria -Bertani (LB) medium 1% (w /v) tryptone, 1% (w /v) NaCI 
0.5% (w /v)yeast extract 
LB Agar lx LB broth, 1.5% (w /v) Bacto -Agar 
Phosphate- buffered saline (PBS) 150mM NaC1, 2.5mM KCI, 
10mM Na2HPO4, 1mM KH2PO4 [pH 7.4] 
Rnase -free H2O dH2O, 0.1% (v /v) Diethylpyrocarbonate, 
Autoclave 
SOC medium lx LB broth, 20mM glucose, 20mM MgC12 
20 x SSC 3M NaC1, 300mM Na citrate [pH7.0] 
TE buffer 10mM Tris -HCI [pH8.0], 1mM EDTA 
TBE buffer 45mM Tris -borate, 1mM EDTA 
Tris- buffered saline (TBS) 50mM Tris -HC1, 150mM NaC1 [pH 7.6] 
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Appendix 2: Oligonucleoties utilized in this study 
All primers were synthesized by SIGMA Genosysis, Invitrogen or Gibco BRL Life 
Technologies 







5'- GGGGTACCATGGTACACACA '11"1"1TTGATTGTCCC -3' 
Xbal 











5'- GGGGTACCATGGCTAGCCTCTTCATTTCATTACC -3' 








5'- GGGGTA CCATGGCTAGCCTCTTCATTTCATTACC -3' 









5'- GACTCTCGAGCCATGTCTAGCCTCTTCATTTC -3' 
Hi» d1II 
































5'- GCCACGATGCTTGTCCTGCG -3' 
5'- TTAGGAGCTTAGTCTACAAACRG -3' 
55 °C 
(1min) 
MHV -68 ORF74 










nt 2932 -3127 and 
MHV -68 M4 frag. 









nt 1 -364 and 
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Trepeat 
M4 -B 
5'- GCGCCAGGAGGAGCTAGGCCACG -3' 









5'- GACGGATCCGGCACATTTGCTGCAGAACCC -3' 
5'- TGCCTTAAGGAACGGCGCCTGTGTACTC -3' 
55 °C 
(45s) 
MHV -68 ORF50 




5'- TGGATATTGTTGCCATCAATGACC -3' 






5'- AGTGGTGACCCAGGATGAA -3' 







5'- GCCCTAGCAGTGCTCTTAAT -3' 





* This set of primers was used for the site directed mutagenesis of the RGD sequence 
within vOX2 (in pCR2.1- TOPO /vOX2), with the following cycling conditions: lx 
95 °C for lmin, 18x (95 °C for 50s, 60 °C for 50s, 68 °C for 10min [2min/plasmid kb]), 
lx 68 °C for 7min. 
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Appendix 3: Cloning vectors utilised in this study 
Vector pGEM -T Easy. 
This vector was obtained from Promega. 
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acZa.ATû 
N;;,i III Kpl I Cc I Bav?HI Soe I 
hA13 ReYerse Primer I 
I I I I I 
CA.a - " ='T _TG 
" 
=TC =.TT - - - TT> CTA CCG ACC TCG GAT CTA 
:;TC' CTT TGT __,-- T=._ T_; TA: T. T1;1' ',..:.;T TC; r_.. _:;T ,.. - TCG ._a_ _TA ;LT G°-.T 
BOO EcoR I F,TR I 
GTA ACC GCC CCC AGT GTG I CTG GAA TTC GCC CTT . _.Aj, TTC TCC 
CAT T3^ -..., CJA T_F: Cr._ GAC CTT AAG _GG GA TIC --' CTT AAG AC-. 
EcvR V ctsoc I Atoll Xlx, I h'si I Xtra I Aa.: I 
I I I I I I 1 
AGA TAT CCA TCA CAC TvG CGG CCG CT_ GAG CAT GCA TCT AGA AAT TC 
TCT ATA GGT AGT GTil ACC GCC GGC GAG CTC GTA CGT AGA TCT _ C_ GGG TTA ACC 
T7 Promoter 1113 Forward r -20: Primer 
AGT GAG TCG TAT TA 




AAT T'A CTG GC'C GTC GTT TTA W;Ft CGT CGT GAC T3'_; GAA AAC 
G TTA A _;T CAC Cg_; CAC CAA. AAT GTP CCT. GCA CTG ACC _ CTT T'I'G 
pC R"=`2.1-TO PO" 
3.9 kb 
Vector pCR®2.1 -TOPO. 
The vector pCR®2.1 -TOPO was obtained from Invitrogen. 
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' Than is an ATG upstream 
of th.;.Xbo I B:1,11-11 
T I 111 
A I 9),' it; 
Vector pcDNA3. 




Ileu Val Pro Arg Gr? Seri Fro Glu File Pro GI? Ana La Glu Arla Fro Hs Arg 
CTG GTT CCG G GA T 0)3 G=CCG4.363.1, CTC XT G 
BA mH I ExP I L----;-rnt---'31 :pl irul Nci I Slop coleus 
Vector pGEX-4T-1. 
The vector pGEX-4T-1 was obtained from Pharmacia Biotech. 
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CZ Z3 
IQx myc epitope 6xHis 




A, B, C 
5.5 kb 
Vector pcDNATM3.1 /myc- HIS( -). 




The vector pSecTag2/PSA was obtained from Invitrogen. 
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The vector pBV.IRES.EGFP1 was kindly supplied by Dr James 
Stewart, at the University of Edinburgh. 
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BgIII 













laso iom iom neo r: 
5'MCS: AGGCTAGCCTCGAGAATTCACGCGTGGTACCTCTAGAGGATCC 
Mel Doi Loll A/frI Kim I FamHI 
DU 3t;a :347U :}lfll :}HU 
3'MCS: TAAAGCGGCCGCGACTCTAGAGTCGACCCGGGCGGCCGCTT 
Not I I Sal i Sma I ."6r I 
Acci 
Vector pHygEGFP. 
The vector pHygEGFP was obtained from BD Biosciences 
Clontech. 
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BSIG I (1389) 
Not I (1402) 
Xba I* (1412) 
Af/ II (1640) 
Dra III (1874) 
1".n1 CAI nll .. Pi C.4 ... ,.. EaiP 
G CTA GCG CTA CCG GAC TCA GAT CTC GAG CTC MG CTT CGA ATT CTG CAG TCG ACG GTA CCG CGG GCC CGG GAT CCA CCG GTC GCC ACC ATG GTG 
Nha I Eco97 HI BgIII Xho I 
ac 
Hind III EcoN I Pst I Sol I Kpn I Ape I BemH I Age I 
S I 
Ee1196 II 
Acc I Asp718 I` 115111201 Xme 1 
Sac II Smal 
Vector pEGFP -N1. 
The vector pEGFP -N1 was obtained from BD Biosciences Clontech. 
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BssH II 619 BamHI 


















Vector pBluescript II KS( -) 
The vector pBluescript II KS ( -) was obtained from Stratagene. The 
clone pBSIIKS- 76LHE, was generated by Alastair Macrae by inserting 
a 3Kb fragment of MHV -76 (corresponding to 9539 -12569 of MI-W- 
68 accession number U97553) into the BamHI and EcoRI site in the 
multiple cloning site. 
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Appendix 4: Commercial suppliers of reagents and equipment used 
in this study 
Ambion Inc., Ambion (Europe) Ltd., Ermine Buisness Park, Spitfire Close, 
Huntingdon, Cambridgeshire, PE29 6XY, UK 
www.ambion.com 
Amersham Pharmacia Biotech UK Ltd., Amersham Place, Little Chalfont 
Buckinghamshire, HP7 9NA, UK 
www.apbiotech.com 
BD Biosciences, 21 Between Towns Road, Cowley, Oxford, OX4 3LY, UK 
www.bd.com 
BD Biosciences Clontech UK, Unit 2, Intec 2, Wade Rd., Basingtoke, Hampshire 
RG24 8NE, UK 
www.clontech.com 
BD PharMingen, 10975 Torreyana Road, San Diego, CA 92121 
www.pharmingen.com 
Bio -Rad Laboratories Ltd., Bio -Rad House, Maylands Avenue, Hemel Hempstead 
Hertfordshire, HP2 7TD, UK 
www.bio -rad.com 
DAKO Ltd., Denmark House, Angel Drove, Ely, Cambridgeshire, CB7 4ET, UK 
www.dako.com 
EquiBio, Action Court, Ashford Road, Ashford, Middlesex, TW 15 1 XB, UK 
www.equibio.com 
Flowgen, Novara House, Excelsior Road, Ashby Park, Ashby de -la Zouch, 
Leicestershire, LE65 1NG, UK 
www.flowgen.co.uk 
Invitrogen Life Technologies, Invitrogen Ltd, 3 Fountain Drive , Inchinnan 
Business Park, Paisley, PA4 9RF, UK 
www.invitrogen.com 
Merck Ltd., Hunter Boulevard, Magna Park, Lutterworth, Leics, LE17 4XN 
www.merckeurolab.ltd.uk 




{:IIAIY1'1-?R. 1 WT AND \W TI 10I),, 
Miltenyi Biotec Ltd., Almac House, Church Lane, Bisley, Surrey, GU24 9DR 
www.miltenyibiotec.com 
Molecular Probes Europe, Poort Gebouw ,Rijnsburgerweg 10 ,2333 AA Leiden 
The Netherlands 
www.probes.com 
MWG- Biotech AG, Mill Court, Featherstone Road, Wolverton Mill South, Milton 
Keynes, MK12 5RD, UK 
www.mwg- biotech.com 
New England Biolabs (UK) Ltd., 73 Knowl Piece, Wilbury Way, Hitchin, 
Hertfordshire, SG4 OTY, UK 
www.neb.com 
Roche Diagnostics Ltd., Bell Lane, Lewes, East Sussex, BN7 1 LG, UK 
http: //biochem.roche.com 
QIAGEN Ltd., Boundary Court, Gatwick Road, Crawley, West Sussex, RH 10 2AX 
www.qiagen.com 
Santa Cruz Biotechnology, 2161 Delaware Avenue, Santa Cruz, CA 95060 USA 
www.scbt.com 
Serotec Ltd., 22 Bankside, Station Approach, Kidlington, Oxford, OX5 1JE, UK 
www.serotec.com 
Sigma -Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham, Dorset, 
SP8 4XT, UK 
www.sigma-aldrich.com 
Stratagene Europe, Gebouw California, Hogehilweg 15 , 1101 CB Amsterdam 
Zuidoost,The Netherlands 
www.stratagene.com 
Surgipath Europe Ltd., Venture Park, Stirling Way, Bretton, Peterborough 
PE3 8YD, UK 
www.surgipath.com 
ThermoHybaid, Action Court, Ashford Road. Ashford, Middlesex, TW15 1XB, UK 
www.thermohybaid.com 
Vivascience AG, Feodor- Lynen- Strasse 21, 3065 Hanover, Germany 
www.vivascience.com 
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Chapter Three: Characterisation of the 
vOX2 protein 
3.1 Analysis of vOX2 protein sequence 
3.2 Generation of anti -vOX2 antibody 
3.3 Cellular localisation of vOX2 
3.4 Expression of secreted vOX2 protein 
3.5 Discussion 
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Chapter Three: Protein Expression Studies 
At the time of commencing these studies, information on the KSHV vOX2 
protein was very limited. The aim of the following work was to characterise the 
vOX2 protein, including the generation of an antibody against vOX2, determination 
of the cellular localisation and interaction with cellular receptors. This was hoped to 
aid in further understanding the function of vOX2 and its potential role in KSHV 
pathogenesis. 
3.1 Analysis of vOX2 protein sequence 
The vOX2 ORF is predicted to encode either a 348 or 271 amino acid protein; 
there are two potential initiating codon sequences that could be used (Figure 3.1). 
However, a common signal peptide sequence is encoded directly after the second 
methionine initiating coding site suggesting that the second site is utilised. Neither 
initiating coding site contain a Kozak sequence. There are 5 or 6 potential N- linked 
protein glycosylation sites in vOX2. Several conserved cysteine (C) residues and 
blocks of homologous sequence with the human, mouse and rat CD200 protein, 
suggest that the vOX2 protein is also made up of IgG domains as illustrated in 
Figure 1.12 (Figure 3.3 shows homology with 271 as vOX2 protein). A 
hydropathicity plot of the vOX2 protein and hCD200 amino acid sequence was 
performed (Figure 3.2); this also confirmed a similar pattern between both proteins. 
Areas containing any transmembrane or membrane -anchoring regions typically 
contain a 20 amino acid hydrophobic region (Kyte and Doolittle, 1982). Both vOX2 
and hCD200 contain a single transmembrane region. 
A database search was performed using the program "BLAST' against all 
protein entries and found sequence homology with other viral CD200 homologues 
listed in Table 1.4 including HHV -6, HHV -7, RRV, and Myxomavirus. 
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1 MIHTFFDCPG RRVVEGGVIS SYFLIGAPGR TAIKTEEGVS 
41 ALQNLPPTVL PVAGTGSVVR PVVCAPPWTT PSASRGSMSS 
81 LFISLPWVAF IWLALLGAVG GARVQGPMRG SAALTCAITP 
121 RADIVSVTWQ KRQLPGPVNV ATYSHSYGVV VQTQYRHKAN 
161 ITCPGLWNST LVIHNLAVDD EGCYLCIFNS FGGRQVSCTA 
201 CLEVTSPPTG HVQVNSTEDA DTVTCLATGR PPPNVTWAAP 
241 WNNASSTQEQ FTDSDGLTVA WRTVRLP:_':' NTTPSEGICL 
281 ITWGNESISI PASIQGPLAH DLPAAQGTLA GVAITLVGLF 
321 GIFALHHCRR KQGGASPTSD DMDPLSTQ 
Figure 3.1 Diagrammatic representation of the potential post -translational 
modifications present in the vOX2 protein. The KSHV vOX2 DNA sequence (nt 
127884 to 128940) is translated into 348 or 271 amino acids, depending on which 
initiating codon sequence is utilised. There are two possible in -frame methionine initiating 
coding sequences, underlined in purple, and a common signal peptide sequence, 
indicated in pink. The predicted N- linked glycosylation sites are shown in red. The RGD 
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Figure 3.2 Hydropathicity 
plot of the human CD200 
and KSHV vOX2 protein. 
Hydrophobicity plots using the 
method of Kyte and Doolittle 
(1982) display hydrophobic 
regions of the protein as 
positive values and hydro- 
philic regions are assigned 
negative values for proteins 
(A) human CD200 and (B) 
KSHV vOX2 (vOX2 protein of 
348 aa and 271 aa are 
indicated at the bottom of the 
plot). The first large hydro- 
phobic peak in both plots 
(position -25 in plot A and 
-90 in plot B) is the signal 
sequence, whereas the 
second peak (position -250 in 
plot A and -310 in plot B) is 
representative of a single 
transmembrane region. 
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hCD200 QVQWTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHGWIQPAY 60 
mCD200 QVEWTQDERKALHTTASLRCSLKTSQEPLIVTWQKKKAVSPENMVTYSKTHGWIQPAY 60 
rCD200 QVEWTQDERKLLHTTASLRCSLKTTQEPLIVTWQKKKAVGPENMVTYSKAHGWIQPTY 60 
v0X2 --AVGGARVQGPMRGSAALTCAITPRADIVSVTWQKRQLPGPVNVATYSHSYGVWQTQY 58 
* *.* *. *****:: * *. *.* .***.* * 
hCD200 KDKINITQLGLQNSTITFWNITLEDEGCYMCLFNTFGFGKISGTACLTVYVQPIVSLHYK 120 
mCD200 KDRINVTELGLWNSSITFWNTTLEDEGCYMCLFNTFGSQKVSGTACLTLYVQPIVHLHYN 120 
rCD200 KDRINITELGLLNTSITFWNTTLDDEGCYMCLFNMFGSGKVSGTACLTLYVQPIVHLHYN 120 
vOX2 RHKANITCPGLWNSTLVIHNLAVDDEGCYLCIFNSFGGRQVSCTACLEVTSPPTGHVQVN 118 
... *:* ** *... . * ..:*****.*.** ** :* **** . * . 
hCD200 FSEDHLNITCSATARPAPMVFWKVPRSGIENSTVTLSHPNGTTSVTSILHIKDPKNQVGK 180 
mCD200 YFEDHLNITCSATARPAPAISWKGTGTGIENSTESHFHSNGTTSVTSILRVKDPKTQVGK 180 
rCD200 YFEDHLNITCSATARPAPAISWKGTGSGIENSTESHSHSNGTTSVTSILRVKDPKTQVGK 180 
vOX2 STEDADTVTCLATGRPPPNVTWAAPWNNASSTQEQFTDSDGLTVAWRTVRLPRGDNTTPS 178 
** .** ** ** * * .* * 
C2 domain -I- Transmembrar. 
hCD200 EVICQVLHLGTVTDFKQTVNKGYWFSVPLLLSIVSLVILLVLISILLYWKRHRNQDRGEL 240 
mCD200 EVICQVLYLGNVIDYKQSLDKGFWFSVPLLLSIVSLVILLVLISILLYWKRHRNQERGES 240 
rCD200 EVICQVLYLGNVIDYKQSLDKGFWFSVPLLLSIVSLVILLVLISILLYWKRHRNQERGES 240 
vOX2 EGICLITWGNESISIPASIQGPLAHDLPAAQGTLAGVAITLVGLFGIFALHHCRRKQGGA 238 
* ** .* * .* .* 
hCD200 SQGVQKMT 248 
mCD200 SQGMQRMK 248 
rCD200 SQGMQRMK 248 
vOX2 SPTSDDMDPLSTQ 251 
* . * 
Figure 3.3 Sequence alignment of the KSHV vOX2 protein with the CD200 
cellular homologues of the human (hCD200), mouse (mCD200) and rat 
(rCD200) proteins. The sequences were aligned using the "ClustralW' program 
with GenBank accession numbers P41217 (hCD200), 054901 (mCD200), P04218 
(rCD200) and U75698 (KSHV vOX2). Residues are identical are marked with * and 
in red, strongly similar are marked with : , and weakly similar with .. 
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3.2 Cellular localisation of vOX2 
In order to determine the true methionine initiation codon site and to confirm 
vOX2 is expressed on the cell surface, the vOX2 ORF was tagged with a FLAG tag 
and expressed in vitro. The vOX2 ORF was amplified with either OXF1 or OXF2 as 
the forward primer and used the OXR -Flag as the reverse primer (see 2.2.1 and 
Appendix 2), respectively generating amplified products of -1080bp and - 1310bp in 
size. The OXR -Flag primer incorporates a FLAG tag sequence (and Xbal restriction 
enzyme site) directly after the vOX2 sequence and is expressed on the intracellular 
C- terminus of the protein. After being cloned into the PCR cloning vector, pGEMT- 
easy (see 2.2.15 and Appendix 3), the vOX2 ORF was cut out at Kpnl and Xbal sites 
and cloned into pcDNA3 (Appendix 3) generating pcDNA3 /vOX348 and 
pcDNA3 /vOX27i. Following the verification of the clones, vectors were transfected 
into HEK293 cells using the effectene transfection reagent (QIAGEN) (see 2.1.5.2). 
The cells were harvested 48 hours after transfection, and air -dried onto glass slides. 
Samples were fixed in ice -cold methanol /acetone (1:1) (see 2.9.1). 
Samples were stained by indirect immunofluorescence targeting the fused 
FLAG epitope, using mouse anti -FLAG, followed by anti -mouse Ig alexa -fluro 594 
(red). Red fluorescence was visualised on the surface of cells in both sets of 
transfected cells (Figure 3.4 A and B). This indicates that the second methionine of 
vOX2 at amino acid 78 can be used as an initiation codon. Control cells that were 
incubated with no primary antibody followed by anti -mouse Ig alexa fluro 594 
conjugate showed no red fluorescence (Figure 3.4 -C). 
3.3 Generation of anti -vOX2 antibody 
In order to further investigate vOX2 interaction and function both in vitro and 
in vivo, it was decided to generate an antibody against the vOX2 protein. Initial 
attempts were undertaken to generate a vOX2 -GST fusion proteins using the pGEX 
expression system (see 2.7), as this system provides a convenient method to express 
and purify proteins. The vOX2 ORF was amplified by PCR using primer pair GEX1 
and GEX2 (see 2.2.1 and Appendix 2). The amplified product ( -'820bp) was first 
cloned into the PCR cloning vector pGEMT -Easy and then excised with Apal and 
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C 
Figure 3.4 Expression of vOX2 -FLAG 
-epitope tagged protein in HEK293 
cells. HEK293 cells were transfected 
with (A) pcDNA3 /vOX348, (B) 
pcDNA3 /vOX27 or (C) no plasmid- 
HEK293 cells only. Cells were air dried 
on to slides and fixed with ice -cold 
methanol/ acetone, then stained with 
mouse anti -FLAG (1:200), and finally 
with anti -mouse conjugated with alexa 
fluro 594 (red) (1:800). (All images at 
x400 magnification) 
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SacII; these restriction enzyme sites are located within the vOX2 ORF, ApaI is 
directly after the signal sequence and SacII is located before the transmembrane and 
cytoplasmic region. The extracellular portion of the vOX2 ORF was then blunt - 
ended and cloned into the SmaI site of pGEX -4T1 (Appendix 3), to form the vector 
pGEX/vOX2, a control plasmid pGEX/GST was also generated. The vOX2 gene 
was inserted in frame with the glutathione S- transferase gene of Schistosoma 
japonisum, and would be expressed as a GST fusion protein. XL -1 blue bacterial 
clones positive for the vOX2 insert in pGEX -4T1 by mini -prep were tested for their 
ability to express the vOX2 -GST fusion protein. Expression of the fusion protein 
was induced by the addition of 0.5mM IPTG during the exponential growth phase of 
the culture (see 2.7.3). Following induction with IPTG, the repression of the Ptac 
promoter by the lac repressor is stopped leading to expression of the fusion protein 
via the Ptac promoter. The bacterial culture was harvested approximately 3 hours 
after induction, and the bacterial pellet sonicated and the cell lysate analysed on a 
12% gel. As shown in Figure 3.5, a band with an apparent molecular mass of 
- 50kDa indicates the vOX2 -GST fused protein, whereas GST alone is visualised as a 
band - 27kDa; the predicted size of the extracellular portion of vOX2 is -22kDa. 
Following the identification of the vOX2 -GST protein and batch purification, 
a 4001.1g sample was sent to Diagnostic Scotland for the immunisation of a rabbit. 
Following the initial immunisation, the rabbit received three booster injections over a 
period of three months. A blood sample was taken prior to immunisation (pre -bleed) 
and periodically after and before each booster injection. The serum was separated 
from the blood sample and returned for analysis of anti -vOX2 reactivity. The serum 
was first purified using the MAbTrapTM Kit (Amersham Pharmacia), an affinity 
chromatography kit, followed by the removal of low molecular weight contaminants 
using the HiTrap Desalting Kit (Amersham Pharmacia) (see 2.7.5). These two 
procedures assisted in producing a moderately pure IgG antibody sample. 
The anti -vOX2 reactivity of the purified rabbit serum was assessed by 
immunoblot. Identical 12% SDS -PAGE gels were prepared and loaded with purified 
vOX2 -GST fusion protein and GST only. Following Western blotting, membranes 
were either incubated with the purified pre -bleed or third (final) bleed rabbit 
antibody and then anti -rabbit conjugated to AP. Figure 3.6 shows that the third bleed 
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antibody sample recognises the vOX2 -GST fusion protein (panel B), whereas the 
pre -bleed sample does not (panel A). The band (- 50kDa) was in the predicted region 
of the -49kDa vOX2 -GST fusion protein. There were a few extra bands present in 
both lanes on panel B (third bleed), suggesting that the rabbit also produced 
antibodies against other proteins present in the vOX2 -GST preparation. 
The reactivity of the rabbit antibodies to the vOX2 protein was also assessed 
against a KSHV infected cell line, BC3. A combination of latently infected and 
lytically induced cells (overnight incubation with 3mM Butyrate, see 2.1.6) were 
tested. Glycosylation was also inhibited in some samples by an overnight incubation 
with Tunicamycin (0.11.ig /ml) (see 2.1.7). A KSHV negative cell line, BJAB, was 
also used. Samples were loaded on to an SDS -PAGE gel, transferred by Western 
Blot and incubated with the third bleed purified rabbit antibodies. This was followed 
by incubation with anti- rabbit conjugated to AP. Figure 3.7 shows no detection of 
vOX2 in any of the latent or lytically induced KSHV infected cell lines, nor the 
KSHV negative cell line. An aliquot of vOX2 (cleaved from the vOX2 -GST fusion 
protein) was loaded into the last lane as a positive control. 
Other techniques such as immunofluorescence were also used to assess the 
reactivity of the rabbit antibody. BHK -21 cells infected with recombinant viruses 
encoding the vOX2 ORF and GFP (see Chapter 4 and 5) were fixed to slides and 
stained using the purified final bleed rabbit antibody, followed by anti- rabbit alexa 
fluor 546 (red). A combination of varying dilutions and fixation methods was 
performed, but all with no success (Figure 3.8). It is possible that the antibody 
generated was recognising an incorrectly folded protein since the vOX2 -GST fusion 


















Figure 3.5 Expression of the 
vOX2 protein as a GST- fusion 
protein. Bacterial colonies 
transfected with pGEX/vOX2 or 
pGEX/GST were tested for the 
expression of the GST fused 
proteins after induction with IPTG. 
Purified protein (lane 1 = vOX2- 
GST; lane 2 = GST) were analysed 
on a 12% SDS -PAGE gel. The 
immunoblot was probed with anti - 
GST, followed by anti -rabbit Ig -AP 
and visualized using Roche 
NBT /BCIP solution. Molecular 
weights are given in kilodaltons 
(kDa) relative to the rainbow maker 
in the left lane. 
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Figure 3.6 Reactivity of purified rabbit anti -vOX2 antibody. The ability of 
rabbit antibodies to detect the vOX2 protein was assessed by immunoblot. 
Samples of purified protein vOX2 -GST (lane 2) and GST (lane 3) were 
separated on a 12% SDS -PAGE gel, and transferred onto a membrane by 
Western blot. The blots were probed with pre -bleed (A) and third bleed (B) 
purified rabbit serum. The rabbit antibodies were detected using anti -rabbit Ig 
conjugated to AP and visualized using Roche NBT /BCIP solution. Rainbow 
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Figure 3.7 Detection of vOX2 expression in KSHV infected cells. A KSHV 
infected cell line (BC3) and a cell line negative for KSHV infection (BJAB) were grown 
overnight with either Butyrate (3mM) or Tunicamycin (0.14/ml) or a combination of 
both. The addition of Butyrate results in the induction of lytic replication of KSHV and 
Tunicamycin inhibits glycosylation of proteins. Aliquots of lysed cell samples were 
loaded on to a 12% SDS -PAGE gel and then transferred to a membrane by Western 
Blot. Membranes were incubated in blocking solution (with 2% normal goat serum), 
then purified final bleed rabbit anti -vOX2 serum (1:50), and finally with goat anti -rabbit 
Ig conjugated to AP (1:2000). Proteins were visualized using Roche NBT /BCIP 
solution. An aliquot of vOX2 (cleaved from the purified vOX2 -GST protein) was 
loaded into the last lane as a positive control. Rainbow protein molecular weight 
markers were run in the left lane and given in kilodaltons. 
(A) 
r 
Figure 3.8 Detection of vOX2 expression in BHK -21 cells infected with a MHV -76 
recombinant virus encoding the vOX2 ORF and EGFP *. BHK cells were infected 
with a MOI of 0.5 with either (A) a MHV -76 recombinant virus encoding the vOX2 ORF 
and EGFP or (B) MHV -76. After a 24hour period, cells were harvested and air -dried onto 
slides. Samples were fixed with 4% w/v paraformaldehyde and then incubated with the 
purified final bleed rabbit anti -vOX2 serum, and then anti -rabbit alexa fluor 546 (red). 
Cells infected with the recombinant virus can be visualised by the expression of gfp. 
Control slides in which no primary antibody was used, were stained simultaneously and 
no background /non -specific fluorescence was detected (image not shown) (Magnification 
at x400). *see chapter 4 for detailed information regarding the creation of this 
recombinant virus. 
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3.4 Expression of secreted vOX2 protein 
Partly due to the inability to generate an antibody against vOX2 using a 
bacterial system, it was decided to generate vOX2 as soluble protein with an epitope 
tag. Upon successful production of the soluble protein, it would provide the 
opportunity to generate an antibody targeting the soluble protein. However, even 
without the antibody, this soluble protein could also be used to study protein 
interactions, in particular engagement with its predicted receptor, CD200R. The 
epitope tag could be used to detect the protein by the use of commercially available 
antibodies. It was decided to clone the vOX2 ORF into pcDNA3.1 /myc -His -A (see 
2.6.1 and Appendix 3) (this plasmid will be referred to as pcDNA3.1 throughout this 
chapter); this plasmid allows the production of a secreted protein tagged with myc 
and six histidine residues (His6) fused to the carboxy terminus. This method of 
epitope tagging proteins has been used successfully to characterise a wide variety of 
proteins (Kao et al., 1994; Lackner and Condit, 2000). In addition the His6 epitope 
can be used to concentrate and /or purify proteins via affinity chromatography 
(Bornhorst and Falke, 2000; Hochuli et al., 1988). 
The vOX2 ORF was amplified from BCP1 DNA using primer pair Sect and 
Sec2 generating a product approximately 710bp, comprised of the signal sequence 
and the extracellular domains (the transmembrane and cytoplasmic portions were not 
included). This product was digested with Xhol and HindIII and cloned into 
pCDNA3.1 (linearised with XhoI and HindIII) to generate pcDNA3.1 /vOX2. 
In addition, to study the RGD motif in the vOX2 ORF, site directed 
mutagenesis was used to mutate this sequence to generate a non -functional RAD (see 
2.2.12 and 4.1); the vector pCR2.1- TOPO /vOX2 was mutated to generate pCR2.1- 
TOPO /vOX2 -RAD. The vOX2 -RAD ORF was also excised at the XhoI /HindIII 
restriction enzyme sites and cloned into the Xhol /HindIII site of pcDNA3.l to 
generate pcDNA3.1 /vOX2 -RAD. 
Both pcDNA3.1 /vOX2 and pcDNA3.1 /vOX2 -RAD were transfected with 
Effectene (QIAGEN) into HEK293 cells (see 2.1.5.2) in a T175cm2 flask. After 
24hours, the medium was replaced with Optimem (Gibco) and incubated for a further 
24hours. At this point all medium was taken off and passed through a His- SelectTM 
HC Nickel Affinity Gel (SIGMA) to purify the sample. The eluted protein ( '-4m1) 
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was then concentrated to a volume of approximately 100 -3001.11, using a Vivaspin4 
column (Vivascience) (see 2.6.1). 
The same transfection and protein concentration procedure was performed 
using plasmid pSecTag -PSA (Appendix3) as a positive control for the transfection 
procedure; this plasmid was provided with an alternative secretion protein plasmid 
kit that was also tested for use with vOX2 but was not successful. When transfected 
into cell lines, the -33kDa prostate- specific antigen (PSA) fused to the c -myc epitope 
and the polyhistidine tag is generated. 
Aliquots of all secreted proteins (vOX2, vOX2 -RAD and PSA), and of lysed 
cell pellets (see 2.6.1) were separated on a 12% SDS -PAGE gel and transferred to a 
membrane by Western Blot. An aliquot of non -transfected HEK293 cells was also 
subjected to the same experimental procedures was included to eliminate any non- 
specific hybridisation. Samples were analysed by targeting the fused myc epitope; 
incubation first with mouse anti -myc (1:2500), followed by goat anti -mouse 
conjugated to biotin (1:500) and then a final incubation with streptavadin conjugated 
to AP (1:500). 
Illustrated in Figure 3.8 is the membrane in which a faint band (-45 kDa; 
indicated by the red arrows) is present in lanes loaded with vOX2 and vOX2 -RAD 
secreted protein. The predicted size of the glycosylated secreted vOX2 fused to the 
myc epitope and the polyhistidine tag is -44kDa1. Additional faint bands (- 35kDa) 
and a smearing effect (-35- 45kDa) are visible in the lysed cell samples from vOX2 
and vOX2 -RAD presumably representing partially and non -glycosylated forms of the 
protein. 
A band of -33kDa (indicated by the black arrows) is present in the positive 
control transfection reactions (pSecTag -PSA) and in the last lane an aliquot of PSA 
from a previous experiment was loaded as an additional positive control for the 
Western blotting and immunoblotting procedures. 
J The predicted size for the extracellular domains of vOX2 (and vOX2 -RAD) is approximately 
25.5kDa, added to this is -3kDa for the c -myc epitope and polyhistidine tag, and a further 3kDa for 
each N- glycosylation; there are five predicted N- linked glycosylation sites in the vOX2 protein. 
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Figure 3.9 Detection of secreted vOX2 and vOX2 -RAD proteins. HEK293 cells 
were transfected with pcDNA3.1 /myc- His /vOX2, pcDNA3.1 /myc- His /vOX2 -RAD or 
pSecTag -PSA. After the collection and concentration of secreted proteins, samples 
of protein and lysed cell pellet were separated on a 12% SDS -PAGE gel and 
transferred by Western Blot. The membrane was incubated with mouse anti -myc, 
followed by goat anti -mouse conjugated to biotin, and then finally streptavidin AP. 
Proteins were visualized using Roche NBT /BCIP solution. An aliquot of secreted 
PSA protein from a previous experiment was loaded into the last lane as an 
additional positive control. Red arrows indicate vOX2 protein and black arrows 
indicate PSA protein. Rainbow protein molecular weight markers were run in the 
left lane and given in kilodaltons. 
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3.5 Discussion 
Although not all successful, these studies have shown that the glycosylated 
extracellular region of the vOX2 protein has a molecular mass of approximately 
40kDa and is expressed on the cell surface. Based on hydropathicity plots of vOX2 
and its cellular homologue (hCD200) and sequence analysis, it is highly like that the 
vOX2 protein also assumes the IgSF formation and is comprised of a V and C2 Ig 
domain, a single transmembrane region and a short cytoplasmic tail. The KSHV 
vOX2 protein has approximately 27% sequence identity ( -60% sequence similarity) 
with the cellular hCD200, and also mCD200 and rCD200. 
Cellular localisation studies whereby the vOX2 ORF was tagged with a 
FLAG- epitope, confirmed the second methionine at amino acid 78 can be utilised as 
an initiation codon. Furthermore, a combination of this finding along with the 
detection of a common signal peptide sequence directly after the second methionine, 
strongly imply the second methionine to be the true initiation codon. This would 
therefore result in the generation of a protein that is 271 amino acids in length, a size 
comparable with its cellular homologue CD200 (hCD200 and mCD200 are both 
278 aa) and the RRV protein R14 (253 aa). 
Initial attempts were undertaken to generate an antibody against the vOX2 
protein using a GST fusion system. An antibody was made, but only one that would 
recognise the vOX2 -GST fused protein, not vOX2 expressed in its natural state, i.e. 
KSHV infected cells. The antibody was also not able to detect vOX2 when 
expressed in a variety of other cell types. This was most likely the direct result of 
generating an antibody targeting a non -glycosylated form of the protein, and as 
vOX2 has 5 or 6 potential N- linked glycosylation sites, the antibody would probably 
not have the correct conformation. 
In hindsight generating an antibody against an extracellular protein should 
not have been performed using a bacterial system. However, it has been suggested 
by Wright et al. (2000) that based on mutagenesis studies on the human 
CD200:CD200R interaction (Preston et al., 1997) (both also possessing high N- 
linked carbohydrates) and other similar IgSF interactions, engagement is mediated by 
protein and not carbohydrate. It is further suggested that the role of the carbohydrate 
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is to aid in preventing unwanted cis -interactions and retain the orientation of the 
protein with respect to the membrane. 
As it was desirable to have an antibody recognising the vOX2 protein to 
study protein interaction, an alternative approach was attempted. Expressing vOX2 
as a secreted protein tagged with a myc -His6 epitope would not only allow protein 
interaction to be investigated through the use of commercial antibodies (targeting the 
tagged epitope) but also provide another opportunity to generate an antibody against 
the protein. In addition, a mutated form of the vOX2 protein was to be studied. It is 
not known if the RGD motif within the vOX2 ORF is functional, therefore by 
mutating the sequence to generate a non -functional RAD sequence, studies on the 
mutated vOX2 -RAD could also be performed. 
Unfortunately this was not fully achieved. The generation of the secreted 
protein was difficult to optimise and did not yield high amounts of protein. This was 
mostly associated with the low transfection efficiency (<1%). Eventually after 
purifying the proteins via affinity chromatography and concentrating the elutant, 
secreted vOX2 and vOX2 -RAD was detected by immunoblot analysis. Not enough 
protein was generated at this point to perform any protein interaction studies. 
Unfortunately due to time constraints this experiment could not be continued. 
Ideally, the system would be optimised further to produce a larger amount of soluble 
protein which would then be used to (i) generate an antibody targeting the vOX2 
protein and (ii) study vOX2 protein interaction with other cell types, in particular its 
potential receptor, CD200R. 
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Chapter Four: Generation of Recombinant 
Viruses 
4.1 Cloning strategy 
4.2 Generation and purification of viruses 
4.3 Southern analysis 
4.4 In vitro growth studies 
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Chapter 4: Generation of recombinant viruses 
The study of recombinant viruses into which specific genes have been 
inserted, deleted and or mutated has become a fundamental tool in elucidating the 
function of viral genes. This method is used by many groups, for example, in 1968, 
Ejercito et al., were able to identify mutated genes within a new strain of herpes 
simplex virus due to an altered plaque phenotype. 
Due to the stringent host range and inability to grow permissively in cell 
cultures, studies of many gammaherpesviruses have been difficult. However, the 
closely related murid gammaherpesvirus, MHV -68, does not encounter this problem, 
as it replicates efficiently in cell culture and is often used as a model to study human 
gammaherpesviruses. With the use of recombinant virus technology the generation 
and characterisation of MHV -68 mutants has been valuable for studying and 
predicting the role(s) of several unique genes within the left hand end of its genome 
(Clambey et al., 2000; Jacoby et al., 2002; Macrae et al., 2003; Townsley et al., 
2004). Moreover, MHV -76, a natural deletion mutant of MHV -68, has provided an 
opportunity to use this virus as a vector to study other unique gammaherpesvirus 
genes. 
The substantial deletion at the left -terminus of the MHV -76 genome, 
compared to MHV -68, has provided a novel opportunity to insert a unique gene from 
KSHV along with selection markers, resulting in the generation of recombinant 
viruses. In addition to in vitro studies, these recombinant viruses can be further 
studied in vivo, ultimately allowing observations to be made on the potential role of 
the gene of interest in an animal model. 
4.1 Cloning strategy 
A variety of murine recombinant viruses incorporating the KSHV vOX2 ORF 
were generated. The initial strategy was to construct an MHV -76 -based recombinant 
virus that integrated the KSHV vOX2 ORF, a human CMV promoter and a 
hygromycin resistant (HygR) - enhanced green fluorescent protein (EGFP) gene by 
homologous recombination. In addition, a control recombinant virus was generated; 
this virus contained an identical insert cassette minus the vOX2 gene. 
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A schematic diagram of the cloning strategy used to generate the plasmids 
used for the construction of the recombinant viruses is outlined in Figures 4.1 -A, -B 
and -C. The first plasmids generated comprised the insert cassette (CMV, HygR- 
EGFP, IRES, vOX2, and a polyadenylated tail (AAA)), adjoining 3Kb of MHV -76 
DNA within the pBSIIKS -76LHE plasmid; this plasmid was generated by A.MacRae 
(2002) and incorporates homologous DNA from the left hand end of the genome 
corresponding to nt 9539 -12569 from MHV -68. The cloned insert was incorporated 
into the pBSIIKS -76LHE plasmid in two orientations resulting in the generation of 
the clones pBSIIKS -76L1-1E -vOX2F and pBSIIKS -76LHE- vOX2R. A detailed step - 
by -step procedure is outlined in Figure 4.1A and sections 2.3.1. 
In addition to these clones possessing the vOX2 ORF, control plasmids were 
also created as outlined in Figure 4.1B. The vOX2 insert was cut out of the plasmids 
pBSIIKS -76LHE -vOX2F and pBSIIKS -76LHE -vOX2R to generate two control 
plasmids, pBSIIKS -76LHE -IRES.F and pBSIIKS -76L1-1E -IRES.R. 
In order to investigate whether the RGD motif within vOX2 was functional, a 
mutated recombinant virus was also generated. The RGD motif within the vOX2 
sequence in pCR- TOPO -vOX2 plasmid was changed to a non -functional RAD 
sequence by site directed mutagenesis (see 2.2.12). The RAD -vOX2 gene was then 
cloned into the control plasmid pBSIIKS -76LHE -IRES.F and is schematically 
outlined in Figure 4.1C. All of the final plasmids mentioned above were used in the 
following experiments, to generate recombinant viruses. 
4.2 Generation and Purification of Recombinant Viruses 
A homologous recombination strategy was utilised for the generation of 
recombinant viruses in which the insert cassette was incorporated into the left 
terminus of the MHV -76 genome, schematically illustrated in Figure 4.2A. All 
plasmids were digested with PvuII and EcoRV to release the insert cassette that 
contains a 3Kb fragment of MI -IV -76 (corresponding to the left hand end of the 
genome, directly after the terminal repeat region). However, in order to find a 
unique restriction enzyme site outside the insert cassette, the Pvull site in 
pBlueScriptllKS was utilised; resulting in the incorporation of -90bp of the 
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Figure 4.1A Schematic diagram of cloning strategy. Diagramatic representation of 
cloning performed in generating plasmid used in homologous recombination reactions to 
create recombinant viruses possessing the vOX2 gene. The entire vOX2 ORF was 
amplified by PCR using primers vOX -1 and vOX -2 from BCBL -1 DNA, and then cloned 
into pCR2.1 -TOPO. ( The vOX2 insert was cut out with BspHl and Ncol, and subcloned 
into the pBVIRES.GFP vector (linearised with Ncol). The IRES -vOX2 sequence was 
digested with Xhol and Ncol and inserted into the Smal /Sall site of pHygEGFP1, 
transformation was performed into Epicurian Coli SCSIIO competent cells (Dam/Dcm -) 
due to the blocking of the BsaBl site. The IRES- vOX2 /pHygEGFP1 clone was 
digested with BsaBI and a Bg /Il linker added to the end. The plasmid was then 
digested with Bg/Il to cut out the CMV- HygR- EGFP- IRES -v0X2 -AAA insert, however due 
to difficulty separating the large insert from the small fragment of the plasmid backbone, 
the insert was cloned into the Bg/II site of the pHygEGFP.N1 vector; this is a Kanamycin 
resistant vector. Following the purification of the clone grown in the presence of 
Kanamycin, the same insert was cut out using Bg/II and then cloned into the Bg /ll 
linearised pBSIIKS -76LHE plasmid; this plasmid was generated by A.MacRae and 
incorporates approximately 3Kb of MHV -76 DNA from the left hand end (corresponding 
to nt 9539 -12569 of MHV -68). The insert cassette incorporated into the clone in two 
orientations, generating pBSIIKS -76LHE -vOX2F (forward) and pBSIIKS -76LHE -vOX2R 
(reverse). [Note: RE sites in blue indicate insert digestion sites complementary to those in 
a plasmid] 
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sc1 ascl 





CMV HygR-EGFP IRES LIE-MHV76 
Amp 
pBSIIKS-76LHE-IRES.F 
Figure 4.1B Schematic diagram of cloning strategy. Diagramatic 
representation of cloning performed to generate a plasmid that was 
used in a homologous recombination reaction to generate a control 
recombinant virus (vOX2 insert cut out with Fsel and Ascl and plasmid 
re- ligated, the same procedure was performed on the reverse plasmid 
to generate pBSIIKS -76LHE -IRES.R). 
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Fsel RAD Ascl 
TOPO 
Site directed mutagenesis 
CMV HygR-EGFP IRES LHE-MHV76 
Amp pBSI IKS-76LHE-IRES.F i 
p 
pBSIIKS-76LHE-RAD 
Figure 4.1C Schematic diagram of cloning strategy. Diagramatic 
representation of cloning performed to generate a plasmid that is to be used 
in a homologous recombination reaction to generate a recombinant virus 
possessing a mutated vOX2 gene. (i) The RGD motif is changed to a non- 
functional RAD site by site directed mutagenesis and then (ii) the mutated 
vOX2 gene was inserted into the final plasmid to be used for the generation 
of a recombinant virus. 
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plasmid. This fragment of DNA was situated either before the CMV promoter or 
after the polyadenylation. 
The recombinant viruses generated included those possessing the vOX2 gene 
(MHV76- vOX2.F, MHV76- vOX2.R and MHV76 -RAD) and two control viruses 
(MHV76 -IRES.F and MHV76 -IRES.R) (Figure 4.2B). 
All recombinant viruses were grown in the presence of hygromycin 
(100µg /m1) and only those isolates expressing gfp (Figure 4.3), were purified by 
limiting dilution and plaque purification. After each round of purification PCR 
analysis was performed on extracted DNA to ensure the presence or absence of 
vOX2, the position of the insert cassette, the presence of virus, and absence of the 
wild -type MHV -76 (Figure 4.4); Table 4.1 summarises the expected PCR results for 
the various viruses generated. For example, based on the PCR results in Figure 4.4, 
only MHV76- vOX2.F isolates 1 and 2 would be used, as these samples are positive 
for vOX2, polyA/M4 (correct location) and ORF74 but negative for wild -type virus, 
unlike isolate 3. Recombinant viruses possessing a reverse orientated insert cassette 
where checked for correct location by amplifying the CMV /M4 region (data not 
shown, primers; CMV -A + M4 -B, product size; -450bp) 
Viral samples were only saved for further analysis after certain requirements 
were satisfied: an agarose overlay plaque pick (see 2.3.2); a minimum of four rounds 
of limiting dilution plaque purification (some viruses required more than four rounds 
of purification); when an isolate was identified to satisfy all the PCR requirements 
and to be free of wild -type virus (MHV -76). 
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9539-9785 I 11215-14523 
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CMV HygR-EGFP IRES vOX2 I LHE-MHV76 





CMV HygR-EGFP IRES vOX2 ORF4 > 6 -11 -- 
Figure 4.2A Schematic diagram of homologous recombination to 
generate a recombinant virus. Plasmid pBSKSII- 76LHE- vOX2.F was 
lineraised with EcoRV and Pvull, mixed with viral MHV -76 DNA and 
electroporated. Following a crossover homologous recombination 
event the CMV->v0X2 insert cassette was incorporated into the left - 
terminus of the MHV -76 genome to generate the recombinant virus 
MHV76- VOX2.F (See Figure 4.2B for the schematic diagrams of all the 
recombinant viruses generated). 
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(A) M HV76-vOX2. F 
















Q n [n 
Figure 4.2B Schematic diagram of recombinant viruses 
generated. 
Viruses include; (A) MHV76- vOX2.F, (B) MHV76- vOX2.R, 
(C) MHV76 -RAD, (D) MHV76 -IRES.F and (E) MHV76 -IRES.R. 
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Figure 4.3 Viral plaque expressing gfp. 
BHK -21 cells infected with MHV76- vOX2.F is 
visualised through the expression of gfp 
(Magnification x1000). 
Table 4.1 Summary of PCR analysis during recombinant 
virus purification. Following each round of purification 
DNA extracted was amplified for the presence of vOX2, 
orientation of insert (polyA/M4 or CMV /M4), presence of viral 
ORF74 and wild -ty ?e virus, MHV -76. 
PolyA/M4 
Wild Type 


































Figure 4.4 PCR analysis during purification of recombinant viruses. Examples 
of PCR analysis performed during the purification of MHV76- vOX2.F. DNA samples 
were isolated from limiting dilution samples (e.g isolates 1 to 4), grown in 96 well 
plates, and amplified for (A) vOX2, (B) polyA -M4, (C) ORF74 and (D) the presence 
of wild -type virus, MHV -76 (Primers used include; (A) vOX2F + vOX2R; (B) polyA -R 
+ M4 -B; (C) ORF74 -5'+ ORF74 -3'; (D) Trepeat + M4 -B). PCR products were 
analysed on a 1.2% agarose gel concurrently with a 1 Kb+ DNA molecular weight 
marker (on left hand end). All reactions included the use of a positive control ( +ve) 
(DNA from pBSIIKS- 76LHE -vOX2F for (A) and (B); DNA from MHV -76 for (C) and 
(D)) and a negative control ( -ve), dH2O for all sets. 
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4.3 Southern Analysis 
Viral DNA was extracted from infected BHK -21 cells (see 2.3.5) for two 
isolates per recombinant virus, and used for Southern analysis to determine the 
genomic alignment at the left- terminus (see 2.4) (southern images shown only 
include the final virus isolate used in all further experiments). Following the 
digestion of viral DNA with either MfeI or NheI, samples were analysed using a 
digoxigenin (DIG)- hybridisation probe. Isolates were firstly hybridised with a 
sequence specific probe against the left -terminus of MHV -76 adjoining the cloned 
insert cassette; this probe is referred to as the `76' probe (nt 9539 -10461 from MHV- 
68) (Figure 4.6A). Following this the membrane was stripped and re- probed directly 
against the cloned selection markers using a `GFP' probe (nt 1821 -2878 from 
pHygEGFP) (Figure 4.6B). Southern analysis showed that the recombinant viruses 
yielded profiles similar to those predicted following digestion with either MfeI or 
NheI (Figures 4.5B -E). For example, a 1.1kb fragment is observed in recombinant 
viruses MHV76- IRES.F, -vOX2.F and -RAD when digested with MfeI and probed 
with the `76' probe (Figure 4.6A). In contrast, when probed with the `GFP' probe a 
laddering effect is seen due to the addition of sequences from the terminal repeat 
region (Figure 4.6B). As the laddering effect from MHV76 -RAD was not clearly 
visualised, this sample was also checked by digesting viral DNA with either BamHI 
or XbaI and then probed using the `76' probe; this yielded the correct profile (data 
not shown). Another initial discrepancy was detected in the size of the hybridisation 
band yielded by MHV76 -IRES.R (generated by Dr J Douglas) when digested with 
NheI and probed with the `GFP' probe. This was confirmed to be the correct size 
(- 4.0kb) as further southern blot analysis and sequencing performed by Dr J Douglas 
(data not shown) identified an inclusion of approximately 1 kb of a cloning plasmid 
(pBlueScriptKSII) after the terminal repeat region but before the polyadenylated tail. 
This fragment of plasmid contained an NheI digestion site, thus yielding the profile 
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Figure 4.6A Southern anaylsis of MHV -76 and 
recombinant viruses using the `76' probe. DNA was 
isolated from BHK -21 cells infected with either MHV -76, 
MHV76- lRES.F, MHV76- vOX2.F, MHV76 -RAD, MHV76 - 
IRES.R, or MHV76- vOX2.R. Following the digestion of 5µg 
viral DNA with either Mfel or Nhel, samples were run on a 
0.8% gel, transferred and then analysed using a digoxigenin 
(DIG)- hybridisation probe against the region in MHV -76 
adjoining the cloned insert (76' probe; nt 9539 -10461 from 
MHV -68). Molecular weight markers (kb) are included in the 
first and last lane. 
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Figure 4.6B Southern anaylsis of MHV -76 and 
recombinant viruses using the `GFP' probe. DNA was 
isolated from BHK -21 cells infected with either MHV -76, 
MHV76- IRES.F, MHV76- vOX2.F, MHV76 -RAD, MHV76 - 
IRES.R, or MHV76- vOX2.R. Following the digestion of 5µg 
viral DNA with either Mfel or Nhel, samples were run on a 
0.8% gel, transferred and then analysed using a digoxigenin 
(DIG)- hybridisation probe against the EGFP region within the 
cloned insert (`GFP' probe; nt1821 -2878 from pHygEGFP). 




.__. GENERATION OF RECOMBINANT VIRUSES 
Some other samples also displayed a small number of non -specific bands. 
When directly compared with the predicted sizes of bands, all non -specific bands 
were of lesser intensity and were not believed to be significant. Additionally, some 
non -specific hybridisation may be the result of fragments of DNA that were not fully 
digested, and thus appear as larger bands than those predicted. 
Southern analysis of the wild -type virus (MHV -76) yielded the expected 
laddering effect with both restriction enzymes, when probed with the `76' probe 
(Figure 4.5A). As expected, the `GFP' probe did not hybridise with viral DNA from 
MHV -76 (Figure 4.6B). 
4.4 In vitro growth studies 
To investigate whether the inclusion of vOX2 or any of the selection markers 
resulted in an altered replication phenotype in vitro, all recombinant viruses were 
compared with MHV -76 during a single round (MOI =5) (Figure 4.7) and multiple 
rounds (MOI =0.05) (Figure 4.8) of replication in BHK -21 cells, respectively called a 
single -step and multi -step growth curve (see 2.3.6). The data from the single- and 
multi -step growth curves demonstrate that most (MHV76- vOX2.F, MHV76 - 
MHV76 -IRES.F and MHV76 -IRES.R) of the viruses replicate with similar 
kinetics to the wild -type virus, MHV -76. Therefore, it can be inferred that neither 
vOX2 nor any of the selection markers have any influence on in vitro replication or 
cell -cell spread. 
However, when compared with both MHV -76 and MHV76- vOX2.F, the 
MHV76 -RAD virus did display attenuated properties in both the single- and multi- 
step growth curves (Figures 4.7 and 4.8). As attenuation is present in both growth 
curves, it is assumed that this result is due to a mutation(s) elsewhere in the virus and 
not due to the direct mutation made within the RGD site of vOX2. As the RGD 
motif is associated with cell adhesion, theoretically a mutation generating a non- 
functional RAD site could potentially affect cell -to -cell spread of the virus and 
therefore would be expected to have no effect in a single -step growth curve. 
Consequently, due to an unidentified mutation in this virus, it was decided that the 
MHV76 -RAD virus would not be used in any further experiments. 
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Hours post- infection 
Figure 4.7 Single -Step Growth Curve. BHK -21 cells were infected with an 
MOI of 5 with MHV -76 ( ), MHV76- IRES.F (A), MHV76 -IRES.R (v), 
MHV76- vOX2.F ( ), MHV76- vOX2.R ( ), or MHV76 -RAD (C). Values 
plotted are mean of two samples per time point, with each sample titrated in 
duplicate. Data points shown represent the virus titre logio ± standard error. 
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24 48 72 96 120 
Hours post- infection 
Figure 4.8 Multi -Step Growth Curve. BHK -21 cells were infected with an 
MOI of 0.05 with MHV -76 ( ), MHV76- IRES.F (A), MHV76- IRES.R (®), 
MHV76- v0X2.F ( ), MHV76- vOX2.R ( ), or MHV76 -RAD ( ). Values 
plotted are mean of two samples per time point, with each sample titrated in 
duplicate. Data points shown represent the virus titre login ± standard error. 
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4.5 Transcriptional expression of the recombinant viruses 
To verify transcription of the vOX2 ORF, Northern blot analysis was 
performed on RNA samples extracted from BHK cells infected with the recombinant 
viruses. BHK-21 cells were infected overnight with either MHV-76, MHV76- 
IRES.F, MHV76-vOX2.F or MHV76-vOX2.R at a multiplicity of infection (MOI) of 
5, before the infected cells were harvested and total RNA extracted using an Rneasy 
mini kit (Qiagen, UK) (see 2.5.1.1). Approximately 101.tg of total cellular RNA was 
electrophoresed, blotted onto nylon membranes and subsequently hybridised with a 
[a32P]dCTP-labelled double-stranded DNA probe, corresponding to the vOX2 ORF 
(nt 128112-128930). An additional lane was loaded with a mock-infected sample. 
The results of Northern analysis are shown in Figure 4.9. 
As expected, following hybridisation with the 32P-labelled vOX2 probe, only 
cells infected with MHV76-vOX2.F and MHV76-vOX2.R displayed a dominant 
-3.7kb transcript. The size of this transcript is consistent with the predicted size of a 
mRNA encoding HygR-EGFP and vOX2. Both samples displayed equivalent signal 
intensity. Importantly, no hybridisation was detectable in those lanes loaded with 
samples from MHV-76, MHV76-IRES.R or the mock infection. As a control for 
viral RNA loading, membranes were stripped and then hybridised with a 32P-labelled 
MHV-76-ORF 50 sequence-specific probe (nt 68483-68838), yielding a profile 
comprised of four predominant bands (-2.0, 2.9, 5.0 and 10-kb) of similar intensity 
in all samples, with the exception of the mock-infection. This expression pattern is 
consistent with previous observations of ORF 50 transcription (Liu et al., 2000; Wu 
et al., 2001). Thus, Northern analysis shows that vOX2 is abundantly expressed 
along with the other selection markers (HygR-EGFP) in vitro in both MHV76- 
v0X2.F and MHV76-vOX2.R. 
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Figure 4.9 Northern analysis of vOX2 transcription by MHV -76 
and recombinant viruses. RNA was isolated from BHK -21 cells 
infected with an MOI of 5 with MHV -76, MHV76- IRES.R, MHV76 - 
vOX2.F or MHV76- vOX2.R, and a mock infection. Samples were 
analysed by Northern blot on a 1% formaldehyde gel, and 
successively hybridized with an [122P]dCTP- labelled probe 
spanning the (A) vOX2 region (nt 128113 -128930 in KSHV) and 
then spanning the (B) ORF 50 (nt 68483 -68838 in MHV -68). The 
molecular weight marker was stained with Coomassi Blue, shown 
on the left of the autoradiograph. 
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4.6 Discussion 
These results describe the cloning strategy, generation and purification of 
several recombinant viruses containing the vOX2 ORF and selection markers, 
hygromycin (HygR) and EGFP, and relevant control viruses. All recombinant viruses 
were generated by homologous recombination and the genes of interest, commonly 
referred to as the insert cassette, cloned into the left -hand end of the MHV -76 
genome, directly after the terminal repeat region. In addition to vOX2, the cloned 
insert was comprised of a CMV promoter, a fused HygR -EGFP selection marker, an 
IRES and finally a polyadenylation site. 
The incorporation of the HygR -EGFP gene not only allowed the recombinant 
viruses to be visualised through the expression of the gfp, but also enhanced the 
selective growth of the recombinant virus over the wild type virus, as hygromycin 
was added to the growth medium. Two recombinant viruses were generated that 
contained the vOX2 gene; these were termed MHV76- vOX2.F and MHV76 - 
vOX2.R, whereby the identical insert cassette was incorporated in both orientations. 
Similarly, a control recombinant virus was created for each of the afore mentioned 
viruses, and are identical in all aspects except that they lack the vOX2 gene. These 
control viruses are referred to as MHV76 -IRES.F and MHV76 -IRES.R. Attempts 
were made to generate further controls where homologous recombination was used 
to create revertant viruses, i.e. re -form wild -type viruses from the recombinant 
viruses. This form of control virus would ensure that any phenotypic results 
observed were due to the inserted genes and not due to a mutation elsewhere in the 
virus. Various techniques were attempted but with no success. It was therefore 
decided that the generation of two independent viruses (i.e. the forward and reverse) 
and suitable control recombinant viruses would be adequate. In addition, another 
virus was created that contained a mutation in the RGD motif within the vOX2 gene. 
The RGD sequence was changed to a non -functional RAD, with the intention of 
using this virus to determine whether the RGD motif was used; this virus was termed 
MHV76 -RAD. 
All recombinant viruses were purified by limiting dilution and plaque 
purification and screened by PCR analysis for a minimum of four rounds. After the 
viruses were found to be pure isolates by PCR (see Table 4.1), the genomic 
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structures of the samples were further verified by Southern blot analysis (Figures 
4.6A and B). All viruses yield profiles similar to those predicted, although partial 
digestion and use of the DIG -hybridisation method are believed to be the reason for 
the small amount of non -specific hybridisation. Southern analysis also confirmed 
that all isolates were pure and free of the wild -type virus, as in a couple of 
circumstances viral isolates thought to be pure by PCR analysis were found to be 
contaminated with a small amount of MHV -76. Further rounds of purification, often 
including an agarose overlay, resulted in the enrichment of the recombinant virus and 
complete loss of the wild -type virus; this was again verified by southern analysis. 
Preliminary characterisation studies performed on all of the recombinant 
viruses have shown that most of the viruses replicate in vitro with similar kinetics to 
the wild -type virus MHV -76. However, one virus that showed attenuated properties 
in both the one -step and multi -step growth curve was MHV76 -RAD. This virus was 
identical in all aspects to MHV76- vOX2.F with one small mutation made in the 
RGD motif within vOX2. It is thought the debilitating effect seen during its 
replication in vitro was not a direct result of the mutation made in the vOX2 ORF but 
most likely due to an unseen mutation elsewhere in the genome; primarily because 
the RGD motif is associated with cell adhesion, attenuation in replication during the 
multi -step growth curve could be explained, but not attenuation during one round of 
replication i.e. the single -step growth curve. Thus the MHV76 -RAD recombinant 
virus was not included in any further experiments and unfortunately due to time 
constraints no attempts were made to try and generate a new version of this virus. 
Finally, Northern blot analysis was performed to ensure transcription of the 
inserted genes. As it is clearly evident that the HygR -EGFP ORF is expressed, a 32P- 
dCTP probe was only generated to hybridise to the vOX2 ORF. Following the 
infection of BHK -21 cells with the recombinant viruses, RNA was isolated and 
MHV76- vOX2.F and MHV76- vOX2.R were both found to be expressing the vOX2 
ORF. All viruses were probed against another gene within the virus, ORF50, as a 
positive control. 
These results have outlined the production of several recombinant viruses 
possessing the KSHV vOX2 ORF and relevant control recombinant viruses. In vitro 
analysis reveals that neither the vOX2 gene nor any of the other insert genes enhance 
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or attenuate replication of the virus in vitro. Unfortunately the MHV76 -RAD 
recombinant virus, generated to study the RGD motif, displayed attenuated 
properties resulting in the discontinued use of this virus in further studies. However, 
the remaining recombinant viruses generated (MHV76- vOX2.F, MHV76- vOX2.R, 
MHV76 -IRES.F, and MHV76 -IRES.R) need to be further characterised and analysed 
in order to study the properties of the vOX2 ORF in vivo. Data describing in vivo 
studies is detailed in the following chapters. 
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Chapter Five: In Vivo Studies using 
BALB/c Mice 
5.1 Lytic Replication 
5.1.1 Viruses in the lung 
5.2 Latency 
5.2.1 Viruses in the MLN 
5.2.2 Viruses in the spleen 
5.3 Discussion 
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Chapter 5: Animal Model Studies using BALB /c Mice 
Following the purification and in vitro analysis of the recombinant viruses, 
the next stage was to study viral replication and pathogenesis in vivo. Female 
BALB /c mice, 4 -6 weeks old, were infected intranasally with 4 x105 PFU of virus 
(MHV -76, MHV76- IRES.F, MHV76 -IRES.R, MHV76- vOX2.F or MHV76 - 
vOX2.R). Lung, spleen and MLN samples were removed at a variety of time -points 
and analysed for the presence of virus and other resultant pathogenic effects. 
5.1 Lytic Replication 
5.1.1 Viruses in the lung 
5.1.1.1 Replication in the lung 
In the initial experiment, BALB /c mice were infected with MHV -76 and 
recombinant viruses: MHV76 -IRES.R, MHV76- vOX2.F or MHV76- vOX2.R. Viral 
titres in the lung were assessed at days 5, 10, 14 and 21 post- infection (p.i.) by 
plaque assay (see 2.3.4). Productive virus was only detected on day 5 p.i., with both 
the recombinant viruses encoding vOX2, MHV76- vOX2.F and MHV76- vOX2.R, 
having significantly higher levels (up to 10 -fold) than the wild -type virus MHV -76 
and the control recombinant virus MHV76 -IRES.R (Figure 5.1A) (Day 5 lung titre: 
MHV76- vOX2.F vs. MHV76 -IRES.R ; P < 0.001 and MHV76- vOX2.R vs MHV76 - 
IRES.R; p <0.001). 
This experiment was repeated and productive virus measured at earlier time - 
points, including days 3, 5, 7 and 9 p.i. (Experiment 2). For all viruses, peak viral 
titres were observed 5 days p.i. and viral clearance by day 9 p.i. (Figure 5.1 B). Both 
MHV76- vOX2.F and MHV76- vOX2.R viral levels were 10- 100 -fold higher than the 
control MHV76- IRES.R at days 3 and 5 p.i. (both p <0.001) (Figure 5.1C). MHV76 - 
IRES.R viral titres were also lower than the wild -type MHV -76 at all time points 
(day 5 p <0.001). 
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Figure 5.1A Viral titres in the lungs of BALB /c mice - Experiment 1. Mice 
were infected intranasally with 4 x105 PFU of MHV -76 (tl ), MHV76- IRES.R 
(), MHV76- vOX2.F ( ), or MHV76- vOX2.R ( ). (A) Samples were taken at 
days 5, 10, 14 and 21 days post -infection. Mean virus titre log10 per lung ± 
standard error mean is shown for four mice per group for each time point. 
indicates statistically significant difference between viral titres in mice infected 
with MHV76- vOX2.F or MHV76- vOX2.R and mice infected with the control 
recombinant virus MHV76 -IRES.R (p <0.001 for both sets). (B) Detailed plot of 
results from 5 days post- infection, where each point is representative of an 
individual mouse. Dashed line ( - --) indicates the limit of detection. 
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Figure 5.1B Viral titres in the lungs of BALB /c mice - 
Experiment 2. Mice were infected intranasally with 4x105 PFU of 
MHV -76 ( ), MHV76- IRES.R (u ), MHV76- vOX2.F ( ), or MHV76 - 
vOX2.R ( ). Mean virus titre login per lung ± standard error mean is 
shown for four mice per group for each time point. * indicates 
statistically significant difference between mice infected with MHV76 - 
vOX2.F or MHV76- vOX2.R and mice infected with the control 
recombinant virus MHV76 -IRES.R (p <0.001 for all sets indicated). 
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These findings imply that the insertion of vOX2 within the recombinant 
viruses is enhancing viral replication at the very early time -points. However, vOX2 
expression has no effect on viral clearance from the lung when compared with the 
control recombinant virus, since both viruses were cleared by day 10 p.i. 
5.1.1.2 Detection of viral DNA 
To verify infection of the lung with recombinant viruses, both DNA and RNA 
samples were simultaneously isolated, using a QIAGEN RNA/DNA kit (see 2.8.7), 
from frozen lung samples (5 days p.i., from experiment 2) from mice infected with 
MHV -76, MHV76- IRES.R, MHV76- vOX2.F and MHV76- vOX2.R. DNA was 
amplified using the vOX2 primers (vOX -1 and vOX -2), and also using the MHV -76 
ORF 50 primers (ORF50 -F and ORF50 -R) to ensure the presence of virus in the 
lung. Results seen in Figure 5.2 show amplification of correctly sized sequences for 
vOX2 (-850bp) in the MHV76- vOX2.F and MHV76- vOX2.R samples only, and for 
ORF 50 (-350bp) in all samples. 
5.1.1.3 Detection of viral transcripts 
To ensure the vOX2 ORF and other viral transcripts actually being 
expressed in the lung, RNA samples were analysed. Isolated RNA samples were 
treated with DNase, and then oligo dT primers used to generate cDNA (see 2.5.2 and 
2.5.3), which was amplified using a variety of primers, including: vOX2 primers 
(vOX -1 and vOX -2), ORF 50 primers (ORF50 -F and ORF50 -R), and GAPDH 
primers (GAPDH -1 and GAPDH -2). 
vOX2 transcripts were detected in lung samples from mice infected with the 
recombinant viruses MHV76- vOX2.F and MHV- 76vOX2.R only (Figure 5.3 -A). 
However another viral gene, ORF50, was found to be expressed in all lung samples 
(Figure 5.3 -B). GAPDH primers were used to amplify a housekeeping gene, 
GAPDH, that was detected in all samples (Figure 5.3 -C); GAPDH is expressed at 
substantial levels in all cells. RNA samples were also amplified using the GAPDH 
primers to ensure that there was no residual DNA present; as expected Figure 5.3 -D 
shows no amplified product. 
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Figure 5.2 Detection of viral DNA in the lungs of BALB /c mice 5 days 
post -infection. DNA samples were isolated from lung tissue from mice 
infected with MHV -76, MHV76- IRES.R, MHV76- vOX2.F or MHV76- vOX2.R. 
DNA samples were amplified using (A) vOX2 primers and (B) ORF 50 
primers. PCR products were analysed on a 1.2% agarose gel with a 1 Kb+ 
DNA molecular weight marker (on left hand end). All reactions included the 
use of dH2O as a negative control ( -ve) and (A) BCBL -1 DNA or (B) MHV -68 
DNA as a positive control ( +ve). 
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Figure 5.3 Detection of viral transcripts in the lungs of BALB /c 
mice five days post -infection. RNA samples were isolated from lung 
tissue from mice infected with MHV -76, MHV76- IRES.R, MHV76 - 
vOX2.F or MHV76- vOX2.R. RNA samples were used in reverse 
transcriptase reactions using oligo dT primer and the cDNA was 
amplified by PCR using (A) vOX2 primers, (B) ORF50 primers and (C) 
GAPDH primers. As an additional negative control, the RNA samples 
were amplified by PCR using (D) GAPDH primers. PCR products were 
analysed on a 1.2% agarose gel with a 1 Kb+ DNA molecular weight 
marker (on left hand end). All reactions included a negative control 
( -ve), dH2O, and positive control ( +ve), BCBL1 -DNA for (A), MHV -68 
DNA for (B), and genomic DNA for (C) and (D). 
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5.1.1.4 Detection of recombinant viruses in the lung 
Cells infected with recombinant viruses within the lung could be visualized 
through the expression of gfp. This is evident in Figure 5.4, in which, following 
fixation with 4% w/v paraformaldehyde, frozen lung sections (5 days p.i., experiment 
2) could be examined for viral infection by detecting regions of gfp expression. 
Sections were also stained for the presence of other MHV -76 viral antigens using a 
polyclonal MHV -68 antisera. Gfp and MHV -76 viral antigens were detected in 
sections made from lungs samples taken days 3, 5 and 7 p.i. only, no virus was 
detected in samples taken 9 days p.i. Only minor amounts of fluorescence were 
visible on days 3 and 7 (images not shown), particularly when directly compared 
with the levels of gfp expression and MHV -76 associated fluorescence displayed 5 
days p.i. (Figure 5.4). This further support the lung titration results, where 
productive viral titres were also seen to peak 5 days p.i. 
When comparing the levels of gfp and MHV -76 viral antigen expression in 
the lung sections, the areas infected with MHV76- vOX2.F and MHV76- vOX2.R 
appear to be more extensive than the control virus, MHV76 -IRES.R. These data 
agree with the 10 -100 fold increase in lung titres of the vOX2 recombinant viruses 
when compared with the control recombinant virus, MHV76 -IRES.R. 
5.1.1.5 Histology 
Following intranasal infection of the mice with the wild -type virus (MHV -76) 
or recombinant viruses, MHV76- vOX2.F or MHV76- vOX2.R, a mild inflammatory 
response was observed in haematoxylin and eosin (H &E) stained lung sections 3 
days p.i. (Figure 5.5, from experiment 2). This included a small amount of 
infiltration of inflammatory cells into the perivascular and peribronchial region, and 
minor vasculitis was observed in the MHV -76 sample. Mice infected with the 
control recombinant virus, MHV76 -IRES.R, showed no indication of an immune 
response and the section is representative of a healthy/ uninfected lung (Figure 
5.5 -B). The presence of haemorrhaging in some of the sections is most likely due to 
the preparation of the sample and not a result of infection with any of the viruses. 
167 
CHAPTER FIVE IN VIVO STUDIES: BALB /c 
Figure 5.4 Detection of recombinant viruses in the lung. Gfp 
expression from recombinant viruses is visible in frozen lung sections 5 
days post- infection, from mice infected with (A) MHV76- IRES.R, (B) 
MHV76- vOX2.F or (C) MHV76- vOX2.R. Other viral antigens expressed 
by MHV -76 were also detected when samples were stained using 
polyclonal anti- MHV -68 antiserum, and then stained with anti -rabbit IgG 
Alexa Fluor 546 (red). (Samples fixed in 4% (w /v) paraformaldehyde; All 
images at x 400 magnification) 
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By day 9 p.i., the inflammatory changes observed during infection with 
MHV76- vOX2.F and MHV76- vOX2.R were significant, consisting of perivascular, 
peribronchial and interstitial lymphoid infiltration, with the later being the most 
severe and involving a greater number of macrophage within the interstitial region 
(Figure 5.5 -G and 5.5 -H). Perivascular inflammation and local interstitial wall 
thickening was visible, but to a lesser degree in the lungs of mice infected with the 
wild -type virus, MHV -76 (Figure 5.5 -E). Mice infected with MHV76 -IRES.R 
showed a minimal amount of immune response at 9 days p.i., including: perivascular 
inflammation, oedema and minimal interstitial involvement (Figure 5.5 -F). 
From these findings, a general grading of severity due to the immune 
response towards the virus would be as follows: MHV76- vOX2.F & MHV76 - 
vOX2.R > MHV -76 > MHV76 -IRES.R. 
5.1.1.6 mCD200 expression levels 
To investigate if expression levels of mCD200 were down -regulated in the 
lungs of infected mice, lung sections were stained for the protein. OCT frozen lung 
sections were fixed with either 4% (w /v) paraformaldehyde (2 hours) or ice -cold 
methanol /acetone (1:1) (2 minutes). The first attempts were made by staining for 
mCD200 using a primary antibody from Serotec (rat a mCD200), followed by a 
secondary antibody from Molecular Probes (goat a rat -AF350 (blue)) (see 2.9.2). 
This was performed in combination with staining for other viral antigens using the 
polyclonal anti -MHV -68 sera with goat a rabbit -ÁF546, as previously described in 
5.1.1.4. Theoretically a combination of these two immunostained antigens along 
with gfp expression from the recombinant viruses should be visualized. However 
after several attempts at optimising staining conditions, mCD200 could not be 
detected although gfp and MHV -76 viral antigens were visualised (data not shown). 
A variety of other secondary antibodies against the rat a mCD200 and varying 
dilutions were also tested but with no success (mCD200 expression was detected in 
the spleen using rabbit a rat -TRITC (red) as the secondary antibody, but mCD200 
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Figure 5.5 Histopathological changes in BALB /c mice lungs. Mice were infected 
with wild -type MHV -76 and recombinant viruses, MHV76 -IRES.R, MHV76- vOX2.F or 
MHV76- vQX2.R and lung sections stained with haematoxylin and eosin from days 3 
(A -D) and 9 (E -H) post- infection (Images A -F original magnification at x100, images G 
and H at x250; Abbreviations: B- bronchiole; BV- blood vessel; I- interstitial infiltration; 
PB- peri- bronchial inflammation; PV- perivascular inflammation; V- vasculitis). 
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5.2 Latency 
5.2.1 Viruses in the MLN 
Latent viral levels were measured in the MLN from BALB /c mice infected 
with MHV -76, MHV76- IRES.F and MHV76- vOX2.F, at days 5, 7 and 9 p.i. 
(Experiment 3). Due to the size of the organ, samples were pooled from 3 to 4 mice 
per time -point before performing an infective centre assay (see 2.8.3) on 
approximately 4 x106 cells. The number of infective centres detected was very low 
and at most time -points dropped below detectable levels for all viruses (data not 
shown). These results may not be indicative of the actual viral levels, due to the fact 
that samples were pooled, identification of MLN difficult, and only a small 
proportion of cells analysed. 
5.2.2 Viruses in the spleen 
5.2.2.1 Infective centre assay 
The establishment of latency in vivo was determined by performing an 
infective centre assay (see 2.8.3) to detect latently infected splenocytes in mice 
infected with MHV -76, MHV76 -IRES.R, MHV76- vOX2.F and MHV76- vOX2.R. 
Spleen samples from experiment 1 on days 5, 10, 14 and 21 p.i. were measured. No 
latent virus was detected at 5 days p.i. Latent MHV -76 was detected at all other 
time -points and peaked 10 days p.i., when levels varied from approximately 10 to 
450 infective centres per spleen (Figure 5.6). The highest amount of latent 
recombinant virus was detected on day 10 and minimal amounts on day 21 p.i., often 
with levels nearing the limit of detection (Figure 5.6). These consistently low levels 
were observed in all mice that were infected with a recombinant virus. 
5.2.2.2 Virus -induced splenomegaly 
Splenomegaly occurs in mice that have been infected with MHV -68, but this 
is not a pathogenic effect of MHV -76 infections. To ensure that infection with any 
of the recombinant viruses did not show this feature, splenocyte numbers were 
measured at 5, 10, 14 and 21 days p.i. from experiment 1 (see 2.8.3 - splenocytes 
counted were used to determine the number of splenocytes 107 per spleen). A plot of 
the splenocyte numbers during the specified time -points (Figure 5.7) indicates a 
171 








5 10 14 
Days post -infection 
21 
Figure 5.6 Latent virus in the spleen of BALB /c mice. Mice were 
infected intranasally with 4x105 PFU of MHV -76 (m ), MHV76- IRES.R ( ), MHV76- vOX2.F (0), or MHV76- vOX2.R ( ). Amount of latent 
virus determined by infective centre assay. Mean infectious centres per 
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Figure 5.7 Splenocyte numbers of BALB /c. Mice were infected 
intranasally with 4x105 PFU of MHV -76 (u ), MHV76- IRES.R (v), 
MHV76- vOX2.F (,), or MHV76- vOX2.R ( ). Number of splenocytes 
± standard error is shown for four mice per group for each time point. 
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general increase in number over the duration of the experiment, however no 
significant difference was observed between mice infected with the wild -type virus 
or any of the recombinant viruses. Splenocyte numbers did increase at the later time - 
points, however these values are still too low to be considered as splenomegaly. 
5.2.2.3 Detection of viral DNA 
The consistent low levels of latent virus in mice infected with any of the 
recombinant viruses implied that either the viruses were not trafficked to the spleen 
or alternatively, were present but not being reactivated. To investigate this further, 
viral DNA was extracted from spleen samples, using the QIAamp® DNA Mini Kit 
(see 2.8.6), and amplified using a common viral gene, ORF 74 (primers ORF74 -5' 
and ORF74 -3'). Limiting dilution PCR was performed on the extracted DNA 
(-400ng to 3ng) and detected by southern blot analysis using an ORF 74 probe 
(nt 68483 -68838, from MHV -68). 
Initial observations, presented in Figure 5.8, indicate a general trend where all 
viruses are present at the early time -points (days 5 and 10), followed by a marked 
decrease of viral DNA at the later time -points (days 14 and 21), particularly in those 
mice infected with a recombinant virus. However, when the procedure was repeated 
on DNA samples extracted from different mice from within the same group, 
conflicting results were observed. When compared with the previous results, the 
spleens of mice infected with the recombinant viruses MHV76- vOX2.F and 
MHV76- vOX2.R display a greater amount of viral DNA present at the later time - 
points (days 14 and 21) (Figure 5.8 -day 21(ií), data for second set on day 14 p.i. not 
shown). Mice infected with MHV76 -IRES.R appear to be lower in the second set of 
reactions. MHV -76 is consistently high at all time -points in all mice. These data are 
consistent with results observed in the infective centre assays, i.e. MHV -76 is higher 
than the recombinant viruses at the later time -points. 
As viral DNA was detected in the spleen for both the wild -type and the 
recombinant viruses, it implies that some virus has reached the spleen. These results, 
however, cannot verify if the virus is intact or if the technique has just detected 






































































































































































































































































































































































































































































































































































Initial observations of H &E stained spleen sections 14 days pi., found 
evidence of active inflammation as seen by follicular hyperplasia, with the formation 
of germinal centres and a minor increase in the marginal zone within the white pulp 
area in all mice infected with a virus (Figure 5.9). Characteristic features such as 
mitotic figures and "starry sky" scenarios involving tingible body macrophages' 
were visible in the germinal centres. No germinal centres were detected in spleen 
sections taken from uninfected mice. In addition to the increased number of 
lymphocytes within the germinal centres, mice infected with either of the 
recombinant viruses (MHV76 -IRES.R or MHV76- vOX2.F), also displayed a large 
increase in the number of lymphocytes in the red pulp area (Figure 5.9 -C and -D). 
This is particularly noticeable due to the lymphocytes congregating in the centre of 
the red pulp area and thus causing a halo effect around the white pulp areas. The red 
pulp hyperplasia is seemingly a common non -specific response to anything that 
could cause up- regulation of colony stimulating factors and was only present in the 
recombinant virus samples. 
The lymphocyte aggregates in the red pulp of those mice infected with a 
recombinant virus, seem to regress after 21 days p.i. but the spleens still possess the 
germinal centre formations. The germinal centres are also present at day 21 in mice 
infected with MHV -76 (data not shown). There were no detectable histopathological 
differences observed between the mice infected with MHV76- vOX2.F and the 
control recombinant virus, MHV76 -IRES.R. 
The more severe immune response observed in the spleen of those mice 
infected with either of the recombinant viruses may explain some of the previous 
findings, including the low latent viral loads and varying amounts of viral DNA 
detected. It seems likely that the expression of gfp is eliciting a strong immune 
response against the recombinant viruses. 
Tingible macrophages are phagocytic macrophage of apoptotic lymphocytes, filled with nuclear 
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5.2.2.5 Immuno- fluorescent detection of viruses 
Frozen sections of spleen samples from mice infected with MHV -76, 
MHV76- IRES.R, MHV76- vOX2.F, and MHV76- vOX2.R were observed for the 
expression of gfp and immuno- stained for viral antigens from MHV -76, using a 
polyclonal MHV -68 antisera, at 5, 10, 14 and 21 days p.i. No gfp or other viral 
antigens were detected in any of the spleen samples at any of the time -points (data 
not shown). These data therefore indicate that no lytic virus was present. It is not 
known if the GFP gene would be expressed when the recombinant viruses are in a 
state of latency. 
5.3 Discussion 
These sets of experiments have been designed to investigate the pathogenesis, 
lytic and latent states of infection of BALB /c mice with the recombinant viruses 
generated in chapter four. Two recombinant viruses were created that incorporated 
the KSHV vOX2 ORF and selection markers into the left-end of the MHV -76 
genome; these viruses were termed MHV76- vOX2.F and MHV76- vOX2.R. In 
addition, two control recombinant viruses were also generated, MHV76 -IRES.F and 
MHV76 -IRES.R. In vitro analysis showed that all the recombinant viruses replicated 
with similar kinetics to the wild -type virus MI-IV-76. The results described in this 
chapter detail findings following in vivo infection. 
Following intranasal infection of laboratory mice, the natural route of 
infection, MHV -76 productively replicates in the lungs. Virally infected cells, 
predominately macrophage and dendritic cells, are drained to the lymph nodes where 
latently infected B cells further disseminate the virus to the spleen. vOX2 
recombinant virus (MHV76- vOX2.F or MHV76- vOX2.R) replicated to a 10 -100 
fold higher level in the lungs of BALB /c mice, when directly compared to the control 
recombinant virus (MHV76- IRES.R).t In addition, in the first experiment MHV76 - 
vOX2.F and MHV76- vOX2.R viral levels were higher than the wild -type virus at 
day 5; levels were more comparable to MHV -76 in the second experiment, with the 
MHV76 -IRES.R was used as the control recombinant virus in the first two experiments measuring 
viral replication in the lung, as MHV76 -IRES.F was still being generated. An additional experiment 
was performed using MHV76 -IRES.F to verify it had similar properties in vivo. The results did show 
a similar trend to those seen in experiments 1 and 2. 
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exception of MHV76- vOX2.F on day 7, which was marginally higher than all other 
viruses. These data suggest that expression of vOX2 enhances viral replication. At 
all time -points the control recombinant virus displayed lower viral titres than the 
wild -type virus. One explanation for this is that the selection marker (HygR -EGFP) 
is attenuating lytic replication within the lung due to an immune response directed 
against it. It is possible, therefore that vOX2 compensates for this attenuation and 
allows even more viral replication to occur, surpassing the titres observed for 
MHV -76. 
Cells infected with recombinant viruses could be directly visualised though 
the expression of the GFP gene. Frozen lung sections taken from the peak time -point 
(day 5 p.i.), were fixed in paraformaldehyde and then additionally stained for other 
viral antigens expressed by MHV -76. These findings reflect the previous results, 
whereby those mice infected with either MHV76- vOX2.F or MHV76- vOX2.R 
displayed a greater amount of staining for viral antigens co- localising around foci of 
gfp. These data also support the role of vOX2 in allowing an increase in viral 
replication. 
H &E stained lung sections taken from day 3 reveal a mild degree of 
inflammation in those mice infected with MHV -76, MHV76- vOX2.F or MHV76 - 
vOX2.R. Samples taken at the same time -point from a MHV76 -IRES.R infected 
lung remain healthy in appearance. Interestingly, all groups exhibit a marked 
increase in inflammation by day 9, the time -point at which viral titres dropped below 
detectable levels (Figure 5.1B). This could be the point at which any growth 
advantage provided by vOX2, is overcome by the immune response. This is visible 
through the increased amount of perivascular, peribronchial and interstitial lymphoid 
infiltration, which is most evident in mice infected with either MHV76- vOX2.F or 
MHV76- vOX2.R. 
As an additional reassurance that the recombinant viruses possessing vOX2 
were infecting the lung, samples of DNA and RNA were simultaneously isolated. 
Mice infected with MHV76- vOX2.F and MHV76- vOX2.R were positive for vOX2 
DNA and mRNA transcripts. Other infected mice were also deemed positive for the 
presence of viral DNA and mRNA transcripts, i.e. wild -type and control recombinant 
virus. 
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In summary, these experiments have shown that the expression of vOX2 
enhances viral replication within the lung. It is possible that vOX2 interacts with 
CD200R expressed on macrophage, resulting in the re- direction, down -regulation or 
suppression of activation of these cells. This could be the result of inhibiting 
cytokine production. In vitro studies have found that the interaction of a soluble 
recombinant vOX2 protein with the CD200R resulted in restricting local macrophage 
activation by inhibiting TNF -a production (Foster- Cuevas et al., 2004). Therefore 
one could envisage that this temporary suppression of the immune system has 
provided these recombinant viruses with an advantage allowing more viruses to 
replicate prior to clearance; this is apparent as data shows productive viral titres to be 
higher at the early time -points (days 3 to 7 p.i.). However, it is highly likely that the 
vOX2 protein is only having a local effect as all viruses are cleared from the lung by 
9 days p.i. This is also the time point at which histology sections show a more 
aggressive immune response. Could this be due to the fact that more virus has been 
generated in the earlier time -points? Further analysis needs to be performed to 
confirm these findings. 
Attempts were made to study mCD200 expression levels in the lungs from 
virally infected and uninfected mice. It is whether mCD200 expression 
levels decrease at times of pathogenic infection allowing the tightly regulated 
macrophage to become activated or migrate to the infected sites. Ideally, areas of 
infected lung would be compared with the local expression of mCD200, however this 
was not possible, as mCD200 could not be detected in the lung of either infected or 
uninfected samples by immunostaining. Attempts were also made to use 
immunostaining to detect macrophage (F4/80) and compare this with infected areas 
of the lung, but this too was not successful. Further optimisation and an alternative 
preparation method, such as paraffin fixed sample may be options for future work, as 
this would be an interesting experiment once optimised. 
Studies performed on the MLN were inconclusive. Attempts were made to 
measure lytic and latent virus in pooled samples of MLN from infected BALB /c 
mice, but levels were often below the limits of detection. Additionally, gfp 
expression, from the recombinant viruses, was not detected in frozen sections taken 
from infected MLN samples. 
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Conflicting results were obtained when the latent viral loads within the spleen 
were measured. Initial findings suggested that unlike the wild-type virus MHV-76, 
the recombinant viruses weren't efficiently establishing latency; this was either due 
to the virus' inability to re-activate or alternatively, not being trafficked to the spleen. 
To investigate this further, DNA samples were extracted from spleen samples and 
analysed for the presence of viral DNA using a highly sensitive technique. This 
entailed a single round of limiting dilution PCR of a single viral gene, ORF 74, 
followed by southern blot analysis, where samples were probed for the ORF 74 
product (Figure 5.8). Using this method viral DNA was detected in the spleens at 
early time points (days 5 and 10), but much reduced levels (compared with MHV-76) 
were found at later time points (days 14 and 21). However, it cannot be determined 
whether this method is detecting whole virus or partial fragments of DNA, which 
have been degraded by the immune system. Further evidence of a strong immune 
response against the recombinant viruses in the spleen is noticeable when studying 
H&E sections. It appears that all recombinant viruses, including the control virus 
(MHV76-IRES.R), triggered responses. Therefore, the inability to efficiently 
establish latency is probably not due to vOX2 but most likely to the HygR-EGFP 
gene within the insert cassette. Previous studies have also reported problems with 
the incorporation of selection markers, such as GFP, into MHV-68 recombinant 
viruses (Clambey et aL, 2002; Adler et al., 2000). Investigation on the state of 
latency was not initially considered to be a priority, primarily because the gene of 
interest, vOX2, is naturally expressed during lytic replication of KSHV. Further 
studies could be performed on a recombinant MHV-76 virus generated without the 
HygR-EGFP selection marker, or alternatively, infection via the intra-peritoneal 
cavity; past studies have suggested that this route of infection may effect the 
establishment of latency and reactivation (Clambey et al., 2000). 
To summarise these findings, the incorporation of the vOX2 ORF into 
MHV-76 enhances viral replication in the lung. This is likely to be the result of the 
expression of vOX2 suppressing local macrophage activation or re-directing their 
migration. This has allowed a greater number of recombinant viruses to replicate 
before clearance by the immune system. 
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Chapter Six: CD200 Knock-Out Animal 
Studies using C57BL/6 Mice 
6.1 Productive viral titres in wild-type C57BL/6 
mice 
6.2 Productive viral titres in CD200-/- C57BL/6 
mice 
6.3 Histology 
6.4 Expression of mCD200 and mCD200R 
6.5 Discussion 
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Chapter 6: CD200 knock -out in vivo studies using 
C57BL /6 mice 
It was throughout the duration of this research that other groups performed 
the majority of investigations on both the cellular and murine CD200 homologues. 
Before this time, information was very limited and it was only in 2000 that the 
CD200- receptor (CD200R) was identified (Wright et al., 2000). Later in 2003, 
Wright et al., discovered that the human CD200 (hCD200) protein was not only able 
to interact with the human CD200- receptor (hCD200R) but also with the murine and 
rat receptors, mCD200R and rCD200R. More recently the viral homologue (vOX2) 
has also been found to bind to hCD200R with virtually identical kinetics to the 
hCD200:hCD200R interaction (Foster- Cuevas et al., 2004). 
The role of mCD200 in the control of myeloid- derived cells, has been 
revealed through the use of transgenic mice. In 2000, Professor Neil Barclay's group 
at Oxford University, along with DNAX Research Institute of Molecular and 
Cellular Biology in California generated CD200 gene- targeted mice using C57BL /6 
embryonic stem cellsf, referred to as CD2004" mice. These mice were normal in all 
aspects of behaviour, appearance, life -span and breeding, with the exception of 
harbouring increased levels of macrophages and granulocytes. Initial experiments 
mimicking autoimmune encephalomyelitis (EAE) and arthritis (CIA) in these knock- 
out mice, verified an important immuno -regulatory role between CD200 and its 
receptor (Hoek et al., 2000). 
Following the kind donation of several mating pairs of these CD2004" mice 
by Professor Neil Barclay, further studies could be performed combining infection of 
these transgenic mice with recombinant viruses possessing a viral homologue of the 
knocked -out gene. However, prior to these experiments, all procedures first needed 
to be performed on wild -type mice from the same genetic background, i.e. 
C57BL /6( +i +) 
In both sets of experiments, groups of mice (wild -type C57BL /6( 
+i +) or 
CD200(4") C57BL /6) were sex and age (4 -7 weeks old) matched as best as possible, 
J The Neal fragment (within the V -like Ig domain) was replaced with a PGK -neon cassette and used to 
generate a C57BL /6 CD2004" breeding colony. Supplementary details can be found in the paper by 
Hoek et al., 2000. 
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into groups that were infected with 4x105 PFU of either MHV -76, MHV76- vOX2.F 
or MHV76 -IRES.F. Groups of wild -type mice consisted of four mice per virus. In 
the first experiment using the CD200-'- mice groups were made up of three mice 
(data not shown) and six in the follow -up experiment. Lung samples were measured 
for levels of productive virus (see 2.8.4) and analysed for pathogenesis. 
6.1 Productive viral titres in wild -type C57BL /6( +i +) 
Initial observations of productive viral titres in the lungs of wild -type 
C57BL /6( 
+1 +) indicated a similar trend to that depicted in the BALB /c mice (Figure 
6.1A); peak infection was observed on day 5 p.i. and all viruses were cleared by day 
9 p.i. (data not shown for day 9). Detailed analysis of the plots (Figure 6.1B) show 
equal amounts of all viruses at day 3, with marginally lower levels of MHV76 - 
IRES.F on days 5 and 7 when compared with MHV -76 and MHV76- vOX2.F. There 
is no significant difference between viral titres of MHV76 -IRES.F and MHV76 - 
vOX2.F at any time point. 
6.2 Productive viral titres in CD2004- C57BL /6 mice 
The initial experiment using the CD2004- mice, involved measuring 
productive virus levels in the lung of mice infected with either MHV76 -IRES.F or 
MHV76- vOX2.F. Only three mice were examined at days 3, 5 and 7 p.i. (data not 
shown). A similar trend, with a peak at day 5 was observed, however as on days 3 
and 7 p.i. two of the three mice were below the limit of detection no conclusive 
results could be derived. This same experiment was repeated using six mice per 
time -point per virus, and mice were infected with MHV -76, MHV76 -IRES.F or 
MHV76- vOX2.F. 
The viral titres in the lung from days 3, 5 and 7 p.i. are illustrated in Figure 
6.2A with the same trend observed (titres peaking 5 days p.i.). However, in contrast 
with all previous experiments, the average viral titre of mice infected with MHV76 - 
IRES.F surpassed those levels measured in mice infected with MHV76- vOX2.F at all 
time -points, with the difference on day 5 being statistically significant (p <0.001). 
Detailed plots show tight clusters (Figure 6.2B) and the most prominent difference 
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Day 3 pi. Figure 6.1B Detailed plot of lung titres in C57BL/6 mice at 
5- days 3, 5 and 7 post- infection. 
Each point is representative for 
4- an individual mouse at each 
time- point. Dashed line ( - --) 
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7 
Figure 6.1A Viral titres in the lungs of C57BL /6 mice (wild -type). 
Mice were infected intranasally with 4 x105 PFU of MHV -76 ( ), 
MHV76- IRES.F (-, ), or MHV76- vOX2.F ( ). Mean virus titre login per 
lung ± standard error mean is shown for four mice per group for each 
time point. 
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Figure 6.2A Viral titres in the lungs of C57BU6 CD2004- mice. Mice 
were infected intranasally with 4 x105 PFU of MHV -76 ( ), MHV76- 
IRES.F ( ), or MHV76- vOX2.F ( ). Mean virus titre Iogw per lung ± 
standard error mean is shown for six mice per group for each time point. 
* indicates statistically significant difference between viral titres of 
MHV76- IRES.F and MHV76- vOX2.F (p <0.001) 
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lung titres in C57BL/6 
CD2004 mice at days 3, 5 
and 7 post- infection. Each 
point is representative for an 
individual mouse at each time - 
point. Dashed line ( - --) 
indicates the limit of detection. 
MHV-76 IRES.F vOX2 
5- 
4- c) c 
= 






Day 7 p.i. 
MHV-76 IRES.F vOX2 
187 
CW\PTER SIX 01)200 IN VIVO STUDIES C57BL/Q 
6.3 Histology 
Lung samples were taken and sectioned for histological analysis (see 2.8.8). 
As previous studies have observed an increased number of macrophages and 
granulocytes in CD200-/- mice, sections of uninfected lungs were first assessed 
(Figure 6.3.1). As expected no abnormalities was detected in the wild-type 
C57BL/6(+/+) (Figure 6.3.1-A), however in the CD2004- lung section a slight increase 
in the number of monocytes and neutrophils were detected (Figure 6.3.1-B). In 
addition some vascular walls displayed areas of thickening; this may be due to 
hypertension rather than a normal phenotype of the knock-out mouse. Another lung 
section from a different CD2004 mouse additionally displayed increased numbers of 
mononuclear cells but also some perivascularitis (data not shown). It is not clear if 
this is part of the normal pathology but seems unlikely. Unfortunately due to the 
shortage of CD200-/- mice, more samples couldn't be analysed. 
The majority of samples (all viruses in both wild-type and CD2004- mice) 
viewed at 3 days p.i. showed no signs of pathogenesis (Figure 6.3.3); those samples 
that did have changes only included low grade peribronchial inflammation and 
perivasculitis (Figure 6.3.3-B,-C and -E). In addition, on day 9 p.i. little variation 
was observed in CD2004- mice when infected with MHV-76, MHV76-IRES.F, or 
MHV76-vOX2.F (Figure 6.3.4-D to -F); all samples displayed a moderate to severe 
degree of perivasculitis and interstitial infiltration, particularly monocytes. In the 
wild-type mice at the same time-point, similar pathology was evident, but slightly 
decreased for those mice infected with MHV-76 or the control recombinant virus 
(Figure 6.3.4-A and -B). With the assistance of Dr S Rhind, these sections have been 
graded with descriptions of the histopathological changes, the data are summarised in 
Table 6.1. 
As a further control, several C57BL/6(+/+) (wild type) were mock infected/ 
and lung samples sectioned on days 3 and 9 p.i. Very mild perivascular 
inflammation is present on day 3, however this was not considered to be significant. 
No abnormalities were detected in the section taken 9 days p.i. (Figure 6.3.2). 
11n replacement of viral aliquots mice were infected with 40u1 of cell (BHK-21) lysate (prepared in 
the same method as virus samples). 
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Figure 6.3.1 Histology section of uninfected lungs from the wild -type and 
CD2004" C57BL /6 mice. Lung sections were stained with haematoxylin and 
eosin (Images original magnification at x250). 
Figure 6.3.2 Histology section of mock -infected lungs 3 and 9 days post - 
infection from the wild -type C57BL /6 mice. Mice were infected with diluted 
BHK -21 cell lysate. Lung sections were stained with haematoxylin and eosin 
















CD200 Knock -Out 
C57BL /6 
3 Days post -infection 
Figure 6.3.3 Histopathological changes observed 3 days post -infection in 
wild -type and CD2004- C57BL/6 mice. Mice were infected with wild -type MHV -76 
and recombinant viruses, MHV76 -IRES.F and MHV76- vOX2.F. Lung sections 
were stained with haematoxylin and eosin (Images (A -F) original magnification at 
x250; Abbreviations: B- bronchial; BV- blood vessel; PB- peri- bronchial 















CD200 Knock -Out 
C57BL /6 
9 Days post -infection 
Figure 6.3.4 Histopathological changes observed 9 days post- infection in 
wild -type and CD2004" C57BU6 mice. Mice were infected with wild -type MHV -76 
and recombinant viruses, MHV76- IRES.F and MHV76- vOX2.F. Lung sections 
were stained with haematoxylin and eosin (Images (A -F) original magnification at 
x250; Abbreviations: BV- blood vessel; I- interstitial infiltration; PB- peri- bronchial 
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6.4 Expression of mCD200 and mCD200R (RT -PCT) 
Samples of mRNA were isolated from the blood (PBMCs), liver, lung, spleen 
and MLN from both the wild -type and CD2004" C57BL /6 mice to study expression 
levels of the mCD200R and mCD200 genes in the transgenic mice. The SIGMA 
messenger RNA micro isolation kit (see 2.5.1.2) was utilised for the direct isolation 
of mRNA from the above -mentioned samples. Following the generation of cDNA 
by use of the Invitrogen Thermoscript RT -PCR system (used oligo(dT) primers; see 
2.5.3) and degradation of DNA (see 2.5.2), cDNA (3µl) was amplified for mCD200, 
mCD200R and GAPDH, as a positive control (Primers used: mCD200= mCD200- 
5'+mCD200-3'; mCD200R= mCD200R- 5' +mCD200R -3'; GAPDH= GAPDH -1 
+GAPDH -2; see Appendix 2). Photographs of the amplified products are shown in 
Figure 6.4. In the wild -type mice, with the exception of the MLN sample, where the 
GAPDH control PCR indicated there were low levels of substrate, all other samples 
were positive for both mCD200 and mCD200R. In contrast, the CD2004" mice 
samples were all negative for mCD200 and positive for mCD200R, most at levels 
similar to the wild -type mice. mCD200R levels are slightly higher in the CD200"'" 
PBMC sample. 
As an additional control, samples of DNase treated mRNA were directly 
amplified using the same GAPDH primers to ensure no residual DNA was present; 
no amplification was detected in any of the samples. 
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(A) Wild Type C57BL/6 mice 
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Figure 6.4 Amplification of mRNA extracted from organ samples taken 
from wild -type and CD200 "'" C57BL /6 mice. mRNA samples were 
extracted from fresh samples of PBMCs, liver, lung, spleen and MLN taken 
from both the (A) wild -type and (B) CD200 -/- knock -out C57BU6 mice. 
Once mRNA was isolated, cDNA was generated and used in RT -PCR 
using primers for the generation of mCD200, mCD200R and GAPDH. 
Samples of mRNA were directly amplified using the GAPDH primers to 
ensure no DNA was present. Amplified products were analysed on a 1.5% 
agarose gel and ran with a 1 Kb+ DNA molecular weight marker (on left 
hand end). All reactions included the use of dH2O as a negative control 
( -ve) and genomic DNA as a positive control ( +ve) in both GAPDH 
reactions. 
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6.5 Discussion 
Previous in vivo studies (chapter 5) have implied that vOX2 may be 
responsible for assisting in evading the immune response and enhancing viral 
replication during acute infection in the lung. To further investigate the role of 
vOX2 and the possible pathway utilised to gain this advantage, CD2004- transgenic 
mice were used. These CD200-/- mice were kindly donated by Professor Neil 
Barclay and have been described as displaying normal aspects of behaviour, 
appearance, life -span and breeding, with the exception of harbouring increased levels 
of macrophages and granulocytes (Hoek et al., 2000). 
To date there has been no data published studying the direct interaction of 
vOX2 with the mouse CD200R. However, one could assume this is possible, as 
studies have shown that the human CD200 is able to engage with both the mouse and 
rat CD200R (Wright et al., 2003). Furthermore, vOX2 has been found to interact 
with the hCD200R with the same kinetics as the hCD200:hCD200R engagement 
(Foster -Cuveas et al., 2004). 
The current belief is that CD200 is able to govern the local macrophage 
population through the direct cell surface engagement via the CD200- receptor. Thus 
in mice lacking the CD200 gene (CD2004- knock -out), an increased number of 
activated macrophages are seen. This poses the question, is vOX2 able to replace the 
missing endogenous CD200 and mimic a regulatory control on the local macrophage 
population? The experiments performed in this chapter were aimed at answering this 
question. 
Before proceeding with studies using the CD2004- mice, viral titres were first 
measured in the lung from the wild -type strain of C57BL /6 mice. This experiment is 
a repeat of those previously performed in BALB /c mice (see 5.1.1). One immediate 
difference noticeable is the overall decrease in viral titres; the average value is 
approximately 100 -fold lower in C57BL /6 mice compared with those measured in 
BALB /c mice. Differences in immune response and susceptibility to MHV -68 
infection in C57BL /6 and BALB /c mice has previously been reported (Weinberg et 
al., 2004). As the overall values were lower and group size relatively low, 
comparison between the groups was difficult. The wild -type mice infected with 
vOX2- recombinant virus (MHV76- vOX2.F) yield marginally higher titres than those 
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infected with the control recombinant virus (MHV76 -IRES.F), but these were not 
statistically significant. A trend similar to previous in vivo studies was observed 
whereby the lung titres of the majority of viruses peak 5 days p.i. This trend was 
also visible in the CD2004" mice. Differences in the MHV76- vOX2.F and MHV76 - 
IRES.F viral titres were negligible on days 3 and 7, in the CD2004" mice. Whereas 
on day 5, viral titres were significantly higher for the control recombinant virus 
compared to the virus containing vOX2 (p<0.001). 
As previous studies (Hoek et al., 2000; Broderick et al., 2002) have reported 
an increase number of macrophages in the CD200 "/" mice, uninfected lungs sections 
were examined. Histological examinations of the lung sections confirmed a slight 
increase in the number of macrophages in the CD200 "'- mice compared to the wild - 
type C57BL /6 mice. In addition, the lungs from mock -infected C57BL /6 micef were 
examined on days 3 and 9 p.i.; a very mild inflammatory response was detected in 
some sites 3 days p.i., however no abnormalities were detected 9 days p.i. Thus 
confirming that any pathogenesis seen in virally infected samples is likely to be the 
direct result of the virus and not the preparation media. 
The pathology observed in the lung histology sections on days 3 and 9 p.i. is 
reflected in the viral titrest. A summary of these findings is outlined in Table 6.1. 
After 3 days p.i. most samples show little if any evidence of inflammation, however 
on day 9 all samples in both the wild -type and knock -out mice show greater areas of 
perivasculitis and monocyte infiltration within the interstitial regions. Wild -type 
mice infected with MHV76- vOX2.F displayed a more severe immune response than 
those mice infected with MHV -76 or MHV76 -IRES.F (9 days p.i.). However, due to 
the limitation on the number of mice available, only one lung sample per time point 
per virus was studied, therefore making it difficult to determine if these images 
represent normal statistical variation of the phenotype or a genuine inter -group 
difference. 
J C57BL /6 mice were infected with a preparation of cell (BHK -21) lysate made in the same manner as 
all virus samples. CD2004- knock -out mice were not mock -infected due to a limitation on the number 
of mice available. 
Based on the previous findings in BALB /c mice (see Chapter 5) and due to the limited number of 
CD2004" mice available, histological samples were only taken at the most extreme time -points, days 3 
and 9 post- infection. 
196 
CHAPTER SIX CD200'_IN VIVO STUDIES: C5 L-3L 6 
Unfortunately these data have not been able to confirm the role of vOX2 and 
the complexity of the CD2004" mice phenotype, i.e. increased number of 
macrophages, complicates analysis of the results. However, several scenarios could 
exist. 
Scenario A 
In the event that vOX2 is not able to engage with the mCD200R, viral titres in 
the CD200-' mice should either be identical to those seen in the wild -type mice, or an 
across the board decrease in viral titres (for all viruses) should be observed, 
resulting from rapid clearance by the more abundant macrophages. 
Scenario B 
Assuming vOX2 is able to engage with the mCD200R and down -regulate or 
re- direct locally activated macrophage, this would allow increased viral replication 
and be reflected in higher viral titres and perhaps less evidence of inflammation at 
the earlier time points. 
Scenario C 
Again, assuming vOX2 is able to engage with the mCD200R and down - 
regulate or re- direct locally activated macrophage, the increased number of 
macrophages present at the initial stages of acute infection could negate the 
advantage vOX2 provides during viral replication. This would be reflected by the 
viral titres of MHV76- vOX2.F dropping to the levels of MHV76 -IRES.F and the 
generation of an immune response also more similar to the control recombinant 
virus. 
Due to the large number of varying factors, arriving at a conclusion from 
these results is difficult. However, scenario A can be excluded as a possibility as the 
trend observed in the wild -type mice is not the same in the CD200 "'- mice. In the 
CD2004- mice, the viral titres of the MHV76- vOX2.F are equal or lower than the 
control recombinant virus, MHV76 -IRES.F. Furthermore, scenario B is also 
unlikely. In the CD2004- mice, viral titres are not higher for the vOX2- recombinant 
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virus and the degree of inflammation in the histological samples is comparable with 
that seen in the wild -type mice. 
From these limited results it seems likely that these data reflect scenario C. 
i.e. in the wild -type mice, expression of vOX2 provided a small advantage during 
viral replication but this is lost in the CD200 -/- mice. Higher titres of productive 
virus, particularly on day 5, and a more severe inflammatory response observed in 
the histological section are seen in those wild -type mice infected with the vOX2 
recombinant virus. However, in the CD200 -'- mice, the vOX2- recombinant viruses 
have lost the advantage gained through the expression of vOX2. This is most likely 
due to the vast number of activated macrophage present at the earlier stages. In the 
CD200 -/- mice the MHV76- vOX2.F titres are lower than the recombinant virus at all 
time -points measured and both histological samples from the MHV76- vOX2.F and 
MHV76 -IRES.F infected mice were graded with equal severity. These data would 
suggest that vOX2 (and possibly CD200) is unable to down -regulate previously 
activated macrophage, but is capable of blocking the activation of unstimulated 
macrophage. This is reflected in both the viral titres and histopathological samples. 
Various tissue samples from wild -type and CD2004- mice were examined for 
of mCD200 and mCD200R. As expected, all samples in the CD200 "/" 
mice were negative for mCD200, whereas in the wild -type mice only the spleen, 
lung, liver and PBMCs tested positive for mCD200. All samples from both the wild - 
type and CD2004" mice were positive for mCD200R with similar low expression 
levels, with the exception of the wild -type MLN sample, which obviously had lower 
levels of RNA to start with (this is evident by the faint GAPDH band yielded 
compared with the other samples). This experiment was performed to investigate 
whether expression levels of mCD200R varied between the wild -type and CD200 -'" 
mice, and from these preliminary findings most samples seem to be expressing 
similar levels. However, the PBMC sample from the CD200 -'- mice does appear to 
be slightly more intense compared with the other samples; this may be due to the 
increased numbers of circulating macrophage. Further investigation using a more 
sensitive method such as immuno -histochemistry staining or reverse -transcriptase 
real time PCR would need to be performed to confirm any conclusions. 
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In summary, these data imply that in the CD2004- mice, recombinant viruses 
encoding the vOX2 ORF have lost the ability to enhance viral replication previously 
seen during infection of wild-type mice. This is most likely a result of the phenotype 
of these CD2004" mice, which harbour increased numbers of activated macrophages. 
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The results presented in this thesis demonstrate that the KSHV vOX2 protein 
is involved in an immunomodulating role. The precise mechanism is not known but 
it is likely to involve evasion of immune clearance by mimicking the endogenous 
protein (CD200). It is possible that the vOX2 protein is engaging with the CD200- 
receptor (CD200R) and either maintaining the down -regulatory signal or re- directing 
the migration of local CD200R- expressing cells. This would provide an environment 
whereby the virus could replicate to higher titres. 
The vOX2 protein is expressed during lytic KSHV infection and is located on 
the surface of the cell in the form of an IgSF protein. The protein is highly 
glycosylated and is structurally similar to other IgSF proteins, containing the 
common V /C2 set arrangement; the glycosylated extracellular domains are 
approximately 40kDa in size. Most of these findings are in accord with those 
published by Chung et al. 2002, although their predicted role of vOX2's involvement 
as a pro -inflammatory signal, differs to the findings reported here. 
Primarily due to the restricted host range of KSHV, studies on the closely 
related murid herpesviruses have been undertaken to better understand the 
pathogenesis of many human herpesviruses. One virus in particular that has been 
studied in depth because of its similarities in pathogenesis to human gamma - 
herpesviruses is the murine gammaherpesvirus -68 (MHV -68). Furthermore, a 
natural deletion mutant of this virus, MHV -76, has provided an opportunity to 
generate recombinant murine gammaherpesviruses to aid in the study of unique 
genes. The KSHV vOX2 ORF and selection markers (HygR -EGFP) were expressed 
in an MHV -76 genomic background to create a novel gain -of- function recombinant 
virus, MHV76 -vOX2. The studies detailed within this thesis not only describe the 
generation of these recombinant viruses but also the ability of the virus to replicate in 
vitro with similar kinetics to the wild -type virus, MHV -76. In addition, in vivo 
analysis has demonstrated that those recombinant viruses encoding the vOX2 ORF 
have enhanced viral replication at early times post- infection in the lung. The 
advantage provided by vOX2 is most likely due to its ability to mimic the host 
CD200 by maintaining the down -regulatory status of the local macrophage, as 
illustrated in the diagrams in Figures 7.1 and 7.2. 
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Figure 7.1 Macrophage activation and interaction with virally- infected 
cells. Detailed legend on following page. 
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Figure 7.1 Macrophage activation and interaction with virally- infected cells. 
Resident macrophage populations in different organs such as avelolar 
macrophages (lung), Kupffer cells (liver) and microglia (CNS) adapt to their local 
microenvironment and undergo local activation in response to various 
inflammatory and immune stimuli. (A) Resident macrophage express the 
CD200R which is able to engage with the CD200 IgSF protein, expressed on the 
surface of a wide variety of cell types, including B- cells, T- cells, some dendritic 
cells, neurons, vascular endothelium and some smooth muscle. This 
engagement is thought to be partly responsible for maintaining the basal state of 
the local macrophage; we speculate that CD200 expression is down -regulated 
following viral infection of a cell. It is likely that the viral homologue of the 
CD200 protein, KSHV vOX2, is also able to interact with the cellular CD200R 
and in turn maintain the suppressive signal received by the resident 
macrophage. This does not occur in situations whereby the same cell type (e.g. 
B -cell) is infected with a different virus, such as the control recombinant virus 
(i.e. without vOX2). These infected cells trigger the immune response and 
enhance recruitment of activated macrophage. (B) In CD200 -'- mice, the 
phenotype is different from wild -type mice; the CD200 -'- mice have increased 
numbers of only activated macrophage. (C) At present it is still not clear how the 
































































































































































































































































































































































































































Figure 7.2 Theoretical courses of infection and pathogenesis occurring in 
the lung of wild -type and CD200-/- mice following intranasal inoculation 
with a MHV -76 recombinant virus encoding the vOX2 ORF or a control 
recombinant virus. In the wild -type mice, prior to infection, there are only a 
limited number of macrophage present. These are commonly known as the 
resident alveolar macrophage (pink) and are typically in a resting state 
(unstimulated), partially due to the down -regulatory signal received via the 
CD200:CD200R interaction. Following infection with a recombinant virus 
encoding the KSHV vOX2 ORF (a viral homologue of CD200) or a control 
recombinant virus (i.e. without vOX2), some of the resident macrophage become 
activated (purple). This results in the secretion of pro -inflammatory cytokines 
and recruitment of circulating macrophage. However, this is delayed in those 
mice infected with the vOX2- recombinant virus; the vOX2 protein replaces the 
down -regulated CD200 and maintains the suppressive signal on the local 
macrophage via the vOX2:CD200R interaction, thus allowing the virus to survive 
and replicate. Viral replication peaks at approximately 5 days post- infection for 
both viruses, although as more of the vOX2- recombinant virus was able to 
replicate this resulted in a greater influx of macrophages and other inflammatory 
cells ( -9 days p.i.) compared to the control recombinant virus. 
The normal phenotype of CD200-1- mice is similar to the wild -type mice 
with one major difference; all macrophage are in an activated state and more 
numerous. The vOX2- recombinant virus has no added advantage in this model, 
as the numbers of macrophages present are too high and already in an 
activated state; therefore able to recruit more inflammatory cells faster. Both 
viruses replicate at a similar rate, and both also yield a similar immune response, 
resulting in inflammation and viral clearance by approximately 9 days post - 
infection. 
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It is speculated that once CD200- expressing cells have become infected with 
a virus, expression of CD200 is down -regulated leading to a loss of the suppressive 
signal received by the local macrophage. It is the loss of this signal that contributes 
to the macrophage becoming activated and ultimately recruiting more circulating 
inflammatory cells. It is likely that vOX2 is compensating for the down -regulated 
CD200 and delaying the influx of inflammatory cells and allowing the virus to 
replicate to higher titres. These higher viral titres ultimately lead to an increased 
inflammatory response (see Figure 7.2). Preliminary in vivo studies using CD2004" 
mice further supported this theory, as the enhanced viral replication gained by the 
vOX2- recombinant virus is lost. This was possibly due to the increased number of 
activated macrophages present from the initial point of infection, resulting in a more 
rapid clearance of the virus. Further studies regarding both CD200 and CD200R 
expression patterns during viral infection would not only greatly assist in 
understanding the control mechanism of macrophage but also the immunomodulating 
role of vOX2. Additionally, if CD200 and vOX2 have the ability to maintain the 
basal state of local macrophage, how is resolution restored? (see Figure 7.1). The 
process by which this occurs is still unknown, however the identification of the 
CD200 protein and its receptor is still very recent and there are still many aspects 
relating to their interaction that need to be investigated. 
As our understanding of the control of macrophage via the CD200:CD200R 
interaction has increased, so has the importance of viral homologues of the CD200 
protein. As mentioned earlier, a variety of viruses encode a homologue of CD200, 
seemingly picked -up during viral evolution and aiding in viral fitness. The results 
within this thesis further support the theory that the KSHV vOX2 protein plays an 
immunomodulating role by evading immune clearance and ultimately assisting in 
viral pathogenesis, a theory similarly presented by Foster -Cuveas et al., 2004. 
The precise involvement of macrophages in KSHV pathogenesis is not fully 
understood. However, like MHV -68, KSHV is able to infect macrophage and may 
use this as for viral dissemination (Blasig et al., 1997; Cornali et al., 1996). 
Furthermore, macrophages may play a more pivotal role in the formation of KS 
lesions. KS is a highly angioproliferative disease requiring inflammatory cytokines 
for the formation of the lesions. In particular the infiltration of CD8+ T cells and 
206 
CHPTE.R SEVEN__ ON;:: 
CD14 + /CD68+ monocytes- macrophages producing high levels of y- interferon (yIFN) 
further promote the formation of KS spindle cells with angiogenic phenotypes 
(Fiorelli et al., 1998; Sirianni et al., 1998). 
The requirement for macrophages during the development of KS lesions is 
contradictory to our hypothesis that KSHV's vOX2 is involved in evading clearance 
by macrophages by prolonging their non- activated state. However, we speculate that 
the role of vOX2 is more crucial during primary infection with KSHV. Most aspects 
of primary infection with KSHV are unknown, but analogy with primary infection by 
other y- herpesviruses leads us to believe that following initial infection of B- cells, 
clonal expansion occurs followed by the dissemination of virus and establishment of 
latency. We speculate that it is during this stage of infection that the proposed role of 
vOX2 comes into effect. The expression of vOX2 during primary infection will 
ultimately assist in allowing the virus to replicate and establish latency. 
Previous studies have reported that expression of vOX2 is significantly 
induced (up to 168 -fold) during lytic replication of KSHV in PEL cell lines (Jenner 
et al., 2001; Paulose- Murphy et al., 2001). More interestingly, the vOX2 transcript 
is detectable on a minor population of unstimulated PEL cells. Is it possible that a 
small subset of lytic cells, within a predominate latent infection, are able to prohibit 
an immune response against these virally infected cells? Further studies on gene 
expression profiles in PEL, KS lesions and asymptomatic KSHV positive individuals 
would generate a better understanding with respect to the involvement of vOX2 in 
KSHV pathogenesis. 
The overall results in this thesis have revealed an important immuno- 
regulatory role for the KSHV vOX2 protein. If vOX2 does indeed have the ability to 
suppress activation of local macrophage, this finding would be paramount in KSHV 
pathogenesis, and perhaps all other viruses encoding CD200- homologues. 
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Future Work 
The studies described within this thesis are preliminary experiments designed 
to investigate the role of the KSHV -vOX2 protein. Although many of these studies 
suggest that vOX2 may play an important immuno- regulatory role during viral 
pathogenesis, there are still several aspects and additional details that could be 
further investigated. The two main areas on which to focus in the future include 
protein interaction studies and further in vivo analysis of infection with the 
recombinant viruses. 
One of the most useful tools in this study and any future work would be the 
generation and use of an antibody against vOX2. This antibody would not only 
allow protein interaction (e.g. with CD200R and CD200R- expressing cells) to be 
studied in vitro but also in vivo. A closer examination of the cell types in the vicinity 
of infected cells during infection with the recombinant viruses would also be 
advantageous. In particular the earlier time points (those between the initial point of 
infection and five days post- infection) need to be further scrutinized, as it is most 
likely that the maximum effect of vOX2 expression is occurring during these early 
stages of infection. 
Ultimately future studies should also focus on other viral -CD200 homologues 
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